var title_f33_37_34384="Dark flow void from AVM on MRI";
var content_f33_37_34384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A dark flow void is seen on MRI (arrow) surrounding the nidus of an arteriovenous malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34384=[""].join("\n");
var outline_f33_37_34384=null;
var title_f33_37_34385="I exercise for scapula stability";
var content_f33_37_34385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    \"I\" exercise for scapular stabilizers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"I\" exercises begin with the involved arm hanging straight down from the shoulder. Keeping the elbows straight, extend your shoulders until the arms are pointing straight down and are adjacent to your torso. Hold this position for one second, and then slowly return the arms to the starting position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34385=[""].join("\n");
var outline_f33_37_34385=null;
var title_f33_37_34386="Tooth discoloration";
var content_f33_37_34386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tooth discoloration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ischemic necrosis of the pulp may be indicated by discoloration of the crown. (A) Primary right central incisor. (B) Permanent left central incisor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Dennis J. McTigue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34386=[""].join("\n");
var outline_f33_37_34386=null;
var title_f33_37_34387="Sodium nitrite and sodium thiosulfate: Patient drug information";
var content_f33_37_34387=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium nitrite and sodium thiosulfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/838?source=see_link\">",
"     see \"Sodium nitrite and sodium thiosulfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32277?source=see_link\">",
"     see \"Sodium nitrite and sodium thiosulfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11460129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nithiodote&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11822297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe red blood cell problems may happen. People with more chance of getting these problems may have an enzyme deficiency called G6PD deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe low blood pressure may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11822280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cyanide poisoning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11822271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium nitrite, sodium thiosulfate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11822273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11822283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11822275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11822282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11822276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16470 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-220.255.2.159-317DDF55DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34387=[""].join("\n");
var outline_f33_37_34387=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11460129\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822297\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822280\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822271\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822273\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822283\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822275\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822282\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822276\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/838?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32277?source=related_link\">",
"      Sodium nitrite and sodium thiosulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34388="Agalsidase beta: Pediatric drug information";
var content_f33_37_34388=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Agalsidase beta: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/34/8741?source=see_link\">",
"    see \"Agalsidase beta: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/56/13188?source=see_link\">",
"    see \"Agalsidase beta: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fabrazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fabrazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enzyme, &alpha;-galactosidase A",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Fabry's Disease, Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/34/8741?source=see_link\">",
"      see \"Agalsidase beta: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Children and Adults: 1 mg/kg/dose every two weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fabrazyme&reg;: 5 mg [contains mannitol; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fabrazyme&reg;: 35 mg [contains mannitol; derived from or manufactured using Chinese hamster ovary  cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Reconstitute each 35 mg vial with 7.2 mL SWI and each 5 mg vial with 1.1 mL SWI to result in 5 mg/mL concentrations; swirl to dissolve; do not shake; further dilute dosage in NS (see chart below for dilution volumes). Initial infusion not to exceed 15 mg/hour (0.25 mg/minute); after patient tolerance to initial infusion rate is established, the infusion rate may be increased in increments of 3-5 mg/hour (0.05-0.08 mg/minute) with subsequent infusions. Per the manufacturer&rsquo;s recommendation: For patients weighing &lt;30 kg, the maximum infusion rate should remain at 0.25 mg/minute; for patients weighing &gt;30 kg, the administration duration should not be less than 1.5 hours (based upon individual tolerability). An initial maximum infusion rate of 0.01 mg/minute should be used for rechallenge in patients with IgE antibodies; may increase infusion rate (doubling the infusion rate every 30 minutes) to a maximum rate of 0.25 mg/minute as tolerated. A 0.2 micron low protein-binding filter may be used during administration. Pretreatment with acetaminophen and an antihistamine is recommended to reduce infusion related side effects",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Minimum Volumes for Dilution",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Minimum Total Volume",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35.1-70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70.1-100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F130794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed:",
"     </b>",
"     Do not mix with other products.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); reconstituted solution is stable for 24 hours refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Fabry's disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2933645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Agalsidase beta may be confused with agalsidase alfa, alglucerase, alglucosidase alfa",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F130793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The most common and serious adverse reactions are infusion reactions (symptoms may include fever, tachycardia, hyper-/hypotension, throat tightness, dyspnea, chills, abdominal pain, paresthesia, pruritus, urticaria, vomiting).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, chest pain/discomfort, facial edema, flushing, hyper-/hypotension, pallor, peripheral edema, tachycardia, ventricular wall thickening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, dizziness, fatigue, fever, headache, hypoesthesia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Bruising, excoriation, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, toothache, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Infusion site reactions, postprocedural complication, procedural pain, thermal burn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, burning sensation, fall, muscle spasms, myalgia, pain in extremity, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Otic: Hearing impairment, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Congestion, cough,  dyspnea, lower respiratory infection, nasal congestion, pharyngitis, sinusitis, throat tightness, upper respiratory tract infection, wheezing,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Feeling cold, fungal infection, IgG antibody formation, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other reported severe reactions: Anaphylaxis, allergic reactions, arrhythmia, ataxia, cardiac arrest, cardiac output decreased, nephrotic syndrome, stroke, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactic shock, angioedema (including dysphagia, edema of ears, edema of eye, edema of lips, edema of tongue, pharyngeal edema), arthralgia, bronchospasm, cerebrovascular accident, erythema, heart failure, hypoxia, hyperhidrosis, lacrimation increased, leukocytoclastic vasculitis, lymphadenopathy, MI, oxygen saturation decreased, palpitation, pneumonia, renal failure, respiratory failure, rhinorrhea, sepsis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to agalsidase beta or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with compromised cardiac function (seen in advanced Fabry's disease) due to an increased potential for severe infusion related reactions; monitor these patients closely; patients may develop IgG antibodies to agalsidase beta",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infusion-related reactions (ranging from mild to severe) including fever, rigors, chest tightness, hypertension, hypotension, pruritus, myalgia, dyspnea, urticaria, abdominal pain, and headache have been reported; these reactions may be minimized by pretreatment with acetaminophen and an antihistamine; if an infusion related reaction occurs, regardless of pretreatment, decreasing the infusion rate, temporarily stopping the infusion, and/or additional administration of analgesics, antihistamines, or corticosteroids may ameliorate the reaction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not demonstrated adverse effects. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential are encouraged to enroll in Fabry registry (www.fabryregistry.com or 1-800-745-4447).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs during infusion; infusion-related reactions; globotriasylceramide (GL3) plasma levels; improvement in disease symptomatology",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal endogenous activity of alpha-galactosidase A in plasma is approximately 170 nmol/hour/mL; in patients with Fabry's disease this activity is &lt;1.5 nmol/hour/mL",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Normal (goal) globotriasylceramide (GL3) &lt;1.2 ng/microliter",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agalsidase beta is a recombinant human &alpha;-galactosidase A enzyme with the same amino acid sequence as the naturally-occurring enzyme. Fabry's disease is an X-linked genetic disorder occurring in 1 in 50,000 male births, which results in a deficiency of &alpha;-galactosidase A. Lack of this enzyme leads to a progressive accumulation of glycosphingolipids, predominantly GL-3, in the vascular endothelium, leading to ischemia and infarction, especially in the kidney, heart, and brain. Clinical manifestations of Fabry's disease in childhood include intermittent severe pain in the extremities, characteristic vascular skin lesions (angiokeratomas), corneal and lenticular opacities that do not affect vision, decreased ability to sweat, intolerance to heat, cold, and exercise, mild proteinuria, and GI problems. By adulthood, this progresses to renal failure, cardiomyopathy, and cerebrovascular accidents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 247-1097 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 80-570 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (dose dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 86-151 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 45-102 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.1-5.8 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.8-4.9 mL/minute/kg",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agalsidase beta is an orphan drug; a Fabry Patient Support Group (800-745-4447) is available to assist patients in obtaining reimbursement from private insurers, Medicare, and Medicaid, and a Charitable Access Program sponsored by Genzyme provides the drug gratis to those patients in need. Detailed information regarding organizations and websites is also available in the Expert Panel Recommendations (Desnick, 2003)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Desnick RJ, Brady R, Barranger J, et al, &ldquo;Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 138(4):338-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34388/abstract-text/12585833 /pubmed\" id=\"12585833 \" target=\"_blank\">",
"        12585833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12896 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34388=[""].join("\n");
var outline_f33_37_34388=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130769\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056276\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056270\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130753\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130740\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056280\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130794\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056273\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056279\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2933645\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130793\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056283\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056269\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056268\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298692\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130747\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130749\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130760\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056275\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056278\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056267\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056282\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056284\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/34/8741?source=related_link\">",
"      Agalsidase beta: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/56/13188?source=related_link\">",
"      Agalsidase beta: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34389="Sulfadoxine and pyrimethamine: Drug information";
var content_f33_37_34389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfadoxine and pyrimethamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/43/2742?source=see_link\">",
"    see \"Sulfadoxine and pyrimethamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/47/8949?source=see_link\">",
"    see \"Sulfadoxine and pyrimethamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fansidar&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute malaria attacks:",
"     </b>",
"     Oral: A single dose of the following number of Fansidar&reg; tablets is used in sequence with quinine or alone: 3 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria prophylaxis:",
"     </b>",
"     A single dose should be carried for self-treatment in the event of febrile illness when medical attention is not immediately available: Oral: 3 tablets",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/47/8949?source=see_link\">",
"      see \"Sulfadoxine and pyrimethamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute malaria attacks:",
"     </b>",
"     Oral: A single dose of the following number of Fansidar&reg; tablets is used in sequence with quinine or alone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-11 months:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1 tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-14 years: 2 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;14 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria prophylaxis:",
"     </b>",
"     A single dose should be carried for self-treatment in the event of febrile illness when medical attention is not immediately available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-11 months:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1 tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-14 years: 2 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;14 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fansidar&reg;: Sulfadoxine 500 mg and pyrimethamine 25 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     malaria in patients in whom chloroquine resistance is suspected; malaria prophylaxis for travelers to areas where chloroquine-resistant malaria is endemic",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Myocarditis (allergic), pericarditis (allergic), periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, hallucinations, headache, polyneuritis, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid function dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, atrophic glossitis, gastritis, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, interstitial nephritis, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory failure, alveolitis (resembling eosinophilic or allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, drug fever, hypersensitivity, Lupus-like syndrome, periarteritis nodosum",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any sulfa drug, pyrimethamine, or any component of the formulation; porphyria, megaloblastic anemia; repeated prophylactic use is contraindicated in patients with renal failure, hepatic failure, or blood dyscrasias; children &lt;2 months of age due to competition with bilirubin for protein binding sites; pregnancy (at term)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash, myelosuppression or active bacterial/fungal infection.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Folate deficiency: Use caution in patients with possible folate deficiency (eg, malabsorption syndrome, pregnancy, alcoholism).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with possible G6PD deficiency; hemolysis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloroquine: Increased adverse reactions are seen in patients also receiving chloroquine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leucovorin: Should be administered to reverse signs and symptoms of folic acid deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Do not give to infants &lt;2 months of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Pyrimethamine and sulfadoxine both cross the placenta. Prophylactic use near term is contraindicated by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrimethamine and sulfadoxine both enter breast milk. Prophylactic use in lactating women is contraindicated by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F223828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, including platelet counts, and urinalysis should be performed periodically",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Croydoxin-FM (IN);",
"     </li>",
"     <li>",
"      Fansidar (AE, AT, AU, BH, BR, CH, CY, EG, FR, GB, GH, GR, ID, IE, IL, IQ, IR, JO, KW, LB, LY, OM, PE, PH, PK, PL, QA, SA, SY, TZ, UG, YE, ZM);",
"     </li>",
"     <li>",
"      Fansitab (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Laridox (IN);",
"     </li>",
"     <li>",
"      Madomine (MY);",
"     </li>",
"     <li>",
"      Malafon (MY);",
"     </li>",
"     <li>",
"      Malerim (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Malocide (IN);",
"     </li>",
"     <li>",
"      Plasmodin (ID);",
"     </li>",
"     <li>",
"      Pyralfin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Rimodar (IN);",
"     </li>",
"     <li>",
"      Suldox (ID);",
"     </li>",
"     <li>",
"      Vansilar (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfadoxine interferes with bacterial folic acid synthesis and growth via competitive inhibition of para-aminiobenzoic acid; pyrimethamine inhibits microbial dihydrofolate reductase, resulting in inhibition of tetrahydrofolic acid synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Sulfadoxine: Well distributed like other sulfonamides; Pyrimethamine: Widely distributed, mainly in blood cells, kidneys, lungs, liver, and spleen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Pyrimethamine: Hepatic; Sulfadoxine: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Pyrimethamine: 80-95 hours; Sulfadoxine: 5-8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and several unidentified metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lynk A and Gold R, &ldquo;Review of 40 Children With Imported Malaria,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(11):745-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/2594448/pubmed\" id=\"2594448\" target=\"_blank\">",
"        2594448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panisko DM and Keystone JS, &ldquo;Treatment of Malaria - 1990,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 39(2):160-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/2183998/pubmed\" id=\"2183998\" target=\"_blank\">",
"        2183998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Randall G and Seidel JS, &ldquo;Malaria,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1985, 32(4):893-916.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/3895138/pubmed\" id=\"3895138\" target=\"_blank\">",
"        3895138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;The Treatment of Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335:800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/8703186/pubmed\" id=\"8703186\" target=\"_blank\">",
"        8703186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria Chemoprophylaxis for the Traveler,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/8505942/pubmed\" id=\"8505942\" target=\"_blank\">",
"        8505942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria: Overview and Update,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1993, 16(4):449-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/37/34389/abstract-text/8513046/pubmed\" id=\"8513046\" target=\"_blank\">",
"        8513046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10090 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-197.136.42.3-D0BB386C34-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34389=[""].join("\n");
var outline_f33_37_34389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709421\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223856\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223847\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223852\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223848\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223830\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223831\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223854\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223835\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223819\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223824\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223826\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287361\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287363\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287362\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223828\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038835\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223818\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223834\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/43/2742?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/47/8949?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34390="Treatment of adrenocortical adenomas";
var content_f33_37_34390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of adrenocortical adenomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34390/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/37/34390/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral tumors or masses of the adrenal gland are common. They are categorized as either functional (hormone-secreting) or nonfunctional, and as either benign or malignant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of adrenocortical tumors are benign, nonfunctioning adenomas that are discovered incidentally on abdominal imaging studies (adrenal incidentalomas).",
"     </li>",
"     <li>",
"      Others are benign, hormone-secreting adenomas that cause Cushing's syndrome, primary aldosteronism, or much less commonly, virilization.",
"     </li>",
"     <li>",
"      Adrenocortical carcinomas (ACCs) are rare, frequently very aggressive tumors that may be functional, and cause Cushing's syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      virilization, or nonfunctional, and present as an abdominal mass or as an incidental finding.",
"     </li>",
"     <li>",
"      Pheochromocytomas are catecholamine-secreting tumors (benign or malignant) that arise from chromaffin cells of the adrenal medulla. These are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of adrenocortical adenomas will be reviewed here. The treatment of adrenocortical carcinoma and the clinical presentation and evaluation of all adrenocortical tumors are discussed separately. The rarer micronodular and macronodular adrenal disorders that cause Cushing's syndrome are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF ADRENOCORTICAL ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical adenomas are benign neoplasms of adrenocortical cells. Although most are nonfunctional, some secrete steroids independently from ACTH or the renin-angiotensin system. Many are discovered incidentally on abdominal imaging studies (adrenal incidentalomas), while others present with symptoms of hormonal excess.",
"   </p>",
"   <p>",
"    After the initial discovery of an adrenal mass, subsequent evaluation should determine whether it is benign or malignant, and whether it is functional or nonfunctional, in order to determine treatment options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional adenomas may hypersecrete cortisol and cause Cushing's syndrome. The approach to establishing the adrenal gland as the source of hypercortisolism in Cushing's syndrome is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"       \"Establishing the cause of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subclinical Cushing's syndrome is very common in patients with adrenal incidentalomas. The suggested evaluation for evidence of hypercortisolism in patients with adrenal incidentalomas is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link&amp;anchor=H18#H18\">",
"       \"The adrenal incidentaloma\", section on 'Subclinical Cushing's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aldosterone-secreting adenomas are one of the main causes of primary aldosteronism and are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      ). Hyperaldosteronism is less common than hypercortisolism in incidentalomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/1\">",
"       1",
"      </a>",
"      ]. Adrenal adenomas rarely produce androgens or estrogen, resulting in virilization or feminization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral adrenalectomy is the treatment of choice for most patients with hormone-secreting unilateral adenomas, and for many with incidentally discovered adrenal masses. The management of adrenocortical carcinoma and bilateral adrenal masses are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Functional adenomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Untreated Cushing's syndrome may be fatal, with most deaths being due to cardiovascular, thromboembolic, or hypertensive complications, or infection. Therefore, for all patients with documented overt Cushing's syndrome due to an adrenal adenoma (who are surgical candidates), we recommend unilateral adrenalectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=see_link\">",
"       \"Overview of the treatment of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most patients with hyperaldosteronism due to a unilateral adrenal adenoma, we suggest surgery over pharmacological therapy. The administration of a mineralocorticoid receptor antagonist is an effective alternative in patients who refuse or are not candidates for surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"       \"Treatment of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidentalomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of adrenal incidentalomas, including evaluation for malignancy and endocrine function, and management is found separately. Suggested management of the incidentally discovered mass is reviewed briefly here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest surgery for patients with subclinical Cushing's syndrome who are younger and who have disorders potentially attributable to ACTH-independent glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and low bone mass).",
"     </li>",
"     <li>",
"      We suggest surgery for patients with unilateral adrenal masses that have either a suspicious imaging phenotype or are greater than 4 cm in diameter, because a substantial fraction will be adrenocortical carcinomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"       \"Treatment of adrenocortical carcinoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evaluation of the resected mass for malignancy is described below. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Histologic analysis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with nonfunctional tumors less than 4 cm in size with a benign imaging appearance we suggest follow-up with repeated scans. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bilateral masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of bilateral adrenal masses is different from that for unilateral masses. The presence of bilateral masses in a patient with ACTH-independent Cushing's syndrome suggests the diagnosis of macronodular or, rarely, micronodular adrenal hyperplasia. Management of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=see_link\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laparoscopic versus open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 308 articles on laparoscopic adrenal surgery suggests that it is safe, effective, and less expensive than open adrenalectomy for patients with aldosteronomas, pheochromocytomas, cortisol-secreting adenomas, and adrenal incidentalomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/2\">",
"     2",
"    </a>",
"    ]. Laparoscopic surgery may require a longer operative time, but it is associated with less postoperative pain and shorter hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/3\">",
"     3",
"    </a>",
"    ]. In a summary of published studies, for example, the average length of stay ranged from 1.5 to 4 days (average 2.7) with laparoscopic adrenalectomy, as compared with 5.3 to 10 days (average 7.4) with open surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either a lateral transabdominal or posterior retroperitoneal approach can be used for laparoscopic surgery. In a study of 36 patients, all tumors approached either way were successfully removed, including eight that were &gt;6 cm. Operating times and mean length of stay (2.2 versus 1.5 days) were similar for both procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, laparoscopic surgery has become the standard surgical approach, at least for patients with smaller adenomas (&lt;6 cm in diameter) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Open adrenalectomy is recommended if an adrenocortical cancer is suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all patients with adrenocortical adenomas are cured by surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. Postoperative glucocorticoid therapy is needed when excess cortisol secretion has suppressed CRH and ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has Cushing's syndrome, the recovery of normal ACTH secretion from pituitary corticotropes after prolonged inhibition may be delayed. There may also be secondary atrophy of nontumorous adrenal zonae fasciculata and reticularis cells. As a result, the patient often requires glucocorticoid replacement therapy for several months to a year and sometimes even longer after resection of the tumor, or life-long therapy after resection of both adrenal glands for bilateral nodular disease (in which case, life-long mineralocorticoid replacement therapy is also required). The principles of glucocorticoid replacement are similar to those for patients with Cushing's disease who are cured by resection of a pituitary adenoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\", section on 'Preoperative glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be given higher than normal glucocorticoid replacement intraoperatively and postoperatively to avoid symptoms and signs of acute steroid withdrawal. A dose of 150 to 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    may be administered by constant infusion or in divided doses intravenously over the first 24 hours after induction of anesthesia. This is followed by daily doses of 100 mg, 75 mg, 50 mg, on successive days thereafter. Hydrocortisone can be given by mouth after the first day or two when oral feeding is possible.",
"   </p>",
"   <p>",
"    Patients with long-standing severe Cushing's syndrome often require supraphysiological replacement doses for a few weeks. We recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    20 mg early morning, 10 mg mid-morning and 10 mg mid-afternoon for a few weeks. Tapering to a single 20 mg replacement dose in the early morning is done progressively by 2.5 mg decreases in total dose every one to two weeks.",
"   </p>",
"   <p>",
"    Most patients with less severe or subclinical Cushing's syndrome can tolerate mild symptoms of glucocorticoid withdrawal and will be given only 20 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (12 to 15",
"    <span class=\"nowrap\">",
"     mg/M2)",
"    </span>",
"    in early morning until normal morning endogenous cortisol levels and response to exogenous ACTH are restored. Patients should wear a medical bracelet and be instructed to increase hydrocortisone dose during stress until the pituitary adrenal axis has fully recovered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical symptoms and signs of Cushing's syndrome disappear gradually over a period of up to 12 months. Hypertension and glucose intolerance improve but may not disappear.",
"   </p>",
"   <p>",
"    The patient with subclinical Cushing's syndrome should also be treated with perioperative glucocorticoid coverage because of the risk of adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link&amp;anchor=H18#H18\">",
"     \"The adrenal incidentaloma\", section on 'Subclinical Cushing's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Aldosteronoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excision of an aldosteronoma may rarely be followed by transient hyperkalemia and mild hyponatremia indicative of suppression of the renin-angiotensin-aldosterone system. These patients may require a high salt diet with or without mineralocorticoid therapy (eg, 0.05 to 0.1 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    daily) for a few days or weeks.",
"   </p>",
"   <p>",
"    After adrenalectomy, hypokalemia is corrected in almost all patients. Hypertension is improved in all, but cured in only 30 to 60 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with pure androgen-secreting tumors do not require postoperative replacement therapy after unilateral adrenalectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Histologic analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between benign and malignant adrenocortical tumors may be difficult and should only be made by a pathologist experienced in using the microscopic Weiss criteria for malignancy. The Weiss diagnostic score examines nine histologic criteria (nuclear grade, atypical and frequent mitosis",
"    <span class=\"nowrap\">",
"     [&gt;5/50",
"    </span>",
"    cells per high power field], eosinophilic tumor cell cytoplasm, diffuse architecture, vascular [venous, sinusoidal] invasion, capsular invasion, and necrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of three or more predicts malignant behavior. Others have proposed alternative histologic criteria to predict malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/11\">",
"     11",
"    </a>",
"    ], although the Weiss criteria are the most widely applied.",
"   </p>",
"   <p>",
"    If the histologic analysis suggests benign clinical behavior, but the final histologic diagnosis is atypical adenoma, regular abdominal and thoracic CT scans or PET scan (if initially positive) should be performed at three month intervals for one to two years to rule out the possibility of metastatic adrenal carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal enzyme inhibitors can be utilized to control hypercortisolism when adrenal surgery needs to be delayed or when the patient is too ill to undergo immediate surgery. In the United States, the available drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mineralocorticoid receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) and potassium-sparing diuretics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ) can be an effective alternative to control primary aldosteronism in patients who refuse or are not candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Androgen-secreting tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adrenalectomy is the treatment of choice, antiandrogen therapy would be expected to improve hyperandrogenic symptoms. This was illustrated in a report of a 55-year old woman with a benign, testosterone-secreting adrenal adenoma, who experienced a significant reduction in hirsutism with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    therapy prior to adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34390/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Unilateral tumors or masses of the adrenal gland are common. They are categorized as either functional (hormone-secreting) or nonfunctional, and as either benign or malignant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of adrenocortical tumors are benign, nonfunctioning adenomas that are discovered incidentally on abdominal imaging studies (adrenal incidentalomas).",
"     </li>",
"     <li>",
"      Others are benign hormone-secreting adenomas that cause Cushing's syndrome, primary aldosteronism, or much less commonly, virilization.",
"     </li>",
"     <li>",
"      Pheochromocytomas are catecholamine-secreting tumors (benign or malignant) that arise from chromaffin cells of the adrenal medulla. These are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adrenocortical carcinomas (ACCs) are rare, frequently very aggressive tumors that may be functional and cause Cushing's syndrome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      virilization, or nonfunctional, and present as an abdominal mass or an incidental finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adrenalectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3691319\">",
"    <span class=\"h3\">",
"     Cushing's syndrome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Untreated Cushing's syndrome is often fatal. Therefore, for patients with overt Cushing's syndrome due to a unilateral adrenocortical adenoma, we recommend unilateral adrenalectomy (unless there is a contraindication to surgery) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=see_link\">",
"       \"Overview of the treatment of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3691326\">",
"    <span class=\"h3\">",
"     Aldosteronomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with primary hyperaldosteronism due to an adrenal adenoma we suggest surgery over pharmacological therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The administration of a mineralocorticoid receptor antagonist is an effective alternative in patients who refuse or are not candidates for surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"       \"Treatment of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3691333\">",
"    <span class=\"h3\">",
"     Pheochromocytomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pheochromocytomas are catecholamine-secreting tumors that arise from chromaffin cells of the adrenal medulla. These are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link\">",
"       \"Treatment of pheochromocytoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adrenal incidentalomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the evaluation and management of adrenal incidentalomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .) They are summarized briefly here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest surgery for patients with subclinical Cushing's syndrome who are younger and who have disorders potentially attributable to glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and low bone mass) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend surgery for patients with unilateral adrenal masses that are greater than 4 cm in diameter, or that have a suspicious imaging phenotype, because a substantial fraction will be adrenocortical carcinomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=see_link\">",
"       \"Treatment of adrenocortical carcinoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evaluation of the resected mass for possible malignancy is described above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Histologic analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonfunctional tumors less than 4 cm in size with a benign imaging appearance we suggest follow-up with repeated",
"      <strong>",
"      </strong>",
"      scans (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Choice of surgical procedure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the reduction in postoperative morbidity, hospital stay, and expense compared with open laparotomy, we suggest laparoscopic adrenalectomy by an experienced endocrine surgeon for adrenal adenomas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Laparoscopic versus open surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with confirmed unilateral adrenal aldosterone hypersecretion (who are not candidates for surgery), we recommend a mineralocorticoid receptor antagonist over other potassium-sparing diuretics as our first choice for pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"       \"Treatment of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with Cushing's syndrome due to a unilateral adrenocortical adenoma or carcinoma or bilateral ACTH-independent hyperplasias will often need adrenal enzyme inhibitors to control hypercortisolism when adrenal surgery has to be delayed or when the patient is too ill to undergo immediate surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=see_link\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"       \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/1\">",
"      Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/2\">",
"      Gill IS. The case for laparoscopic adrenalectomy. J Urol 2001; 166:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/3\">",
"      Linos DA, Stylopoulos N, Boukis M, et al. Anterior, posterior, or laparoscopic approach for the management of adrenal diseases? Am J Surg 1997; 173:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/4\">",
"      Hansen P, Bax T, Swanstrom L. Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Endoscopy 1997; 29:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/5\">",
"      Duh QY, Siperstein AE, Clark OH, et al. Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches. Arch Surg 1996; 131:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/6\">",
"      Cuesta MA, Bonjer HJ, van Mourik JC. Endoscopic adrenalectomy: the adrenals under the scope? Clin Endocrinol (Oxf) 1996; 44:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/7\">",
"      Wells SA, Merke DP, Cutler GB Jr, et al. Therapeutic controversy: The role of laparoscopic surgery in adrenal disease. J Clin Endocrinol Metab 1998; 83:3041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/8\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/9\">",
"      V&auml;lim&auml;ki M, Pelkonen R, Porkka L, et al. Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984; 20:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/10\">",
"      Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/11\">",
"      van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985; 55:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34390/abstract/12\">",
"      L&oacute;szi&oacute; FA, T&oacute;th S, Kocsis J, et al. Testosterone-secreting gonadotropin-responsive adrenal adenoma and its treatment with the antiandrogen flutamide. J Endocrinol Invest 2001; 24:622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 150 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34390=[""].join("\n");
var outline_f33_37_34390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF ADRENOCORTICAL ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Functional adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidentalomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bilateral masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laparoscopic versus open surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Aldosteronoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Histologic analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Androgen-secreting tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3691319\">",
"      - Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3691326\">",
"      - Aldosteronomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3691333\">",
"      - Pheochromocytomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adrenal incidentalomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Choice of surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=related_link\">",
"      Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34391="Psychotherapy for obsessive-compulsive disorder";
var content_f33_37_34391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychotherapy for obsessive-compulsive disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Jonathan Abramowitz, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34391/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/37/34391/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11707907\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obsessive-compulsive disorder (OCD) is characterized by recurrent, intrusive, and distressing thoughts, images, or impulses (ie, obsessions) and repetitive mental or behavioral acts that the individual feels driven to perform (ie, compulsions) to prevent or reduce distress.",
"   </p>",
"   <p>",
"    Treatment with selective serotonin reuptake inhibitors (SSRIs), serotonin&ndash;norepinephrine reuptake inhibitors (SNRIs),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    , and cognitive-behavioral therapy (CBT) have been shown to be efficacious in the treatment of OCD. CBT is a set of techniques that are used to help people with psychological disorders modify maladaptive patterns of thinking and acting to alleviate emotional symptoms. Components of CBT for OCD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Education",
"     </li>",
"     <li>",
"      Cognitive therapy techniques",
"     </li>",
"     <li>",
"      Exposure therapy",
"     </li>",
"     <li>",
"      Response prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychotherapy for OCD is discussed here. The epidemiology, clinical manifestations, and diagnosis of OCD are discussed separately. Pharmacotherapy for OCD, deep brain stimulation for OCD, and OCD in pregnant and postpartum women are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=see_link\">",
"     \"Obsessive-compulsive disorder in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30678?source=see_link\">",
"     \"Deep brain stimulation for treatment of obsessive-compulsive disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10265636\">",
"    <span class=\"h1\">",
"     COGNITIVE BEHAVIORAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11707914\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is effective and indicated for OCD at all levels of symptom severity. Considerations when evaluating a patient for CBT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognition &mdash; CBT requires that the patient grasp a conceptual model of OCD and rationale for treatment. Patients must also be able to implement treatment procedures on their own and consolidate information they learn using the techniques. This may be difficult for individuals who are very concrete in their thinking, developmentally disabled, or cognitively impaired.",
"     </li>",
"     <li>",
"      Insight &mdash; Patients with poor insight into the senselessness of their OCD symptoms show an attenuated response to CBT due to reluctance to engage in exposure and response prevention and difficulty consolidating information learned in CBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/2\">",
"       2",
"      </a>",
"      ]. While CBT is worth attempting, increased use of cognitive therapy techniques might be necessary to help patients recognize the senselessness of their symptoms and engage in (and benefit from) exposure tasks. This approach, however, is not always successful, especially with patients with extremely poor insight.",
"     </li>",
"     <li>",
"      OCD subtypes &mdash; CBT is less beneficial when hoarding symptoms predominate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/3\">",
"       3",
"      </a>",
"      ]. CBT can be adapted to patients with obsessions without overt rituals (ie, mental rituals or &ldquo;pure obsessions&rdquo;).",
"     </li>",
"     <li>",
"      Comorbidity &mdash; OCD patients with comorbid depression or generalized anxiety disorder (GAD) show reduced response to CBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/4\">",
"       4",
"      </a>",
"      ]. Seriously depressed patients may become demoralized and have trouble complying with treatment instructions. Their strong negative affect may also exacerbate OCD symptoms. In GAD, pervasive worry detracts from patients&rsquo; mental resources available for learning skills in CBT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Other Axis I conditions that may impede the process and effectiveness of CBT are those that involve alterations in perception, cognition, and judgment, such as psychotic and manic symptoms. Active abuse of psychoactive substances impedes the ability to benefit from CBT exercises and can also reduce adherence.",
"     </li>",
"     <li>",
"      Severe Axis II psychopathology may also impede the progress of CBT. Anxious (eg, obsessive-compulsive personality disorder) and dramatic (eg, histrionic personality disorder) traits interfere with rapport development; yet, effective treatment is possible if a therapeutic relationship can be established. Patients with personality traits in the odd cluster (eg, schizotypy) present a challenge to CBT due to patients&rsquo; reduced ability to consolidate corrective information from exposure or cognitive interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient preference &mdash; Patient preference for CBT or medication treatment for OCD should be considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/5\">",
"       5",
"      </a>",
"      ]. Reviewing the advantages and disadvantages of each approach with the patient allows him or her to make an informed decision about which therapy they would prefer to receive. Greater adherence to CBT can be expected from patients who agree willingly to a particular plan.",
"     </li>",
"     <li>",
"      Availability &mdash; Providing CBT for OCD requires specialized training and experience. The availability of clinicians trained to provide CBT for OCD varies widely. The International Obsessive-Compulsive Disorder Foundation maintains a database of clinicians trained in the treatment of OCD (www.ocfoundation.org).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11707977\">",
"    <span class=\"h2\">",
"     Theoretical foundation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT for OCD is based on an empirically derived conceptualization of OCD that begins with the well-established finding that intrusions (ie, thoughts, images, and impulses that intrude into consciousness) are normal experiences that most people have from time to time (ie, normal obsessions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/6\">",
"     6",
"    </a>",
"    ]. Sometimes triggered by external stimuli (eg, thoughts of a house fire that are triggered by the sight of a fire truck), such intrusions usually reflect the person&rsquo;s current concerns. Research also shows that people with no history of OCD have intrusive thoughts about &ldquo;taboo&rdquo; topics such as sex, violence, and blasphemy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The cognitive-behavioral conceptual model proposes that these normal intrusions develop into highly distressing and time consuming clinical obsessions when the intrusions are appraised as posing a threat for which the individual is personally responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, consider the unwanted impulse to yell loudly in a quiet place such as a church or a library. Most people would consider such an intrusive impulse as meaningless and harmless (eg, &ldquo;mental noise&rdquo;). Yet such an intrusion might develop into a clinical obsession if the person attaches to it a high degree of importance, leading to an escalation in negative emotion; for example, &ldquo;Thinking about yelling in church means I&rsquo;m an immoral person,&rdquo; or &ldquo;I must be extra careful to make sure I don&rsquo;t lose control.&rdquo; Such appraisals evoke distress and motivate the person to try to suppress or neutralize the unwanted thought (eg, by praying or replacing it with a &ldquo;safe&rdquo; thought), and to attempt to prevent any harmful events associated with the intrusion (eg, by avoiding churches).",
"   </p>",
"   <p>",
"    Compulsive rituals and other safety-seeking behaviors are conceptualized as maladaptive efforts to remove intrusions and to prevent feared consequences. There are several ways in which rituals are counterproductive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They temporarily provide reduction in obsessional distress, and therefore are negatively reinforced, evolving into behavioral patterns that consume substantial time and effort and impair functioning.",
"     </li>",
"     <li>",
"      Because they reduce anxiety in the short term, rituals prevent the abatement of fear that would naturally occur over time.",
"     </li>",
"     <li>",
"      Rituals lead to an increase in the frequency of obsessions by serving as reminders of obsessional intrusions, thereby triggering their reoccurrence. As an example, compulsively checking the stove can trigger intrusions about house fires.",
"     </li>",
"     <li>",
"      Performing rituals preserves dysfunctional beliefs and misinterpretations of obsessional thoughts. That is, when feared consequences do not occur after performance of a ritual, the person attributes this to the ritual that was performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11707991\">",
"    <span class=\"h3\">",
"     Proposed mechanisms of CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is thought to work for OCD via three mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeated and prolonged exposure to feared stimuli produces habituation of anxiety, a natural decrease in conditioned fear. Response prevention aids this process by blocking the performance of rituals which would serve as a premature escape from the anxiety. Thus, CBT reduces obsessional fears and ritualistic urges by repeatedly pairing the fear triggers with feelings of anxiety reduction.",
"     </li>",
"     <li>",
"      CBT corrects dysfunctional beliefs that underlie OCD symptoms by presenting the patient with information that disconfirms these beliefs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CBT helps patients gain self-efficacy by helping them to master their fears without having to rely on avoidance or ritualistic behaviors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11707999\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful assessment and case conceptualization is critical to the effectiveness of CBT. In the context of conducting a comprehensive psychiatric assessment, the clinician should conduct an evaluation of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obsessional thoughts, ideas, impulses",
"     </li>",
"     <li>",
"      Stimuli that trigger the obsessions",
"     </li>",
"     <li>",
"      Rituals and avoidance behavior",
"     </li>",
"     <li>",
"      Anticipated harmful consequences of confronting feared situations without performing rituals (ie, the cognitive links between obsessions and compulsions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to ascertain the functional relationships between obsessions and rituals (eg, unwanted sexual thoughts lead to praying rituals) as well as the onset and historical course of the problem. Prior treatment history (particularly of the effectiveness of therapy and medications for OCD) may inform current recommendations.",
"   </p>",
"   <p>",
"    Use of a structured assessment tool before and after a treatment trial can help to determine the degree to which treatment has been effective. The Yale-Brown Obsessive-compulsive Scale (YBOCS), a semi-structured, clinician-administered interview, includes a symptom checklist and a 10-item severity scale (",
"    <a class=\"graphic graphic_figure graphicRef80107 \" href=\"mobipreview.htm?11/7/11378\">",
"     figure 1",
"    </a>",
"    ). It is the gold standard interview for assessing the breadth and severity of OCD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The symptom checklist is first used to identify the patient&rsquo;s particular obsessions and compulsions. The severity scale then assesses the patient&rsquo;s main obsessions (items 1 through 5) and compulsions (items 6 through 10) on the following five parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Time occupied by obsessive thoughts and compulsive behaviors",
"     </li>",
"     <li>",
"      Interference from obsessions and compulsions",
"     </li>",
"     <li>",
"      Distress from obsessions and compulsions",
"     </li>",
"     <li>",
"      Resistance to obsessions and compulsions",
"     </li>",
"     <li>",
"      Degree of control over obsessions and compulsions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician rates each item from 0 (no symptoms or impairment) to 4 (most severe symptoms or impairment) based on the past week. Two subscales (obsessions and compulsions; range 0 to 20) can be added to produce a total severity score that ranges from 0 to 40. The severity scale is ideal for measuring treatment progress across time.",
"   </p>",
"   <p>",
"    Numerous patient self-report instruments are available for assessing OCD symptoms. One of the newest and most carefully developed is the Dimensional Obsessive-compulsive Scale (DOCS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/11\">",
"     11",
"    </a>",
"    ]. The DOCS is a 20-item self-report measure that assesses the severity of the four most consistently replicated dimensions of OCD symptoms (which correspond to four subscales):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contamination",
"     </li>",
"     <li>",
"      Responsibility for harm and mistakes",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Symmetry/ordering",
"      </span>",
"     </li>",
"     <li>",
"      Unacceptable thoughts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The DOCS subscales are reliable and valid, and the measure is being translated into several languages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708007\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cognitive-behavioral model of OCD leads to specific targets for reducing OCD symptoms: effective treatment must help patients correct maladaptive beliefs and appraisals that lead to obsessional fear, and decrease avoidance and safety-seeking behaviors (eg, rituals) that prevent the self-correction of maladaptive beliefs. The task of CBT is thus to foster an evaluation of obsessional stimuli as non-threatening and not demanding of further action (compulsions such as avoidance or rituals). Patients must come to understand their problem not in terms of the risk of feared consequences, but in terms of how they are thinking and behaving in response to stimuli that objectively pose a low risk of harm. Those with aggressive obsessions must view their problem as lending too much significance to meaningless intrusive thoughts, instead of how they are going to achieve the ultimate guarantee that feared consequences will not occur.",
"   </p>",
"   <p>",
"    As an example, a patient with washing rituals must see his or her problem not as needing a sure-fire way to prevent contamination and infectious illness, but as the need to change how he or she evaluates and responds to a situation that realistically poses a low risk of illness.",
"   </p>",
"   <p>",
"    CBT for OCD includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychoeducation",
"     </li>",
"     <li>",
"      Exposure and response prevention",
"     </li>",
"     <li>",
"      Cognitive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CBT is a skills-based approach. Each treatment session has a fairly specific agenda, and patients are expected to complete &ldquo;homework&rdquo; practice assignments to reinforce the skills learned in the sessions. The therapist functions as a coach, teaching the patient how to understand his or her OCD symptoms, as well as how to use the treatment techniques to reduce obsessional fears and compulsive rituals. An important principle for clinicians and patients is that unwanted (obsessional) thoughts are normal and universal. Therefore, it is not the aim of therapy to make these thoughts go away; rather the aim is to change how the person understands and responds to these intrusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708014\">",
"    <span class=\"h3\">",
"     Treatment planning and psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before active treatment commences, the therapist educates the patient about the conceptual model of OCD. The patient is also given a clear explanation for how CBT is expected to be helpful in reducing OCD. Such education is an important step in therapy because it helps to motivate the patient to tolerate the distress that typically accompanies exposure practice. A helpful rationale includes information about how CBT involves the provocation and reduction of distress during prolonged exposure. Information gathered during the assessment sessions is then used to plan, collaboratively with the patient, the specific exposure exercises that will be pursued. (See",
"    <a class=\"local\" href=\"#H11707977\">",
"     'Theoretical foundation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to explaining and planning a hierarchy of exposure exercises, the educational stage of ERP must also acquaint the patient with response prevention procedures. Importantly, the term &ldquo;response prevention&rdquo; does not imply that the therapist actively prevents the patient from performing rituals. Rather, the therapist helps the patient resist his or her ritualistic urges. Self-monitoring of rituals is often used in support of this goal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708021\">",
"    <span class=\"h3\">",
"     Exposure and response prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most essential component of CBT for OCD is therapist-guided repeated and prolonged exposure to situations that provoke obsessional fear along with abstinence from compulsive behaviors (response prevention). This might occur in the form of repeated actual confrontation with feared low-risk situations (ie, in vivo exposure), or in the form of imaginal confrontation with the feared disastrous consequences of confronting the low-risk situations (imaginal exposure).",
"   </p>",
"   <p>",
"    As examples, an individual who fears accidentally hitting pedestrians while driving her car would practice driving on streets with pedestrians without getting out of the car to check the roadside for victims. A person with repeated checking that the door is locked would practice leaving home after rapidly closing and locking the front door.",
"   </p>",
"   <p>",
"    Response prevention is a critical component of treatment because the performance of rituals to reduce obsessional anxiety would prematurely curtail exposure and rob the patient of learning that the obsessional situation is not truly dangerous, and that the anxiety would naturally subside on its own. Effective exposure and response prevention requires that the patient remain in the exposure situation until the obsessional distress decreases spontaneously, without attempting to reduce the distress by withdrawing from the situation or by performing compulsive rituals or neutralizing strategies.",
"   </p>",
"   <p>",
"    The exposure exercises typically follow a hierarchy beginning with moderately distressing situations, stimuli, and images, and gradually working up to the most distressing situations. Starting exercises that are less evocative of anxiety increases the likelihood that the patient will learn to manage their distress and complete the exposure exercise successfully. Success with initial exposures increases confidence in the treatment and helps motivate the patient to persevere during later, more difficult, exercises. At the end of each treatment session, the therapist instructs the patient to continue exposure without the therapist for several hours and in different environments between sessions. Exposure to the most anxiety-evoking situations is not left to the end of the treatment, but rather, is practiced about mid-way through the schedule of exposure tasks. This allows the patient opportunity to repeat exposure to the most difficult situations in different contexts to allow generalization of treatment effects. During the later treatment sessions, the therapist emphasizes the importance of continuing to apply the CBT procedures learned during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708028\">",
"    <span class=\"h3\">",
"     Cognitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive therapy techniques are best used to augment exposure and response prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/12\">",
"     12",
"    </a>",
"    ]. Specifically, they can help address strongly held, mistaken beliefs about obsessional thoughts so that the patient can engage in and better profit from exposure. Various techniques are used to help patients correct their erroneous beliefs and appraisals in cognitive therapy, such as didactic presentation of educational material and Socratic dialogue aimed at helping patients recognize and correct dysfunctional thinking patterns. &ldquo;Behavioral experiments,&rdquo; in which the patient enters and observes situations that exemplify their fears, are often used to facilitate the collection of information that will allow patients to revise their judgments about the degree of risk associated with obsessions.",
"   </p>",
"   <p>",
"    Specific cognitive techniques used in the treatment of OCD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The &ldquo;pie technique&rdquo; involves the patient giving an initial estimate of the percent responsibility that would be attributable to them if a feared consequence were to occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/13\">",
"       13",
"      </a>",
"      ]. The patient then generates a list of the parties that would have some responsibility for the feared consequence, in addition to the patient himself or herself. The patient and therapist then draw a pie chart, each slice representing one of the responsible parties identified. Next, patient labels all parties&rsquo; slices according to their percent responsibility and labels the slice representing",
"      <span class=\"nowrap\">",
"       himself/herself",
"      </span>",
"      last. By the exercise&rsquo;s end, it is typically clear to patients that the majority of the responsibility for the feared event would not be their own.",
"     </li>",
"     <li>",
"      The &ldquo;cognitive continuum technique&rdquo; involves the patient rating how immoral he or she perceives him or herself to be for having unacceptable intrusive obsessional thoughts (eg, of blasphemy or sexual or violent themes). Next, patient rates the morality level of other individuals who have committed acts of varying degrees of immorality (eg, a serial rapist, abusive parents). Then, patients re-rate themselves and reevaluate how immoral they are for simply experiencing intrusive thoughts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cognitive therapy should not be used to challenge the validity of the content of the patient&rsquo;s obsessional thoughts, but rather to challenge the patient&rsquo;s appraisal of the obsession&rsquo;s meaning. As an example, a patient with obsessional intrusions of molesting children would not use cognitive therapy to evaluate whether he or she is likely to act on this thought, but rather to evaluate the proper way to appraise the obsession (eg, as a normally occurring intrusive thought that is likely meaningless).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708035\">",
"    <span class=\"h3\">",
"     Assessing treatment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to informally assessing progress, evaluation of treatment outcome should include re-administration of symptom measures (eg, Y-BOCS or DOCS). Most patients will report some residual symptoms following even a successful course of CBT. Emphasize that &ldquo;normal&rdquo; obsessions and rituals are a part of everyday life for most people, so such experiences will never completely be absent. However, the goal of treatment is to help the patient respond to obsessional stimuli in new and healthy ways. Distress and functional impairment can be minimized with continued practice of the skills learned in treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261701708\">",
"    <span class=\"h3\">",
"     Frequency and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT can be delivered on an outpatient basis (eg, weekly or twice weekly), on an intensive basis (daily outpatient treatment sessions), or in residential (inpatient) settings depending on the severity of the problem and scheduling constraints. Clinical experience suggests that more frequent sessions are necessary when patients have difficult adhering to exposure and response prevention instructions between sessions. Because of the extreme heterogeneity of OCD symptoms, individual therapy is preferable to group treatment.",
"   </p>",
"   <p>",
"    The format we have found most useful is a few hours of assessment, treatment planning, and psychoeducation, followed by 16 twice-weekly treatment sessions, lasting about 90 to 120 minutes each, over about eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/14\">",
"     14",
"    </a>",
"    ]. Depending on the patient&rsquo;s symptom presentation and the practicality of confronting actual feared situations, treatment sessions might involve varying amounts of actual and imaginal exposure practice. Cognitive therapy techniques are used to challenge strongly held, mistaken beliefs about obsessional thoughts and &ldquo;set the table&rdquo; for exposure exercises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708042\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of eight randomized trials with 241 patients with OCD found that cognitive, behavioral, and cognitive-behavioral psychotherapies led to greater reduction in OCD symptoms than treatment as usual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/15\">",
"     15",
"    </a>",
"    ]. The therapies lead to average symptom reduction between 50 and 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;Several of these trials studied a combination of exposure and response prevention along with cognitive restructuring, but others studied a cognitive or behavioral therapy alone. Results did not vary by type of cognitive or behavioral psychotherapy, nor by delivery in individual versus group formats.",
"   </p>",
"   <p>",
"    A review of 12 trials of 330 patients with OCD found that 83 percent of patients responded to exposure-based CBT; response was defined as at least a 30 percent improvement from baseline. A review of 16 studies reporting on longer-term results (an average of 29 months from the start of treatment) found that 76 percent of patients continued to show reduced symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/17\">",
"     17",
"    </a>",
"    ]. Meta-analyses of clinical trials have also shown reductions in comorbid anxiety and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Open trials suggest that exposure therapy results in comparable improvement in OCD outside the mental health specialty sector in samples lacking the exclusion criteria often used in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analytic review of over 20 studies found additional relationships between CBT and treatment outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Better short and long-term outcomes are achieved when treatment involves in-session exposure practice supervised by a therapist, compared to when all exposure is performed by patient as homework assignments. The number of hours of therapist-directed exposure is positively correlated with outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combining situational (in vivo) and imaginal exposure has led to greater symptom reduction than situational exposure alone.",
"     </li>",
"     <li>",
"      Programs in which patients completely refrain from rituals during the treatment period (ie, complete response prevention) produce superior immediate and long-term effects compared to those that involve only partial response prevention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/18\">",
"       18",
"      </a>",
"      ]. Although complete response prevention is recommended as a goal, partial response prevention might be required at first.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10265793\">",
"    <span class=\"h3\">",
"     Predictors of improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;While CBT is effective for most OCD patients, about 25 to 30 percent of patients drop out of therapy prematurely, and among those who remain in treatment, about 25 percent do not show satisfactory improvement.",
"   </p>",
"   <p>",
"    Clinical trials have identified factors associated with a lesser response to CBT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with poor insight into the senselessness and excessiveness of their OCD symptoms. During exposure exercises, these patients appear to have difficulty learning information that is inconsistent with their OCD beliefs. Their fears may lead them to adhere less to instructions during exposure and response prevention compared to patients with better insight, leading to an attenuated response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies have found that severely depressed OCD patients, but not mildly or moderately depressed patients, have poorer CBT outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/22\">",
"       22",
"      </a>",
"      ]. It is believed that because of their high emotional reactivity, severely depressed individuals fail to undergo the decrease in",
"      <span class=\"nowrap\">",
"       anxiety/distress",
"      </span>",
"      that typically occurs following extended exposure to feared stimuli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/23\">",
"       23",
"      </a>",
"      ]. Thus, they do not have the therapeutic experience of feeling comfortable in the presence of feared stimuli, and therefore fail to learn that obsessive doubts are unrealistic. Motivational difficulties, which often accompany depression, may also account for poor treatment outcome.",
"     </li>",
"     <li>",
"      Patients with family members who are emotionally over involved, express hostility, or who are overly critical of the patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/24\">",
"       24",
"      </a>",
"      ]. When a family member is hostile, the most consistent predictor of negative treatment outcome, the odds of premature termination are about six times greater than when relatives are not hostile. Hostility is also associated with poorer response in patients who completed treatment. These findings underscore the importance of educating family members about OCD and its treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261701643\">",
"    <span class=\"h3\">",
"     Comparing medication and CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence suggests that cognitive behavioral therapy is more efficacious for OCD than treatment with a serotonin reuptake inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link&amp;anchor=H88195853#H88195853\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\", section on 'Comparing pharmacotherapy and psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11708049\">",
"    <span class=\"h3\">",
"     Combining medication and CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited study has not found combined CBT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    to be more efficacious than chlorimipramine alone. D-cycloserine, a partial agonist at the N-methyl-D-aspartate receptor, has shown evidence of efficacy when used to augment exposure therapy for OCD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link&amp;anchor=H88195842#H88195842\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\", section on 'Combining pharmacotherapy and psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10265860\">",
"    <span class=\"h1\">",
"     OTHER PSYCHOTHERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT using exposure and response prevention has been found to be more efficacious than other psychosocial interventions, including progressive muscle relaxation and anxiety management training for OCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/19\">",
"     19",
"    </a>",
"    ]. There have been no randomized trials testing psychodynamic or eclectic psychotherapy for OCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34391/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10266313\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive behavioral therapy (CBT) is indicated for obsessive-compulsive disorder (OCD) at all levels of symptom severity. However, CBT may be less useful for OCD patients with impaired cognition, poor insight, or severe comorbid psychiatric disorders, including severe depression, generalized anxiety, substance use disorders, and personality disorders. (See",
"      <a class=\"local\" href=\"#H11707914\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cognitive behavioral model for OCD proposes that intrusive thoughts, images, or impulses develop into highly distressing and time-consuming clinical obsessions when the intrusions are appraised as posing a threat for which the individual is personally responsible. Compulsions and related behaviors are conceptualized as maladaptive efforts to remove intrusions and to prevent feared consequences. (See",
"      <a class=\"local\" href=\"#H11707977\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT for OCD typically includes: patient and family education, cognitive restructuring, exposure therapy, and response prevention. (See",
"      <a class=\"local\" href=\"#H11708007\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive restructuring addresses strongly held, mistaken beliefs about obsessional thoughts. Patients are helped to interpret their obsessional thoughts as normally occurring intrusions, rather than personally meaningful or threatening images and ideas that need to be controlled or suppressed.",
"     </li>",
"     <li>",
"      Exposure and response prevention involves repeated and prolonged exposure to situations that provoke obsessional fear along with abstinence from compulsive behaviors, allowing the patient to learn that these situations are not harmful and that their anxiety will subside",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend CBT that includes exposure and response prevention, and when necessary to challenge strongly-held obsessional fears cognitive restructuring, to treat OCD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Multiple randomized trials have shown exposure-based CBT to lead to a greater reduction in OCD symptoms compared to control interventions. (See",
"      <a class=\"local\" href=\"#H11708042\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of CBT over medication for first-line treatment of OCD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). One rigorous, randomized trial has found that exposure and response prevention led to greater OCD symptom reduction than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/20/43336?source=see_link\">",
"       clomipramine",
"      </a>",
"      . Serotonin reuptake inhibitors (SRI), including the selective serotonin reuptake inhibitors (SSRIs), serotonin&ndash;norepinephrine reuptake inhibitors (SNRIs), or clomipramine, can be used if CBT is unavailable, not indicated, or if the patient prefers medication. (See",
"      <a class=\"local\" href=\"#H11708042\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link&amp;anchor=H88195853#H88195853\">",
"       \"Pharmacotherapy for obsessive-compulsive disorder\", section on 'Comparing pharmacotherapy and psychotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Based on our clinical experience, combined CBT and an SRI medication should be used for patients with severe OCD or if the patient&rsquo;s symptoms do not improve in response to monotherapy. The use of combined treatment for OCD requires further study. One comparative trial found no difference between monotherapy and combined treatment. However, patients were not selected for the trial based on severity of illness or treatment history. (See",
"      <a class=\"local\" href=\"#H11708042\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link&amp;anchor=H88195842#H88195842\">",
"       \"Pharmacotherapy for obsessive-compulsive disorder\", section on 'Combining pharmacotherapy and psychotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/1\">",
"      Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009; 374:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/2\">",
"      Foa EB, Abramowitz JS, Franklin ME, Kozak MJ. Feared consequences, fixity of belief, and treatment outcome in patients with obsessive-compulsive disorder. Behav Ther 1999; 30:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/3\">",
"      Abramowitz JS, Franklin ME, Schwartz SA, Furr JM. Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. J Consult Clin Psychol 2003; 71:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/4\">",
"      Abramowitz JS, Foa EB. Does comorbid major depressive disorder influence outcome of exposure and response prevention for OCD? Behav Ther 2000; 31:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/5\">",
"      Deacon BJ, Abramowitz JS. Patient&rsquo;s perception of pharmacological and cognitive-behavioral treatments for anxiety disorders. Beh Ther 2005; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/6\">",
"      Rachman S, de Silva P. Abnormal and normal obsessions. Behav Res Ther 1978; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/7\">",
"      Salkovskis P. Obsessional-compulsive problems: A cognitive-behavioral analysis. Beh Res Ther 1985; 23:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/8\">",
"      Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull 1986; 99:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/9\">",
"      Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/10\">",
"      Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/11\">",
"      Abramowitz JS, Deacon BJ, Olatunji BO, et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess 2010; 22:180.",
"     </a>",
"    </li>",
"    <li>",
"     Wilhelm S, Steketee G. Cognitive therapy for obsessive-compulsive disorder: A guide for professionals, New Harbinger, Oakland 2006.",
"    </li>",
"    <li>",
"     Clark, DA. Cognitive-behavioral therapy for OCD, Guilford Press, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/14\">",
"      Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003; 71:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/15\">",
"      Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2007; :CD005333.",
"     </a>",
"    </li>",
"    <li>",
"     Abramowitz, JS. Understanding and treating obsessive-compulsive disorder: A cognitive-behavioral approach, Erlbaum, Mahwah NJ 2006.",
"    </li>",
"    <li>",
"     Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Long-term treatments of anxiety disorders, Mavissakalian MR, Prien RF (Eds), American Psychiatric Press, Inc, Washington, DC 1996. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/18\">",
"      . Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Beh Ther 1996; 27:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/19\">",
"      Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/20\">",
"      Abramowitz J, Franklin M, Foa E. Empirical status of cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analytic review. Rom J Cog Behav Psychother 2002; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/21\">",
"      Franklin ME, Abramowitz JS, Kozak MJ, et al. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000; 68:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/22\">",
"      Abramowitz JS, Franklin ME, Street G, et al.. Effects of comorbid depression on response to treatment for obsessive-compulsive disorder. Beh Ther 2000; 31:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/23\">",
"      Foa EB. Failure in treating obsessive-compulsives. Behav Res Ther 1979; 17:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34391/abstract/24\">",
"      Chambless DL, Steketee G. Expressed emotion and behavior therapy outcome: a prospective study with obsessive-compulsive and agoraphobic outpatients. J Consult Clin Psychol 1999; 67:658.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14636 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34391=[""].join("\n");
var outline_f33_37_34391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10266313\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11707907\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10265636\">",
"      COGNITIVE BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11707914\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11707977\">",
"      Theoretical foundation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11707991\">",
"      - Proposed mechanisms of CBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11707999\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11708007\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11708014\">",
"      - Treatment planning and psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11708021\">",
"      - Exposure and response prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11708028\">",
"      - Cognitive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11708035\">",
"      - Assessing treatment outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261701708\">",
"      - Frequency and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11708042\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10265793\">",
"      - Predictors of improvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261701643\">",
"      - Comparing medication and CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11708049\">",
"      - Combining medication and CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10265860\">",
"      OTHER PSYCHOTHERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10266313\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14636|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/7/11378\" title=\"figure 1\">",
"      Yale Brown OCD rating scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30678?source=related_link\">",
"      Deep brain stimulation for treatment of obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=related_link\">",
"      Obsessive-compulsive disorder in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34392="SLE Tubuloreticular";
var content_f33_37_34392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tubuloreticular inclusions in lupus nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in diffuse proliferative lupus nephritis shows massive subendothelial deposits (D) and characteristic tubuloreticular structures (arrow) in the endothelial cells (En). The subendothelial deposits cause marked thickening of the glomerular capillary wall, leading to a wire loop appearance on light microscopy.",
"    <div class=\"footnotes\">",
"     Ep: epithelial cell; GBM: glomerular basement membrane.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34392=[""].join("\n");
var outline_f33_37_34392=null;
var title_f33_37_34393="Nonimmune hydrops fetalis";
var content_f33_37_34393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonimmune hydrops fetalis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Svena Julien, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34393/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/37/34393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrops fetalis refers to the presence of two or more of the following abnormal fetal fluid collections:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Pericardial effusion",
"     </li>",
"     <li>",
"      Skin edema",
"     </li>",
"     <li>",
"      Polyhydramnios",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonimmune hydrops fetalis (NIHF) comprises the subgroup of cases not caused by red cell alloimmunization (eg, Rh(D), Kell).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread use of Rh(D) immune globulin has dramatically decreased the prevalence of Rh(D) alloimmunization and associated hydrops. As a result, NIHF now accounts for almost 90 percent of hydrops cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of NIHF ranges from",
"    <span class=\"nowrap\">",
"     1/1500",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/3800",
"    </span>",
"    births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Wide variations in reported incidence are due to differences in definitions, populations, and thoroughness of evaluation, as well as whether late pregnancy terminations were included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of NIHF remains unclear, and likely depends, in part, on the underlying disorder. In the fetus, fluid homeostasis within the vascular and interstitial compartments is controlled by both hydrostatic and osmotic pressures as demonstrated by the Starling equation. Cellular mechanisms including the presence of aquaporin (membrane proteins) and the extracellular glycocalyx within the membrane serve to regulate fluid movement and contribute to the &ldquo;Starling forces.&rdquo; NIHF is the result of dysregulation of the net fluid movement between the vascular and interstitial spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/6\">",
"     6",
"    </a>",
"    ]. It is therefore the end result of one or more of the following abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructed lymphatic drainage in the thoracic and abdominal cavities (eg, congenital anomaly, neoplasm);",
"     </li>",
"     <li>",
"      Increased capillary permeability (eg, infection);",
"     </li>",
"     <li>",
"      Increased venous pressure due to myocardial failure or obstructed venous return to the heart;",
"     </li>",
"     <li>",
"      Reduction in osmotic pressure (eg, liver disease, nephropathy, non-immune mediated anemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, studies in humans and animal models have shown that plasma levels of atrial natriuretic factor and aldosterone are abnormal in the hydropic fetus, although a cause and effect relationship between these substances and hydrops has yet to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further investigation is needed to understand the complex interplay between fetal myocardial function, maintenance of intravascular volume, neural and circulating plasma proteins and hormones, and to explain how each factor contributes to hydrops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women carrying a hydropic fetus may have uterine size large for dates and they may notice decreased fetal movement. Up to 35 percent of hydropic fetuses are discovered incidentally during prenatal sonography.",
"   </p>",
"   <p>",
"    Although hydrops is a fetal condition, in many cases there are associated maternal findings, such as theca lutein cysts, preeclampsia, anemia, preterm",
"    <span class=\"nowrap\">",
"     labor/delivery,",
"    </span>",
"    birth trauma, retained placenta, and postpartum hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mirror syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mirror syndrome (also called Ballantynes syndrome) refers to a condition of generalized maternal edema, often with pulmonary involvement, that 'mirrors' the edema of the hydropic fetus and placenta. Although usually associated with NIHF, it can also occur with immune-mediated hydrops. The pathogenesis is unknown. One hypothesis is that the hydropic placenta causes a systemic inflammatory response as a result of increased shedding of trophoblastic debris into maternal blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/11\">",
"     11",
"    </a>",
"    ]. Others have postulated that the hydropic placenta may increase production of soluble fms&ndash;like tyrosine kinase (sFlt1), which is an important mediator of maternal endothelial and vascular abnormalities in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mirror syndrome can occur at any time during the antepartum period and may persist postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/13\">",
"     13",
"    </a>",
"    ]. It may present with rapid weight gain, increasing peripheral edema, and progressive shortness of breath, or with a clinical presentation and course similar to that of severe preeclampsia. In contrast to preeclampsia, the maternal hematocrit is often low (hemodilution) rather than high (hemoconcentration), amniotic fluid volume is often high (polyhydramnios) rather than low (oligohydramnios), and the fetus always shows signs of hydrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delivery is usually required to induce remission of maternal symptoms, which can be life-threatening. However, interventions that result in reversal of fetal hydrops can also reverse the maternal disorder, thereby allowing prolongation of the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Spontaneous resolution of mirror syndrome has also been described after spontaneous resolution of fetal hydrops related to parvovirus infection and after fetal death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prenatal diagnosis of hydrops is established by ultrasound examination. An attempt to determine the etiology of the hydrops should be made at the time of diagnosis, since several etiologies are confirmed or excluded based upon ultrasound findings (eg, twin-to-twin transfusion, cardiac arrhythmias, structural anomalies known to be associated with NIHF) (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Disorders associated with hydrops'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ascites",
"      </strong>",
"      &mdash; An early sign of hydrops is outlining of intraabdominal organs, such as the liver and bladder, by a thin rim of fluid. Sonographic images of the fetal abdomen may reveal fetal ascites, which in its early stage appears as a rim of echolucent fluid just inside the abdominal wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62798 \" href=\"mobipreview.htm?7/10/7331\">",
"       image 1",
"      </a>",
"      ). It is important to distinguish early ascites from pseudoascites, which is actually a hypoechoic band comprised of abdominal wall muscles. With larger amounts of ascites, the bowel may appear compressed (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56150 \" href=\"mobipreview.htm?25/28/26048\">",
"       image 2",
"      </a>",
"      ), and its walls accentuated due to increased ultrasound transmission afforded by the excess intraabdominal fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/4,19\">",
"       4,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pleural effusions",
"      </strong>",
"      &mdash; In the thorax, pleural effusions may be visualized outlining the lungs, just inside the chest wall. Pleural effusions may be unilateral or bilateral, with compression of lung tissue (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54321 \" href=\"mobipreview.htm?14/32/14848\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70095 \" href=\"mobipreview.htm?5/1/5151\">",
"       image 4",
"      </a>",
"      ). Long-standing effusions developing prior to 20 weeks of gestation may retard the growth and development of lung tissue, which leads to pulmonary hypoplasia, a common cause of neonatal mortality in these infants. A variety of techniques for prenatal diagnosis of severe pulmonary hypoplasia have been reported, but none are consistently reliable.",
"     </li>",
"     <li>",
"      <strong>",
"       Pericardial effusions",
"      </strong>",
"      &mdash; Pericardial effusions may be difficult to visualize with standard two-dimensional (2D) images (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53761 \" href=\"mobipreview.htm?8/30/8672\">",
"       image 5",
"      </a>",
"      ). It is important not to mistake physiologic pericardial fluid or the hypoechoic myocardium for an abnormal effusion. Use of M-Mode helps to measure pericardial effusions accurately and differentiate between physiologic and pathologic pericardial fluid when the diagnosis is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/2\">",
"       2",
"      </a>",
"      ]. Generally, during second-trimester fetal ultrasonographic examination, visualization of pericardial fluid up to 2 mm is common and should not be regarded as pathologic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/20\">",
"       20",
"      </a>",
"      ], and even fluid up to 7 mm may be benign [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Skin edema",
"      </strong>",
"      &mdash; The presence of skin edema is a late sign of fetal hydrops (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61425 \" href=\"mobipreview.htm?24/36/25167\">",
"       image 6",
"      </a>",
"      ). Pathologic skin edema has been defined as subcutaneous tissue thickness on the chest or scalp greater than 5 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/22\">",
"       22",
"      </a>",
"      ]. Care must be taken to exclude fat as a cause of increased thickness of the scalp and posterior nuchal region.",
"     </li>",
"     <li>",
"      <strong>",
"       Polyhydramnios",
"      </strong>",
"      &mdash; Polyhydramnios is generally defined as an amniotic fluid index (AFI) greater than 24 cm or a maximum vertical pocket greater than 8 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/22\">",
"       22",
"      </a>",
"      ]. It is present in 40 to 75 percent of pregnancies complicated by NIHF and is often the initial indication for the sonographic evaluation of the pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"       \"Polyhydramnios\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Placentomegaly",
"      </strong>",
"      &mdash; The placenta also may appear abnormal. Placentomegaly may occur due to intravillous edema (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62303 \" href=\"mobipreview.htm?28/10/28832\">",
"       image 7",
"      </a>",
"      ). In general, a placental thickness of greater than 4 to 6 cm is considered abnormal and should prompt further investigation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. On the other hand, massive polyhydramnios can cause the placenta to appear thinned or compressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISORDERS ASSOCIATED WITH HYDROPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous disorders have been associated with NIHF (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ). The cause of hydrops can be determined antenatally in 50 to 85 percent of cases; most of the remaining cases are determined postnatally, although 5 to 8 percent are classified as idiopathic, even after an autopsy has been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/1\">",
"     1",
"    </a>",
"    ]. Common etiological categories of NIHF are listed below and several specific etiologies are discussed. Many other disorders have been described in case reports; a complete list is beyond the scope of this review. The proportion of hydrops cases attributable to each etiologic category depends, in part, on the gestational age at presentation. As an example, NIHF prior to 24 weeks of gestation is usually related to an aneuploidy, while cardiac (structural defects and rhythm disturbances), pulmonary, and infectious etiologies account for the majority of cases after 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common genetic etiology of hydrops is aneuploidy. However, a number of other inherited syndromes may be associated with hydrops fetalis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Aneuploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneuploidy is responsible for approximately 10 percent of NIHF cases (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ). The most common chromosomal cause of NIHF is monosomy X, which accounts for 42 to 67 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/27\">",
"     27",
"    </a>",
"    ]. Other aneuploidies associated with hydrops are Trisomy 21 (23 to 30 percent of cases), other forms of aneuploidy including Trisomy 13, 18, and 12 (10 percent of cases), tetraploidy and triploidy, and rare deletions and duplications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The mechanism for fluid accumulation in these fetuses may involve obstruction or incomplete formation of the lymphatic system in the neck (cystic hygroma) or abdomen, leading to lymphatic dysplasia. Other mechanisms include cardiac failure related to congenital heart disease (present in 15 to 25 percent of aneuploid fetuses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/29\">",
"     29",
"    </a>",
"    ] and Down syndrome associated congenital leukemia. The prognosis is poor, with a mortality rate approaching 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management depends upon the specific chromosomal anomaly and whether there is coexistent heart disease. In non-lethal aneuploidies, fetal and maternal surveillance for signs of decompensation and possible early delivery are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genetic syndromes and gene defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic syndromes causing fetal akinesia may result in hydrops. These include multiple pterygium syndrome, arthrogryposis multiplex congenita, congenital myotonic dystrophy, Pena Shokeir and Neu Laxova syndromes (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ). Pathogenesis may involve decreasing lymphatic flow and increasing intrathoracic pressure secondary to diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skeletal dysplasias involving the thorax, such as camptomelic dysplasia, short rib polydactyly syndromes, lethal chondrodysplasia, thanatophoric dysplasia, and homozygous achondroplasia, cause NIFH secondary to altered venous return and cardiac tamponade (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Single gene defects in which there is a prominent cystic hygroma and lymphatic dysplasia are associated with NIHF and include Familial Nuchal Bleb, Noonan's syndrome, acrocephalopolydactylous dysplasia (also known as Elejalde syndrome), thoracoabdominal syndrome and lymphedema distichiasis syndrome (",
"    <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Metabolic storage diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic storage diseases or lysosomal storage disease (LSD) comprise a heterogeneous group of autosomal recessive disorders that may present in the fetal period as NIHF. They account for 1 to 15 percent of cases of NIHF. These rare genetic disorders are due to lack of specific enzymes necessary to process various metabolites within the lysosome in organs such as the brain, heart, liver, and kidneys. The pathogenesis of hydrops is likely related to congestion of abdominal viscera from accumulation of these metabolites, leading to hepatitis and other organ damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/37\">",
"     37",
"    </a>",
"    ]. This process then leads to increased hydrostatic pressure, decreased oncotic pressure, and possibly cardiomyopathy and cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific therapy in the antenatal period; in utero death usually occurs. It is important to make an accurate diagnosis and offer genetic counseling, as the risk of recurrence in a future pregnancy may be as high as 1 in 4. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13177?source=see_link\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiovascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the cardiovascular system are responsible for as many as 40 percent of cases of NIHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"     28",
"    </a>",
"    ]. Numerous cardiac lesions have been implicated (",
"    <a class=\"graphic graphic_table graphicRef77350 \" href=\"mobipreview.htm?16/5/16475\">",
"     table 2",
"    </a>",
"    ), the three major subgroups are structural anomalies, arrhythmias, and vascular abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Structural",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly encountered cardiac lesions associated with hydrops are atrioventricular septal defect (AVSD), hypoplastic left and right heart, and isolated ventricular or atrial septal defects. Other less common anomalies include Tetralogy of Fallot and premature closure of the ductus arteriosus. Many of these lesions are also associated with aneuploidy. Fetal cardiac tumors are rare, but are often associated with hydrops, ventricular obstruction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most structural lesions are not amenable to in utero therapy and, in the setting of early-onset hydrops, the prognosis for these pregnancies is poor, with a mortality rate close to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients should be offered genetic counseling, as the recurrence risk of congenital cardiac defects is as high as 2 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tachyarrhythmias and bradyarrhythmias can lead to hydrops. The mechanism is believed to be high output cardiac failure with progressive venous congestion in the former, and low cardiac output in the latter.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tachyarrhythmia",
"      </strong>",
"      s &mdash; Tachyarrhythmias associated with NIHF include supraventricular tachycardia (most commonly), followed by atrial flutter, reentrant tachycardias (eg, Wolf-Parkinson-White syndrome), long QT, and ventricular tachycardia. Fetal tachyarrhythmias can often be treated by administration of rate controlling agents to the mother; however, in cases of hydrops, disturbances in the placental transfer may render therapy inadequate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. In such cases, the drugs can be administered directly to the fetus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24202?source=see_link\">",
"       \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In women with Graves disease, fetal tachycardia, particularly in combination with goiter, advanced bone age, poor growth, or craniosynostosis, suggests fetal hyperthyroidism from transplacental passage of maternal TSH receptor-stimulating antibody. Cardiac failure and hydrops may occur with severe disease.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"       Propylthiouracil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      can be given to the mother to treat affected fetuses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link\">",
"       \"Overview of thyroid disease in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bradyarrhythmias",
"      </strong>",
"      &mdash; One-half of persistent bradyarrhythmias are caused by structural abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/41\">",
"       41",
"      </a>",
"      ]. Complex congenital lesions that affect the AV nodal region result in anatomic interruptions in the conduction system leading to atrioventricular dissociation and bradycardia. The other one-half of persistent bradyarrhythmias are related to maternal autoimmune disorders in which maternal IgG antibodies cross the placenta and cause direct damage to fetal bundle of His and Purkinje fibers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Arteriovenous and venous malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorioangiomas of the placenta greater than 4 to 5 cm in diameter may lead to NIHF due to high output heart failure from arteriovenous shunting. This condition is difficult to treat. In case reports, intrauterine endoscopic laser coagulation of the feeding vessels has been attempted with success, but complications such as fetal bleeding, exsanguination, and death have also occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hydrops can also result from arteriovenous fistulas in other locations (eg, sacrococcygeal teratoma, neuroblastoma), large hemangiomas, umbilical cord aneurysms, or obstruction of the vena cava, portal vein, or femoral vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thoracic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic abnormalities account for up to 10 percent of hydrops; thoracic lesions associated with hydrops are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66844 \" href=\"mobipreview.htm?1/48/1803\">",
"     table 3",
"    </a>",
"    ). These lesions increase intrathoracic pressure and can obstruct venous return to the heart, leading to peripheral venous congestion, or they may obstruct the lymphatic duct, resulting in lymphedema. Interference with fluid exchange between the lung and amniotic cavity may also contribute to polyhydramnios.",
"   </p>",
"   <p>",
"    Fetal pleural effusions may be isolated or associated with hydrops, which confers a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/43\">",
"     43",
"    </a>",
"    ]. They can be related to aneuploidy (especially trisomy 21), structural malformations or tumors (eg, involving the heart, lungs, lymphatic system), congenital infection, and genetic syndromes (eg, Noonan, Opitz&ndash;Frias hypertelorism hypospadias syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall prognosis depends, in part, upon the gestational age at the time the lung lesion developed. The presence of persistent pleural effusions prior to 20 weeks of gestation can compromise lung growth and function, and thus is a poor prognostic sign. Unfortunately, the degree of pulmonary hypoplasia cannot be reliably determined sonographically.",
"   </p>",
"   <p>",
"    In fetuses with large pleural effusions, placement of a pleuroamniotic shunt may alleviate the increased intrathoracic pressure, thereby reducing the risk of pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/19,43,45,46\">",
"     19,43,45,46",
"    </a>",
"    ]. It may also reduce venous and lymphatic obstruction and allow hydrops to resolve. This approach is supported by systematic reviews that found the survival rate for fetuses with pleural effusion and hydrops who were shunted was significantly higher than for those who underwent expectant management (over 60 percent versus less than 25 percent survival, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, only uncontrolled observational data from case reports and small case series were available for review; no controlled trials have been performed.",
"   </p>",
"   <p>",
"    Needle aspiration of pleural effusions is generally not recommended, except as a prelude to shunting, because the fluid usually reaccumulates within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/5,48\">",
"     5,48",
"    </a>",
"    ]. Open fetal surgery for management of thoracic lesions potentially causing pulmonary hypoplasia or hydrops has been performed, but this type of intervention is investigational and only available at specialized centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"     28",
"    </a>",
"    ]. One small study of pleurodesis in 45 hydropic fetuses reported it was less effective than shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Primary lymphatic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary congenital pulmonary lymphangiectasis results from thoracic duct obstruction, while secondary congenital pulmonary lymphangiectasis is a consequence of thoracic masses or congenital heart defects or a component of one of the discrete syndromes discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/50\">",
"     50",
"    </a>",
"    ]. Primary congenital pulmonary lymphangiectasis leads to hydrops by reducing venous return or cardiac tamponade and may be treated by pleuroamniotic shunting at midgestation to prevent pulmonary hypoplasia. Generalized lymphangiectasis syndrome results from systemic lymphatic vessel ectasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/51\">",
"     51",
"    </a>",
"    ]. In this condition, subcutaneous and visceral lymphedema occurs concomitantly with chylothorax. Hydrops results from gastrointestinal protein loss, chylothorax and diffuse lymphatic leak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal fetal hemoglobin increases linearly during pregnancy, from about 10-11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at 17 weeks to 14-15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In isoimmunized pregnancies, one investigator found that hydrops occurred at hemoglobin levels 7 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    below the normal mean for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/52\">",
"     52",
"    </a>",
"    ] and another reported hydrops when hemoglobin was less than half the median value for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/53\">",
"     53",
"    </a>",
"    ]. In the latter series, all of the hydrops fetuses had hemoglobin values less than 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal anemia accounts for 10 to 27 percent of hydrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"     28",
"    </a>",
"    ]. It may be due to a variety of causes, including hemorrhage, hemolysis, defective red blood cell production, and production of abnormal hemoglobins. Specific conditions associated with fetal anemia are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62279 \" href=\"mobipreview.htm?38/36/39499\">",
"     table 4",
"    </a>",
"    ). The mechanism for hydrops is thought to be high output cardiac failure.",
"   </p>",
"   <p>",
"    Alpha-thalassemia major is the most common cause of NIHF among southeast Asians. Because there is no alpha globin chain production, affected fetuses have great difficulty in synthesizing a functional hemoglobin molecule. Gamma chains accumulate and form gamma-4 tetramers (hemoglobin Bart's); hemoglobin Bart's binds oxygen, but cannot release it to tissues because its affinity for oxygen is much greater than that of hemoglobin A. Hemoglobin electrophoresis will show greater than 80 percent hemoglobin Barts while the remaining hemoglobin will be of embryonic origin, with a small component of hemoglobin H (beta-4 tetramers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/23\">",
"     23",
"    </a>",
"    ]. The fetus may be severely anemic, and a peripheral slide will show nucleated red cells and target cells. Profound acidosis, hypoxia and hydrops develop early in the midtrimester, followed by intrauterine fetal demise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=see_link&amp;anchor=H25#H25\">",
"     \"Pathophysiology of alpha thalassemia\", section on 'Hydrops fetalis and hemoglobin Bart's'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some fetal anemias are transient; anemia associated with parvovirus infection is an example (see below). In these cases, hydrops may resolve spontaneously; however, when severe anemia persists, therapy with intrauterine transfusion can be offered. Platelets should be available at the time of blood sampling and transfusion since some fetuses may also be profoundly thrombocytopenic. Aggressive therapy and surveillance are warranted, as the prognosis is generally good. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36819?source=see_link\">",
"     \"Intrauterine fetal transfusion of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia secondary to massive fetomaternal transfusion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=see_link\">",
"     \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are responsible for 8 percent of NIHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/54\">",
"     54",
"    </a>",
"    ]. Parvovirus B19 is the most common infectious agent associated with hydrops. Other infections that have been associated with NIHF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TORCH pathogens (toxoplasmosis, rubella, cytomegalovirus, and herpes virus)",
"     </li>",
"     <li>",
"      Syphilis",
"     </li>",
"     <li>",
"      Varicella",
"     </li>",
"     <li>",
"      Adenovirus",
"     </li>",
"     <li>",
"      Coxsackievirus",
"     </li>",
"     <li>",
"      Leptospirosis",
"     </li>",
"     <li>",
"      Trypanosoma cruzi [Chagas disease]",
"     </li>",
"     <li>",
"      Listeria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all fetuses with these infections develop hydrops and causation has not been proven for all of these infections. In some cases, a causative organism may not be identified.",
"   </p>",
"   <p>",
"    The pathogenesis for hydrops related to infection is not well understood in most cases; parvovirus B19 (Fifth disease) is an exception. This virus attacks red blood cells, hepatocytes, and myocardial cells causing transient aplastic crisis, hepatitis, and myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/4,54-56\">",
"     4,54-56",
"    </a>",
"    ]. Since these processes are self-limited, the prognosis is generally good if the fetus is supported by intrauterine fetal transfusions until the disease remits. However, neurodevelopmental abnormalities have been reported in small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/57\">",
"     57",
"    </a>",
"    ]. Platelet concentrates should also be available since some fetuses may also be profoundly thrombocytopenic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link\">",
"     \"Parvovirus B19 infection during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the development of hydrops in fetuses with a TORCH infection reflects multisystem failure (eg, myocarditis leading to heart failure, and liver involvement leading to hypoalbuminemia) and is a poor prognostic indicator. Therapy in these cases is directed toward the infectious agents (",
"    <a class=\"graphic graphic_table graphicRef72575 \" href=\"mobipreview.htm?11/19/11580\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sonographic signs (in addition to hydrops) that suggest in utero infection include calcifications of the brain, liver, or pericardium; microcephaly; cerebral ventriculomegaly; hepatosplenomegaly; and growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gastrointestinal malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anomalies of the gastrointestinal tract associated with NIHF are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef50147 \" href=\"mobipreview.htm?6/55/7035\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"     28",
"    </a>",
"    ]. Ascites and polyhydramnios are characteristically observed with these disorders. More widespread edema may be present when the fetus is aneuploid. The prognosis is dependent upon the karyotype and the presence of other associated disorders (eg, cystic fibrosis).",
"   </p>",
"   <p>",
"    Isolated fetal ascites can also be due to lymphatic dysplasia, ovarian cysts (in female fetuses), or rupture of the urinary bladder (urinary ascites). These cases are not considered true hydrops since only one compartment is affected. Isolated ascites generally does not carry a poor prognosis unless there is compromise of the thoracic cavity leading to pulmonary hypoplasia or compromise of the developing kidney leading to renal dysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Genitourinary malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the genitourinary tract represent a very small proportion of NIHF. Disorders such as posterior urethral valves leading to prune belly syndrome may cause intraabdominal obstruction of venous return. Another rare disorder of renal function, congenital Finnish type nephrosis, leads to hypoproteinemia and NIHF from decreased colloid oncotic pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Twin gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monochorionic twin gestations are at risk for twin-to-twin transfusion syndrome (TTTS) and twin reversed arterial perfusion (TRAP). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .) In other twins, hydrops may develop in one or both twins from any of the etiologies described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732354720\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough search for the etiology of hydrops should be undertaken since it is associated with a broad spectrum of diseases. It is especially important to determine whether a potentially treatable condition is present, and to identify disorders with a risk of recurrence in future pregnancies.",
"   </p>",
"   <p>",
"    Components of an initial basic evaluation are listed below. Many of these tests are performed simultaneously, as the results of individual tests may not be available for several days to weeks, thus precluding sequential studies. However, whenever possible, it is preferable to proceed from the least to the most invasive test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a detailed history of the patient's ethnic background and personal and family history to look for heritable disorders associated with hydrops, such as alpha-thalassemia, metabolic disorders, and genetic syndromes. Consider referring the patient to a genetic counselor.",
"     </li>",
"     <li>",
"      Inquire about recent exposure to infectious agents. Parvovirus B19 is the most common infectious etiology of hydrops, accounting for about 15 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link\">",
"       \"Parvovirus B19 infection during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtain a detailed sonogram to look for major fetal structural abnormalities. A fetal echocardiogram is useful if there is any suspicion of a cardiac abnormality or arrhythmia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4968?source=see_link\">",
"       \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24202?source=see_link\">",
"       \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtain Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity. This procedure has emerged as an accurate noninvasive tool for predicting fetal anemia of any etiology (ie, immune or nonimmune) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/53,59\">",
"       53,59",
"      </a>",
"      ]. If abnormal, evaluate for causes of fetal anemia.",
"     </li>",
"     <li>",
"      Laboratory tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732354580\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732354587\">",
"    <span class=\"h3\">",
"     Maternal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with RBC indices. A mean corpuscular volume (MCV) &lt;80 fL in the absence of iron deficiency suggests thalassemia; additional studies are then required. Hemoglobin electrophoresis will identify carriers of hemoglobin variants and beta-thalassemia. In Asian couples, however, DNA-based genotyping is generally necessary to rule out alpha-thalassemia (hemoglobin electrophoresis is not recommended because it is nondiagnostic of alpha-thalassemia). If iron deficiency is present, the patient should receive iron supplementation and then be retested. The hemoglobin concentration will rise slowly, usually beginning after about one to two weeks of treatment, and will rise approximately 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      over the ensuing three weeks. The hemoglobin deficit should be halved by about one month and should return to normal by six to eight weeks.",
"      <br/>",
"      <br/>",
"      Alternatively, if the mother has a low MCV and iron studies suggest a mild depletion common to pregnancy, a rapid assessment of whether the fetus is at risk for an inherited hemoglobinopathy can be obtained by performing peripheral blood studies on the father of the baby. A MCV and hemoglobin electrophoresis will quickly assess the likelihood the partner is also a carrier of a hemoglobinopathy, and thus, whether the fetus is at risk for an inherited hemoglobinopathy as the etiology of the hydrops. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=see_link\">",
"       \"Prenatal testing for the hemoglobinopathies and thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood type and antibody screen. A positive screen for antibodies directed against RBC antigens suggests immune-mediated fetal anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=see_link\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologies (IgM and IgG for cytomegalovirus, toxoplasmosis, rubella, and parvovirus B19; nontreponemal test for syphilis). We do not obtain serology for herpes simplex virus (HSV) unless the patient has a history of primary genital HSV prior to onset of NIHF. In these cases, we prefer to send PCR of amniotic fluid and correlate with maternal serology. In asymptomatic women, there is a low yield from serology for varicella, adenovirus, coxsackie virus, and other less common infectious agents. We may obtain these tests as a last resort if no etiology for NIHF has been determined by other testing.",
"     </li>",
"     <li>",
"      Kleihauer-Betke acid elution stain to exclude the possibility of significant fetomaternal hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/23,60\">",
"       23,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732354594\">",
"    <span class=\"h3\">",
"     Fetal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the fetal karyotype by amniocentesis, chorionic villus biopsy, or fetal blood sampling (see individual topic reviews on these procedures). Fetuses with structural abnormalities are at particularly high risk of having an abnormal karyotype.",
"     </li>",
"     <li>",
"      In addition to maternal serology studies, PCR for TORCH pathogens, specifically CMV, parvovirus B19, and toxoplasmosis, is performed on fetal blood or amniotic fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/1,61\">",
"       1,61",
"      </a>",
"      ]. An additional 10 mL of fluid is needed for the PCR studies. The infectious disease work-up is guided by the patient's clinical history and results from routine studies for evaluation of NIHF. If a probable cause of NIHF is found, the infectious disease work-up is discontinued.",
"     </li>",
"     <li>",
"      If fetal blood is obtained by umbilical vein sampling, then the fetal hemoglobin concentration should also be determined to exclude anemia as a cause of hydrops.",
"     </li>",
"     <li>",
"      Amniotic fluid should also be frozen and stored in order to test for rare lysosomal storage diseases in the at-risk patient (consanguinity, previous family history, Ashkenazi Jewish or French Canadian descent) or after other investigations have been nondiagnostic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/19,37,62\">",
"       19,37,62",
"      </a>",
"      ]. Alternatively, cells can be cultured, frozen, and stored in case additional studies are required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;NIHF is associated with an overall perinatal mortality rate of 50 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/2,3,58,60,63-65\">",
"     2,3,58,60,63-65",
"    </a>",
"    ]. Despite advances in fetal diagnosis and therapy, the mortality rate has not changed very much over the past 15 years.",
"   </p>",
"   <p>",
"    Prognosis depends upon the etiology, the gestational age at onset, and whether pleural effusions are present. In general, the earlier hydrops occurs, the poorer the prognosis. In particular, pleural effusions and polyhydramnios prior to 20 weeks of gestation are poor prognostic signs because of increased risks of pulmonary hypoplasia and preterm",
"    <span class=\"nowrap\">",
"     labor/premature",
"    </span>",
"    rupture of membranes, respectively. On the other hand, absence of aneuploidy and absence of major structural abnormalities confer a better prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/61,66\">",
"     61,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management options include termination of the pregnancy, therapeutic intervention when possible, and supportive",
"    <span class=\"nowrap\">",
"     care/monitoring",
"    </span>",
"    of the mother and fetus in continuing pregnancies. Antenatal surveillance should include frequent non-stress testing or biophysical profile testing at least weekly with delivery if there is evidence of fetal or maternal decompensation (eg, mirror syndrome). Serial Doppler velocimetry of the middle cerebral artery is not useful in the absence of suspected fetal anemia. Antenatal consultations with relevant subspecialty services (eg, neonatology) should be obtained. Delivery should occur at a tertiary care center, with coordination of the obstetrical, maternal-fetal medicine, neonatal, and pediatric subspecialty teams. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At delivery, there is an increased risk of birth trauma due to soft tissue dystocia, postpartum hemorrhage, and retained placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"     28",
"    </a>",
"    ]. In utero aspiration of the pleural fluid or ascites prior to delivery may reduce the risk of dystocia and facilitate neonatal resuscitation. Cesarean birth should be reserved for routine obstetrical indications; however, the high frequency of nonreassuring fetal heart rate patterns and dystocia increases the likelihood of cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent NIHF depends upon the underlying etiology; therefore, every effort should be made to determine the cause of hydrops. In idiopathic cases, the risk of recurrence appears to be small, but recurrence has been reported in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34393/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Some of these early reports preceded the availability of tools for postmortem diagnosis of metabolic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrops fetalis is defined as the presence of two or more of the following abnormal fetal fluid collections: skin edema, pleural effusion, pericardial effusion, ascites, polyhydramnios. It may be caused by immune or nonimmune mediated processes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women carrying a hydropic fetus may have uterine size large for dates, they may notice decreased fetal movement, and they may develop generalized edema with or without preeclampsia (ie, mirror syndrome). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prenatal diagnosis of hydrops fetalis is established by ultrasound examination. An attempt to determine the etiology of the hydrops should be made at the time of diagnosis, since several etiologies are confirmed or excluded based upon ultrasound findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of nonimmune hydrops are heterogeneous and include aneuploidy, structural abnormalities, metabolic disorders, anemia, and infection (",
"      <a class=\"graphic graphic_table graphicRef70066 \" href=\"mobipreview.htm?36/24/37262\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disorders associated with hydrops'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to determine whether a potentially treatable cause of hydrops is present, and to identify disorders with a risk of recurrence in future pregnancies. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of these pregnancies includes (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A detailed history to look for heritable disorders and exposure to infection",
"     </li>",
"     <li>",
"      A detailed fetal sonogram, echocardiography, and Doppler velocimetry to look for anatomic, cardiac, and anemia-related causes of hydrops",
"     </li>",
"     <li>",
"      Laboratory evaluation, such as red blood cell antibody screen, mean corpuscular volume, Kleihauer-Betke, and appropriate tests to look for infection",
"     </li>",
"     <li>",
"      Fetal karyotype or chromosomal microarray",
"     </li>",
"     <li>",
"      DNA testing for specific genetic conditions based on family history, parental examination, or clinical suspicion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of hydrops is a poor prognostic indicator for perinatal survival. Management and intervention are dictated by the underlying disease process. Intervention on behalf of the fetus should be considered in cases of parvovirus B19 infection and fetal anemias amenable to intrauterine transfusion. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal-fetal medicine specialists and neonatologists should be involved in the management of these pregnancies. Careful surveillance of maternal status is important because of increased risks of preeclampsia, mirror syndrome, dystocia during labor, and postpartum hemorrhage. Delivery should occur at a tertiary care center with a neonatal intensive care unit. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis and management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/1\">",
"      Sohan K, Carroll SG, De La Fuente S, et al. Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment. Acta Obstet Gynecol Scand 2001; 80:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/2\">",
"      Carlson DE, Platt LD, Medearis AL, Horenstein J. Prognostic indicators of the resolution of nonimmune hydrops fetalis and survival of the fetus. Am J Obstet Gynecol 1990; 163:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/3\">",
"      Castillo RA, Devoe LD, Hadi HA, et al. Nonimmune hydrops fetalis: clinical experience and factors related to a poor outcome. Am J Obstet Gynecol 1986; 155:812.",
"     </a>",
"    </li>",
"    <li>",
"     Callen, P. Ultrasonography in Obstetrics and Gynecology, 4th ed, WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/5\">",
"      Anandakumar C, Biswas A, Wong YC, et al. Management of non-immune hydrops: 8 years' experience. Ultrasound Obstet Gynecol 1996; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/6\">",
"      Bellini C, Hennekam RC. Non-immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A 2012; 158A:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/7\">",
"      Moise KJ Jr, Carpenter RJ Jr, Hesketh DE. Do abnormal Starling forces cause fetal hydrops in red blood cell alloimmunization? Am J Obstet Gynecol 1992; 167:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/8\">",
"      Santolaya J, Alley D, Jaffe R, Warsof SL. Antenatal classification of hydrops fetalis. Obstet Gynecol 1992; 79:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/9\">",
"      Ville Y, Proudler A, Abbas A, Nicolaides K. Atrial natriuretic factor concentration in normal, growth-retarded, anemic, and hydropic fetuses. Am J Obstet Gynecol 1994; 171:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/10\">",
"      Ville Y, Proudler A, Kuhn P, Nicolaides KH. Aldosterone concentration in normal, growth-retarded, anemic, and hydropic fetuses. Obstet Gynecol 1994; 84:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/11\">",
"      Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000; 21:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/12\">",
"      Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 2006; 354:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/13\">",
"      Nakamura K, Itoh H, Sagawa N, et al. A case of peripartum cardiomyopathy with a transient increase of plasma interleukin-6 concentration occurred following mirror syndrome. J Perinat Med 2002; 30:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/14\">",
"      Vidaeff AC, Pschirrer ER, Mastrobattista JM, et al. Mirror syndrome. A case report. J Reprod Med 2002; 47:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/15\">",
"      van Selm M, Kanhai HH, Gravenhorst JB. Maternal hydrops syndrome: a review. Obstet Gynecol Surv 1991; 46:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/16\">",
"      Heyborne KD, Chism DM. Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med 2000; 45:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/17\">",
"      Pirhonen JP, Hartgill TW. Spontaneous reversal of mirror syndrome in a twin pregnancy after a single fetal death. Eur J Obstet Gynecol Reprod Biol 2004; 116:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/18\">",
"      Livingston JC, Malik KM, Crombleholme TM, et al. Mirror syndrome: a novel approach to therapy with fetal peritoneal-amniotic shunt. Obstet Gynecol 2007; 110:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/19\">",
"      Jones DC. Nonimmune fetal hydrops: diagnosis and obstetrical management. Semin Perinatol 1995; 19:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/20\">",
"      Dizon-Townson DS, Dildy GA, Clark SL. A prospective evaluation of fetal pericardial fluid in 506 second-trimester low-risk pregnancies. Obstet Gynecol 1997; 90:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/21\">",
"      Di Salvo DN, Brown DL, Doubilet PM, et al. Clinical significance of isolated fetal pericardial effusion. J Ultrasound Med 1994; 13:291.",
"     </a>",
"    </li>",
"    <li>",
"     Romero, R, Pilu G, Jeanty P, Ghidini A, Hobbins J. Prenatal Diagnosis of Congenital Anomalies. Appleton and Lange, Norwalk, CT 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/23\">",
"      Arcasoy MO, Gallagher PG. Hematologic disorders and nonimmune hydrops fetalis. Semin Perinatol 1995; 19:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/24\">",
"      Chitkara U, Wilkins I, Lynch L, et al. The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies. Obstet Gynecol 1988; 71:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/25\">",
"      Kessel I, Makhoul IR, Sujov P. Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Pediatrics 1999; 103:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/26\">",
"      Lallemand AV, Doco-Fenzy M, Gaillard DA. Investigation of nonimmune hydrops fetalis: multidisciplinary studies are necessary for diagnosis--review of 94 cases. Pediatr Dev Pathol 1999; 2:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/27\">",
"      Machin GA. Hydrops revisited: literature review of 1,414 cases published in the 1980s. Am J Med Genet 1989; 34:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/28\">",
"      Forouzan I. Hydrops fetalis: recent advances. Obstet Gynecol Surv 1997; 52:130.",
"     </a>",
"    </li>",
"    <li>",
"     Hess, DB, Hess LW. Fetal Echocardiography. Appleton and Lange, Stamford, CT, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/30\">",
"      Manning MA, Cunniff CM, Colby CE, et al. Neu-Laxova syndrome: detailed prenatal diagnostic and post-mortem findings and literature review. Am J Med Genet A 2004; 125A:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/31\">",
"      Toriello HV, Bauserman SC, Higgins JV. Sibs with the fetal akinesia sequence, fetal edema, and malformations: a new syndrome? Am J Med Genet 1985; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/32\">",
"      Zaki M, Boyd PA, Impey L, et al. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol 2007; 29:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/33\">",
"      Bieber FR, Petres RE, Bieber JM, Nance WE. Prenatal detection of a familial nuchal bleb simulating encephalocele. Birth Defects Orig Artic Ser 1979; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/34\">",
"      Thornton CM, Stewart F. Elejalde syndrome: a case report. Am J Med Genet 1997; 69:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/35\">",
"      Grethel EJ, Hornberger LK, Farmer DL. Prenatal and postnatal management of a patient with pentalogy of Cantrell and left ventricular aneurysm. A case report and literature review. Fetal Diagn Ther 2007; 22:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/36\">",
"      B&uuml;chner M, Dostert S, Falkert A, et al. Perinatal diagnosis of a lymphedema-distichiasis syndrome (LD). Prenat Diagn 2007; 27:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/37\">",
"      Molyneux AJ, Blair E, Coleman N, Daish P. Mucopolysaccharidosis type VII associated with hydrops fetalis: histopathological and ultrastructural features with genetic implications. J Clin Pathol 1997; 50:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/38\">",
"      Wraith JE. Lysosomal disorders. Semin Neonatol 2002; 7:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/39\">",
"      Yinon Y, Chitayat D, Blaser S, et al. Fetal cardiac tumors: a single-center experience of 40 cases. Prenat Diagn 2010; 30:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/40\">",
"      Crawford DC, Chita SK, Allan LD. Prenatal detection of congenital heart disease: factors affecting obstetric management and survival. Am J Obstet Gynecol 1988; 159:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/41\">",
"      Copel JA, Friedman AH, Kleinman CS. Management of fetal cardiac arrhythmias. Obstet Gynecol Clin North Am 1997; 24:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/42\">",
"      Sepulveda W, Wong AE, Herrera L, et al. Endoscopic laser coagulation of feeding vessels in large placental chorioangiomas: report of three cases and review of invasive treatment options. Prenat Diagn 2009; 29:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/43\">",
"      Yinon Y, Grisaru-Granovsky S, Chaddha V, et al. Perinatal outcome following fetal chest shunt insertion for pleural effusion. Ultrasound Obstet Gynecol 2010; 36:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/44\">",
"      Rustico MA, Lanna M, Coviello D, et al. Fetal pleural effusion. Prenat Diagn 2007; 27:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/45\">",
"      Picone O, Benachi A, Mandelbrot L, et al. Thoracoamniotic shunting for fetal pleural effusions with hydrops. Am J Obstet Gynecol 2004; 191:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/46\">",
"      Pellegrinelli JM, Kohler A, Kohler M, et al. Prenatal management and thoracoamniotic shunting in primary fetal pleural effusions: a single centre experience. Prenat Diagn 2012; 32:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/47\">",
"      Aubard Y, Derouineau I, Aubard V, et al. Primary fetal hydrothorax: A literature review and proposed antenatal clinical strategy. Fetal Diagn Ther 1998; 13:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/48\">",
"      Deurloo KL, Devlieger R, Lopriore E, et al. Isolated fetal hydrothorax with hydrops: a systematic review of prenatal treatment options. Prenat Diagn 2007; 27:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/49\">",
"      Yang YS, Ma GC, Shih JC, et al. Experimental treatment of bilateral fetal chylothorax using in-utero pleurodesis. Ultrasound Obstet Gynecol 2012; 39:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/50\">",
"      Stevenson DA, Pysher TJ, Ward RM, Carey JC. Familial congenital non-immune hydrops, chylothorax, and pulmonary lymphangiectasia. Am J Med Genet A 2006; 140:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/51\">",
"      Wieacker P, Muschke P, Pollak KH, M&uuml;ller R. Autosomal recessive non-immune hydrops fetalis caused by systemic lymphangiectasia. Am J Med Genet A 2005; 132A:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/52\">",
"      Nicolaides KH, Soothill PW, Clewell WH, et al. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet 1988; 1:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/53\">",
"      Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/54\">",
"      Xu J, Raff TC, Muallem NS, Neubert AG. Hydrops fetalis secondary to parvovirus B19 infections. J Am Board Fam Pract 2003; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/55\">",
"      Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol 1995; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/56\">",
"      von Kaisenberg CS, Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/57\">",
"      Nagel HT, de Haan TR, Vandenbussche FP, et al. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007; 109:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/58\">",
"      Ismail KM, Martin WL, Ghosh S, et al. Etiology and outcome of hydrops fetalis. J Matern Fetal Med 2001; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/59\">",
"      Borna S, Mirzaie F, Hanthoush-Zadeh S, et al. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J Clin Ultrasound 2009; 37:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/60\">",
"      Graves GR, Baskett TF. Nonimmune hydrops fetalis: antenatal diagnosis and management. Am J Obstet Gynecol 1984; 148:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/61\">",
"      McCoy MC, Katz VL, Gould N, Kuller JA. Non-immune hydrops after 20 weeks' gestation: review of 10 years' experience with suggestions for management. Obstet Gynecol 1995; 85:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/62\">",
"      Burin MG, Scholz AP, Gus R, et al. Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. Prenat Diagn 2004; 24:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/63\">",
"      Heinonen S, Ryyn&auml;nen M, Kirkinen P. Etiology and outcome of second trimester non-immunologic fetal hydrops. Acta Obstet Gynecol Scand 2000; 79:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/64\">",
"      Wy CA, Sajous CH, Loberiza F, Weiss MG. Outcome of infants with a diagnosis of hydrops fetalis in the 1990s. Am J Perinatol 1999; 16:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/65\">",
"      Santo S, Mansour S, Thilaganathan B, et al. Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? Prenat Diagn 2011; 31:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/66\">",
"      Iskaros J, Jauniaux E, Rodeck C. Outcome of nonimmune hydrops fetalis diagnosed during the first half of pregnancy. Obstet Gynecol 1997; 90:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/67\">",
"      Schwartz SM, Viseskul C, Laxova R, et al. Idiopathic hydrops fetalis report of 4 patients including 2 affected sibs. Am J Med Genet 1981; 8:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/68\">",
"      Cumming DC. Recurrent nonimmune hydrops fetalis. Obstet Gynecol 1979; 54:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34393/abstract/69\">",
"      Etches PC, Lemons JA. Nonimmune hydrops fetalis: report of 22 cases including three siblings. Pediatrics 1979; 64:326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6794 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34393=[""].join("\n");
var outline_f33_37_34393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mirror syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISORDERS ASSOCIATED WITH HYDROPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genetic syndromes and gene defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Metabolic storage diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiovascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Structural",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Arteriovenous and venous malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thoracic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Primary lymphatic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gastrointestinal malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Genitourinary malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Twin gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732354720\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732354580\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H732354587\">",
"      - Maternal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H732354594\">",
"      - Fetal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6794|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/10/7331\" title=\"diagnostic image 1\">",
"      Fetal ascites transverse view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/28/26048\" title=\"diagnostic image 2\">",
"      Fetal ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/32/14848\" title=\"diagnostic image 3\">",
"      Fetal pleural effusion unilater",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/1/5151\" title=\"diagnostic image 4\">",
"      Bilateral fetal pleural effusio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/30/8672\" title=\"diagnostic image 5\">",
"      Fetal pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/36/25167\" title=\"diagnostic image 6\">",
"      Fetal skin edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/10/28832\" title=\"diagnostic image 7\">",
"      Placentomegaly and ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/24/37262\" title=\"table 1\">",
"      Causes nonimmune hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/5/16475\" title=\"table 2\">",
"      Cardiac defects causing hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/48/1803\" title=\"table 3\">",
"      Thoracic defects causing hydrop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/36/39499\" title=\"table 4\">",
"      Hematologic causes of NHF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/19/11580\" title=\"table 5\">",
"      Infections causes of hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/55/7035\" title=\"table 6\">",
"      GI defects causing hydrops",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13177?source=related_link\">",
"      Inborn errors of metabolism: Identifying the specific disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36819?source=related_link\">",
"      Intrauterine fetal transfusion of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=related_link\">",
"      Parvovirus B19 infection during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34394="Overview of the possible risk factors for cardiovascular disease";
var content_f33_37_34394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the possible risk factors for cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Peter WF Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/37/34394/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/37/34394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10122097\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is common in the general population, affecting the majority of adults past the age of 60 years. As a diagnostic category, CVD includes four major areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD), manifested by myocardial infarction (MI), angina pectoris, heart failure, and coronary death",
"     </li>",
"     <li>",
"      Cerebrovascular disease, manifested by stroke and transient ischemic attack",
"     </li>",
"     <li>",
"      Peripheral artery disease, manifested by intermittent claudication",
"     </li>",
"     <li>",
"      Aortic atherosclerosis and thoracic or abdominal aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CHD accounts for approximately one-third to one-half of the total cases of CVD. The lifetime risk of CHD was illustrated in the Framingham Heart Study of 7733 participants, ages 40 to 94, who were initially free of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/1\">",
"     1",
"    </a>",
"    ]. The lifetime risk for individuals at age 40 was 49 percent in men and 32 percent in women. Even those who were free from CHD at age 70 had a non-trivial lifetime risk of developing CHD (35 percent and 24 percent in men and women, respectively).",
"   </p>",
"   <p>",
"    Death rates from CVD, CHD, and stroke have declined in the United States since 1975, and evidence from 2000 to 2008 shows a decline in CHD mortality across all major",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups (",
"    <a class=\"graphic graphic_figure graphicRef83599 \" href=\"mobipreview.htm?36/26/37294\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83597 \" href=\"mobipreview.htm?13/58/14254\">",
"     figure 2",
"    </a>",
"    ). CVD and its related complications remain highly prevalent and expensive to treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/2\">",
"     2",
"    </a>",
"    ]. CVD is the leading cause of death in most developed countries, with approximately one million Americans annually dying from CVD. The prevalence of CVD is rapidly increasing in developing countries as well.",
"   </p>",
"   <p>",
"    Many risk factors for cardiovascular disease are modifiable by specific preventive measures. In the worldwide INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population-attributable risk of a first MI: smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, psychosocial factors, daily consumption of fruits and vegetables, regular alcohol consumption, and regular physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with CVD have at least one established or borderline risk factor other than age and gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, it is clear that there are other risk factors, not all treatable, that may be important. The additive value of screening for these risk factors has not been firmly established, and there is only limited evidence that targeted therapeutic intervention will reduce the risk associated with these factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the possible emerging CVD risk factors is presented here. An overview of the established risk factors for CVD, data supporting the importance of the individual risk factors (eg, hyperlipidemia, hypertension, smoking), coronary risk factors of particular importance in women and in young patients, and estimation of coronary risk in an individual patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hypertension in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265268\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122160\">",
"    <span class=\"h2\">",
"     Arterial intima-media thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common carotid and femoral artery intima-media thickness (IMT) are linked to the atherosclerotic process because of their association with known cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Intima-media thickness is a noninvasive marker of early, preclinical atherosclerosis in high-risk children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4873728#H4873728\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Risk factors in childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adult population studies, there was a moderate, graded positive relationship between carotid IMT and the presence of coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/9\">",
"     9",
"    </a>",
"    ]. Increased carotid IMT also correlated with a gradual, graded increase in the risk of future cardiovascular events, but the magnitude of the relationship lessened when traditional risk factors were taken into account [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/9,12-17\">",
"     9,12-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two systematic reviews and meta-analyses have reached different conclusions regarding the impact of carotid IMT on risk assessment over and above the usual risk factors or risk scores.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 meta-analysis of eight cohort studies (37,197 patients), each 0.10 mm increase in common carotid IMT was associated with a relative risk of 1.15 (95% CI 1.12-1.17) for MI and 1.18 (95%CI 1.16-1.21) for stroke after adjusting for age and sex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2012 meta-analysis of 14 cohort studies (45,828 patients), increases in common carotid IMT were associated with greater risks of MI and stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/18\">",
"       18",
"      </a>",
"      ]. However, while the incremental value of carotid IMT for predicting risk beyond that achieved using the Framingham risk score was statistically significant (net reclassification improvement 0.8 percent, 95% CI 0.1-1.6 percent), this result is too small to translate to a meaningful clinical improvement in risk classification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A different 2012 meta-analysis investigated the association between rates of carotid IMT progression and outcomes in 36,984 patients from 16 studies who underwent carotid IMT measurement at least twice (mean four years apart) and who were followed for an average of seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/19\">",
"     19",
"    </a>",
"    ]. While there was a significant correlation between carotid IMT thickness and cardiovascular events, there was no significant association between",
"    <strong>",
"     progression",
"    </strong>",
"    of IMT thickness and a combined endpoint of MI, stroke, and cardiovascular death. Because of the lack of association between progression of IMT thickness and outcomes, there appears to be no role for serial measurements of carotid IMT.",
"   </p>",
"   <p>",
"    Intraluminal arterial plaque can also be detected by ultrasound during the measurement of carotid IMT. Persons with increased carotid IMT and the presence of arterial plaque have been shown to be at the highest risk of developing CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122167\">",
"    <span class=\"h2\">",
"     Arterial stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial stiffness, measured as the aortic pulse wave velocity (PWV) between the carotid and femoral arteries, is a predictor of cardiovascular events. This was demonstrated in a meta-analysis of 17 studies that included over 15,000 patients in whom aortic PWV had been correlated to clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/21\">",
"     21",
"    </a>",
"    ]. The pooled relative risks for total cardiovascular events, cardiovascular mortality, and all-cause mortality were significantly increased comparing high versus low aortic PWV groups: 2.26 (95% CI 1.89-2.70), 2.02 (95% CI 1.68-2.42), and 1.90 (95% CI 1.61-2.24) respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268867\">",
"    <span class=\"h2\">",
"     Arterial calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium deposits in extracoronary arteries, particularly the aortic arch and abdominal aorta, may be a marker for CVD and an increase in cardiovascular events. However, it is not certain if the predictive value of calcification is independent of other coronary risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcification of the aortic arch is associated with a greater risk of CVD. In one study of 139,849 members of a health maintenance organization followed for a median of 28 years, aortic arch calcification identified on a chest x-ray was independently associated with an increased risk of coronary heart disease in men (relative risk 1.27) and women (relative risk 1.22), as well as a 1.46-fold increased risk of ischemic stroke in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/23\">",
"     23",
"    </a>",
"    ]. Ischemic strokes in such patients may reflect embolic as well as thrombotic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to thoracic aortic calcification, calcification of the abdominal aorta is also associated with an increased risk of CVD. In a meta-analysis of 10 studies (22,170 patients), calcification of the abdominal aorta was associated with significantly higher risks of four major endpoints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coronary heart disease events (five studies with 11250 patients; RR 1.81, 95% CI 1.54-2.14)",
"     </li>",
"     <li>",
"      Cerebrovascular disease events (four studies with 9736 patients; RR 1.37, 95% CI 1.22-3.54)",
"     </li>",
"     <li>",
"      Combined CVD events (four studies with 4960 patients; RR 1.64, 95% CI 1.24-2.17)",
"     </li>",
"     <li>",
"      CVD death (three studies with 4986 patients; RR 1.72, 95% CI 1.03-2.86)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcification of the renal arteries has also been reported to be associated with greater overall mortality. Among a cohort of 4450 persons without known CVD who underwent whole body computed tomography, 622 (14 percent) were found to have calcification of one or both renal arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/25\">",
"     25",
"    </a>",
"    ]. Following adjustment for age, sex, and traditional cardiac risk factors, those with renal artery calcification had a significantly greater overall mortality (risk-adjusted hazard ratio 1.63, 95% CI 1.17-2.29).",
"   </p>",
"   <p>",
"    Another method for establishing the presence and severity of aortic calcification and atherosclerotic plaque burden is measurement of aortic elastic properties, based on the biomechanics of pulse wave-vessel wall interaction determined by transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/26\">",
"     26",
"    </a>",
"    ]. The specific elastance is of incremental value to other clinical variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268874\">",
"    <span class=\"h2\">",
"     Coronary artery calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery calcification (CAC) detected by electron beam computed tomography or multidetector row computed tomography can be used to quantify the amount of calcium present in the coronary arteries of a given patient. The coronary calcium score correlates with the risk of cardiovascular events in both asymptomatic and symptomatic patients. Issues related to the possibility utility of CAC scanning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281747\">",
"    <span class=\"h2\">",
"     Electrocardiographic abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283124\">",
"    <span class=\"h3\">",
"     ECG changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic persons with resting ECG abnormalities such as ST depression, T wave inversion, left ventricular hypertrophy or strain, and premature ventricular contractions have a 2 to 10-fold increased risk of CHD compared to those with a normal ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. As an example, among 2192 adults aged 70 to 79 without known CVD who were followed for 8 years, persons with minor (defined as minor ST-T abnormalities) and major (defined as Q waves, left ventricular hypertrophy, bundle branch block, atrial fibrillation or flutter, WPW syndrome, or major ST-T changes) ECG abnormalities were more likely to develop CVD than those with normal baseline ECGs (HR 1.35, 95% CI 1.02-1.81 and HR 1.51, 95% CI 1.20-1.90, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual transition zone, where the R and S wave are equal in amplitude in the precordial leads, usually occurs between V3 and V4. In a cohort of 9067 persons (44 percent male) followed for 24 years, clockwise rotation (also called \"late transition\") was associated with increased risk of CVD (HR 1.49, 95% CI 1.12-1.98), while counterclockwise rotation (also called \"early transition\") was inversely associated with CVD (HR 0.74, 95% CI 0.59-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/30\">",
"     30",
"    </a>",
"    ]. While these data are easily identified from the surface ECG, the exact mechanism by which cardiac rotation on ECG alters the risk of CVD remains undetermined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H4#H4\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Early or late transition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283187\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH), which is associated with hypertension as well as with age and obesity, is a risk factor for CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. This has been identified in several large cohorts, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiographic and anatomic LVH, based upon the finding of an enlarged cardiac silhouette on a chest x-ray, each independently increased the risk of cardiovascular disease in the Framingham study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/32\">",
"       32",
"      </a>",
"      ]. Manifestations of atherosclerosis occurred at two to three times the general population rate in persons with LVH.",
"     </li>",
"     <li>",
"      Among more than 15,000 patients in the Atherosclerosis Risk in Communities Study who were followed for 15 years, both women and men with baseline ECG-identified LVH were significantly more likely to die from CVD than from non-CVD causes (HR in women 8.4, 95% CI 4.5-15.6, HR in men 4.9, 95% CI 3.0-7.8) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiographic evidence of LVH (eccentric or concentric), which is more sensitive than the ECG, also is predictive of cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269183\">",
"    <span class=\"h2\">",
"     Endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction induced by dyslipidemia and oxidative stress is an initial step in atherosclerosis. Several studies have found that coronary artery endothelial dysfunction and increased vascular oxidative stress predict long-term progression of atherosclerosis and an increased incidence of cardiovascular events (",
"    <a class=\"graphic graphic_figure graphicRef74218 \" href=\"mobipreview.htm?15/10/15535\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269190\">",
"    <span class=\"h3\">",
"     Endothelial progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial progenitor cells (EPCs) are derived from the bone marrow and are thought to support the vascular endothelium and prevent the development of atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link&amp;anchor=H10#H10\">",
"     \"Endothelial dysfunction\", section on 'Endothelial progenitor cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decreased numbers of circulation EPCs have been associated with endothelial dysfunction and a higher Framingham risk factor score in patients without established cardiovascular disease and more frequent atherosclerotic events including death at 10 to 12 month follow-up of patients with established CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms by which EPCs might be reduced in patients with or at risk for CVD are not well understood. Two possible contributing factors are selective functional exhaustion of hematopoietic progenitor cells in bone marrow and peripheral blood in ischemic cardiomyopathy and an increased plasma concentration of asymmetrical dimethylarginine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269197\">",
"    <span class=\"h3\">",
"     Asymmetrical dimethylarginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor that may be an independent risk factor for endothelial dysfunction and CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients with and without established coronary heart disease and elevated levels of serum ADMA have an increased risk of acute coronary events compared to individuals with lower ADMA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to direct effects of nitric oxide inhibition on endothelial dysfunction, the adverse effect of ADMA may also be mediated by inhibition of the mobilization, differentiation, and function of endothelial progenitor cells that play a important role in the regeneration on injured endothelium and therefore in limiting the formation of atherosclerotic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/42\">",
"     42",
"    </a>",
"    ]. The mechanism of ADMA elevation in these settings is not clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link&amp;anchor=H5#H5\">",
"     \"Endothelial dysfunction\", section on 'Abnormal nitric oxide metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269565\">",
"    <span class=\"h2\">",
"     Heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resting and peak exercise heart rate may be predictive of cardiovascular and CHD mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In one study of 3527 men followed for eight years, those with a resting heart rate &gt;90 beats per minute had an adjusted relative risk of cardiovascular mortality of 2.02 compared to those with a heart rate &lt;70 beats per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/50\">",
"     50",
"    </a>",
"    ]. In another report, the relative risk of death from cardiovascular causes associated with an increment of 35 beats per minute in the peak heart rate was 2.7 (p = 0.003) for healthy men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in resting heart rate over time also correlate with an increased risk of CHD death. In a prospective cohort study of 29,325 Norwegians (46 percent men) without known CHD, resting heart rate was measured on two occasions approximately 10 years apart, after which the group was followed for an average for 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/51\">",
"     51",
"    </a>",
"    ]. Persons with a resting heart rate &lt;70 bpm at the initial but &gt;85 bpm at second visit had a significantly high risk of CHD death (adjusted hazard ratio [AHR] 1.9 compared to persons with resting heart rate &lt;70 bpm at both visits, 95% CI 1.0-3.6). Similar results were noted for persons with a resting heart rate of 70 to 85 bpm at the initial but &gt;85 bpm at second visit (AHR 1.8, 95% CI 1.2-2.8).",
"   </p>",
"   <p>",
"    A lower than expected peak heart rate during exercise, known as chronotropic incompetence, is also predictive of CHD and all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=see_link&amp;anchor=H4#H4\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate response to exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced heart rate variability is also associated with a greater risk of CHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122202\">",
"    <span class=\"h2\">",
"     Retinal vessel caliber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal arteriolar narrowing or retinal venous dilation is associated with an increased risk for the development of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A meta-analysis of over 22,000 patients in six studies suggested that this relationship is present only in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265276\">",
"    <span class=\"h1\">",
"     OTHER SYSTEMIC CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268070\">",
"    <span class=\"h2\">",
"     Androgen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have shown that reduced serum testosterone concentrations are associated with the subsequent development of metabolic syndrome, diabetes mellitus, and elevated C-reactive protein levels in addition to higher overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/55\">",
"     55",
"    </a>",
"    ]. Among a cohort of 930 British men with angiographically documented CHD prospectively observed for a mean of 7 years, those with low testosterone levels (bio-available testosterone &lt;2.6",
"    <span class=\"nowrap\">",
"     nmol/L,",
"    </span>",
"    21 percent of the group) had significantly greater mortality (21 percent versus 12 percent in those with normal testosterone levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, several observational studies and retrospective analyses of randomized trials have shown an association between therapeutically reduced androgen levels (ie, as treatment for prostate cancer) and higher rates of cardiovascular disease and mortality. However, a systematic review and meta-analysis of randomized trials of androgen deprivation therapy (ADT) showed that ADT was",
"    <strong>",
"     not",
"    </strong>",
"    associated with increased risk of cardiovascular death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/57\">",
"     57",
"    </a>",
"    ]. Detailed discussions of this data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of testosterone deficiency in elderly men\", section on 'Metabolic cardiovascular parameters'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H22#H22\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Cardiovascular disease and diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1270017\">",
"    <span class=\"h2\">",
"     Collagen vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with collagen vascular disease, especially those with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a significantly increased incidence of cardiovascular disease (CVD). In the Nurses' Health Study, those with RA for more than 10 years, compared to those without RA, had an increased risk of CVD (RR 3.1, CI 1.64-5.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/58\">",
"     58",
"    </a>",
"    ]. An even higher relative risk has been demonstrated for patients with SLE, especially among young women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/59\">",
"     59",
"    </a>",
"    ]. This is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122216\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infectious illnesses may be associated with a transient increase in the risk of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In addition it has been proposed that certain types of infections may play a role in the pathogenesis of atherosclerosis by establishing a low-grade persistent inflammatory process; acute or chronic inflammation may result in endothelial dysfunction and may be responsible for a cardiac event.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major organisms that have been studied with respect to chronic inflammation are Chlamydophila (formerly Chlamydia) pneumoniae, cytomegalovirus, and Helicobacter pylori; however, enterovirus (coxsackie viral infection), hepatitis A virus, and herpes simplex virus type 1 and type 2 have also been implicated.",
"      <br/>",
"      <br/>",
"      Large randomized trials do",
"      <strong>",
"       not",
"      </strong>",
"      support benefit from antibiotic therapy against C. pneumoniae to reduce coronary events. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25160?source=see_link\">",
"       \"Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It has been proposed that exposure to sustained high levels of endotoxin constitutes a risk factor for atherosclerosis (",
"      <a class=\"graphic graphic_figure graphicRef70366 \" href=\"mobipreview.htm?38/51/39741\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The potential association between chronic periodontitis and coronary heart disease is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link&amp;anchor=H21#H21\">",
"       \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Association with cardiovascular risk'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267528\">",
"    <span class=\"h2\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart disease is a manifestation of iron overload in hereditary hemochromatosis (HH). Whether minimal degrees of iron overload in HH heterozygotes increases cardiovascular risk remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24276712\">",
"    <span class=\"h2\">",
"     Nonalcoholic fatty liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (also referred to as nonalcoholic steatohepatitis) is a clinico-histopathological entity with features that resemble alcohol-induced liver injury that occurs in patients with little or no history of alcohol consumption. Although its etiology is unknown, it is frequently associated with obesity, type 2 diabetes mellitus, and hyperlipidemia.",
"   </p>",
"   <p>",
"    While patients with nonalcoholic fatty liver disease often meet the diagnostic criteria for the metabolic syndrome, there is evidence for an increased risk of incident cardiovascular disease that is independent of the risk conferred by traditional risk factors and components of the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4485836#H4485836\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Metabolic syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=see_link&amp;anchor=H147569346#H147569346\">",
"     \"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults\", section on 'Associated disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267737\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea is associated with and increased risk for coronary artery disease, cardiac arrhythmias, systemic hypertension, and pulmonary hypertension. These relationships are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267603\">",
"    <span class=\"h2\">",
"     Small for gestational age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults who were small for gestational age infants are at increased risk for ischemic heart disease and related disorders including hypertension, stroke, diabetes, and hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. It is possible that the association between small for gestational age and CVD can be explained by other maternal or socioeconomic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265284\">",
"    <span class=\"h1\">",
"     CIRCULATING SERUM OR PLASMA MARKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4242103\">",
"    <span class=\"h2\">",
"     Aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma aldosterone levels are seen in numerous clinical conditions, including hypertension and heart failure, with evidence suggesting that increased aldosterone levels are associated with greater CVD mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Results from one prospective cohort study of 3153 patients (average follow up 7.7 years) in whom plasma aldosterone levels were measured at the time of coronary angiography suggested greater all-cause and cardiovascular mortality among patients in the top 3 quartiles of plasma aldosterone concentration (most of whom had an aldosterone concentration considered to be in the normal range for this assay) compared with those in the lowest quartile, even after adjusting for traditional CHD risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/68\">",
"     68",
"    </a>",
"    ]. Further studies are needed before recommending this test in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268642\">",
"    <span class=\"h2\">",
"     Antibodies against oxidized LDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In healthy men aged 50 years, circulating immune complexes and autoantibodies against oxidized low density lipoproteins and cardiolipin predict the occurrence of an MI within the subsequent 20 years; the predictive power was independent of that of other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/70\">",
"     70",
"    </a>",
"    ]. In patients with CHD an elevated titer of antibodies against oxidized low density lipoprotein independently predicts the progression of atherosclerosis over six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268557\">",
"    <span class=\"h2\">",
"     BNP and N-terminal pro-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain natriuretic peptide (BNP) is a natriuretic hormone released from myocardial cells in response to volume expansion and possibly increased wall stress. The N-terminal fragment, N-pro-BNP, is also released into the circulation. Serum BNP and N-pro-BNP are increased in patients with HF and are predictors of death and cardiovascular events in asymptomatic patients without HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122223\">",
"    <span class=\"h2\">",
"     Coagulation factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following coagulation factors may be related to cardiovascular risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma fibrinogen levels are independent risk factors for CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. This issue was best addressed in a 2005 meta-analysis of over 150,000 healthy, middle-aged adults in 31 prospective studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/75\">",
"       75",
"      </a>",
"      ]. Within each age group, there was an approximately log-linear relationship between plasma fibrinogen and any CHD, any stroke, and mortality due to other cardiovascular events.",
"     </li>",
"     <li>",
"      Preliminary data suggest an association between CHD and elevated levels of fibrin D-dimer, which reflects fibrin turnover in the circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombomodulin is an integral membrane glycoprotein that has a major role in the regulation of intravascular coagulation. It has anticoagulant activity since, in concert with thrombin, it activates protein C. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      .) Soluble thrombomodulin showed a strong, graded, inverse association with coronary artery disease in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/78\">",
"       78",
"      </a>",
"      ], and one polymorphism of thrombomodulin was associated with an increased risk of CHD in blacks.",
"     </li>",
"     <li>",
"      There are conflicting data as to whether elevated plasma von Willebrand factor (vWF) concentrations predict an increased risk of CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/74,77,79-81\">",
"       74,77,79-81",
"      </a>",
"      ]. A report from the Framingham Offspring Study found the higher levels of vWF were associated with an increased risk of CVD only in patients with diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with hemophilia and carriers of hemophilia appear to have a reduced risk of CHD mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. The protective effect against CHD appears to be less in carriers of hemophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relationship between the activity of coagulation factors XI, XII, VIII and IX, and the risk of a first MI in men was increased with higher levels of factor XI activity and lower levels of factor XII activity, and the highest risk was found among men with both high levels of factor XI and low factor XII activities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/86\">",
"       86",
"      </a>",
"      ]. Higher levels of factor VIII and IX activity were also associated with an increased risk of MI in men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4242132\">",
"    <span class=\"h2\">",
"     Homoarginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homoarginine, an amino acid derived from lysine that serves as a precursor of the vasodilator nitric oxide (NO), may enhance endothelial function, thereby lowering cardiovascular risk. In a cohort of 3305 patients with angiographically-proven CHD (78 percent) or at high risk for CHD who were prospectively followed for nearly eight years, those in the lowest quartile of homoarginine levels had a fourfold higher risk of death from CVD (adjusted HR 4.1 compared with highest quartile, 95% CI 3.0-5.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/87\">",
"     87",
"    </a>",
"    ]. Further studies are needed before recommending this test in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268588\">",
"    <span class=\"h2\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin plays a role in fat metabolism and correlates with insulin resistance and other markers of the metabolic syndrome and was shown in the WOSCOPS trial of primary prevention to be predictive of CHD events after adjusting for body mass index and other classic risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1266837\">",
"    <span class=\"h2\">",
"     Serum phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic kidney disease (CKD) or established CHD, a higher serum phosphate or calcium-phosphate product is associated with increased cardiovascular mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\", section on 'Risk factors unique to CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also evidence that a higher serum phosphate level is associated with an increased risk of CVD in persons without known CHD or CKD. The first evidence for an association between serum phosphate levels and cardiovascular events in individuals without either CHD or CKD comes from analysis of the Framingham Offspring cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/89\">",
"     89",
"    </a>",
"    ]. In a study of 3368 individuals (mean age 44 years) who were followed for a mean of 16 years, a higher serum phosphate was associated with an increased cardiovascular risk in a continuous fashion from the lowest to the highest quartile. Individuals in the highest quartile had a statistically significant 1.55-fold increased risk compared with those in the lowest quartile (95% CI 1.16-2.07).",
"   </p>",
"   <p>",
"    A significant association between serum phosphorus levels and coronary artery calcium levels obtained at the time of computed tomographic scanning has also been found in healthy, younger adults (mean age 25 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/90\">",
"     90",
"    </a>",
"    ]. In multivariate models, higher baseline phosphorus levels, including those within the normal range, were significantly associated with higher coronary artery calcium scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1265380\">",
"    <span class=\"h2\">",
"     Uric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large epidemiologic studies have shown that hyperuricemia is associated with an increased incidence of coronary heart disease (CHD) and increased mortality in those with and without preexisting CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/91-96\">",
"     91-96",
"    </a>",
"    ]. Proposed mechanisms for such an increase in risk include the development of hypertension and oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. It is unclear if hyperuricemia has a causal effect or, as has been more often suggested, is simply a marker for other risk factors such as hypertension, dyslipidemia, and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/99-103\">",
"     99-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperuricemia has also been identified as a risk factor for mortality in patients with heart failure, where it may be a reflection of decreased tissue perfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H34#H34\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Hyperuricemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267013\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267133\">",
"    <span class=\"h2\">",
"     Air pollution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have demonstrated an association between fine particulate air pollution and cardiovascular and cardiopulmonary mortality as well as an increased risk for the development of acute coronary syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/89,104-110\">",
"     89,104-110",
"    </a>",
"    ]. The following are two representative large studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women's Health Initiative Observational study database of more than 65,000 postmenopausal women without prior CVD was used to evaluate the relation between a woman's long term exposure to air pollutants and the risk for a first cardiovascular event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/104\">",
"       104",
"      </a>",
"      ]. Unlike prior studies, potential confounding factors such as age, body mass index, and traditional cardiovascular risk factors were taken into account. The principle findings were that for each 10",
"      <span class=\"nowrap\">",
"       mcg/m3",
"      </span>",
"      increase in pollution concentration, there were significant increases in the risk of any cardiovascular event (hazard ratio 1.24), death from CVD (hazard ratio 1.76), and of cerebrovascular events (hazard ratio 1.35).",
"     </li>",
"     <li>",
"      Mortality data from nearly 450,000 patients in the American Cancer Society Cancer Prevention Study II data base were correlated to air pollution data, including average concentrations of ozone and fine particulate matter (&le;2.5 micrometers in diameter [PM2.5]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/110\">",
"       110",
"      </a>",
"      ]. In multivariate analysis PM2.5, but not ozone, concentration was significantly associated with the risk of death from cardiovascular causes (relative risk 1.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further support for the significance of air pollution comes from a study of death rates in Dublin, Ireland before and after a ban on coal sales that led to a 70 percent reduction in black smoke concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/111\">",
"     111",
"    </a>",
"    ]. Adjusted cardiovascular deaths fell by 10.3 percent in the six years after the ban.",
"   </p>",
"   <p>",
"    In addition to long-term risk, short-term exposure to air pollutants (both ozone and fine particulate matter) has been associated with acute coronary ischemic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/109,112\">",
"     109,112",
"    </a>",
"    ]. In a study of over 12,000 patients living in a defined geographic area, a short-term increase in fine ambient particulate matter positively correlated with an increase in acute ischemic coronary events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/109\">",
"     109",
"    </a>",
"    ]. In a systematic review and meta-analysis of data from 34 studies, carbon monoxide, nitrogen dioxide, sulfur dioxide, and small particulate matter (less than 10 microns and less than 2.5 microns) were all associated with an increased risk of myocardial infarction, with the overall population attributable risk ranging from 1 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible mechanisms by which fine particulate air pollution may increase the risk of CVD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in mean resting arterial blood pressure through an increase in sympathetic tone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the modulation of basal systemic vascular tone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/114\">",
"       114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increase in the likelihood of intravascular thrombosis through transient increases in plasma viscosity and impaired endothelial dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/115\">",
"       115",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The initiation and promotion of atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/116,117\">",
"       116,117",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of air pollution of the respiratory tract is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6089?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic obstructive pulmonary disease: Risk factors and risk reduction\", section on 'Environmental exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267867\">",
"    <span class=\"h2\">",
"     Genetic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several gene loci that affect the risk for the development of coronary heart disease (CHD) have been investigated in multiple studies, with a meta-analysis of 63,746 CHD cases and 130,681 controls reporting 46 single nucleotide polymorphisms (SNPs) across the genome which significantly associated with an increased risk of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/118\">",
"     118",
"    </a>",
"    ]. Among the various implicated SNPs, those appearing on locus 9p21 have shown the strongest association with CHD risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. In a systematic review that evaluated 47 distinct data sets, including 35,872 cases and 95,837 controls, persons with two abnormal alleles at this locus were more likely to have CHD when compared with persons with one at-risk allele (odds ratio 1.25, 95% CI 1.21-1.29) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/121\">",
"     121",
"    </a>",
"    ]. The association with 9p21 SNPs and an increased risk of developing CHD has also been shown in elderly patients greater than 70 years of age without known prior CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/122\">",
"     122",
"    </a>",
"    ]. However, locus 9p21 SNPs have not been definitively shown to significantly improve on the discrimination or classification of predicted risk compared with the use of traditional risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/120-122\">",
"     120-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis evaluated the dose effect of abnormal 9p21 SNPs on the burden of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/123\">",
"     123",
"    </a>",
"    ]. Among 950 non-diabetic patients with early-onset CHD (mean age 56 years) displaying at least one angiographic epicardial stenosis &gt;50 percent seen by coronary angiography, the 9p21 genotype was associated with a risk of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left main CHD (OR 2.38 per copy of risk allele, 95% CI 1.48-3.85)",
"     </li>",
"     <li>",
"      3-vessel CHD (OR 1.45 per copy of risk allele, 95% CI 1.18-1.79)",
"     </li>",
"     <li>",
"      Need for bypass surgery (OR 1.37 per copy of risk allele, 95% CI 1.04-1.79)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest more aggressive CHD occurring at a younger age in patients with abnormal 9p21 genotypes.",
"   </p>",
"   <p>",
"    A specific polymorphism in the gene encoding 5-lipoxygenase activating protein (FLAP) has been associated with a twofold increase in the risk of myocardial infarction and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/124\">",
"     124",
"    </a>",
"    ]. A FLAP inhibitor reduced both serum CRP and other biomarkers of risk in patients who sustained a myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DAB2IP is a protein located on chromosome 9q33, which is thought to be involved in regulating cell proliferation apoptosis. In a case control study of nearly 5000 people (1386 cases of CHD, 3532 controls), a polymorphism in this protein was associated with a great likelihood of CHD (OR 1.16, 95% CI 1.05-1.29) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although individual genetic markers are associated with CVD, their aggregate effect on risk beyond traditional factors has not been established. A genetic risk score created from 101 SNPs associated with CVD did not improve discrimination or reclassification of risk after adjustment for traditional factors in a cohort of over 19,000 white women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic studies of other cardiac risk factors (eg, cholesterol components) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link&amp;anchor=H196198349#H196198349\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'Low HDL-C as a cause of coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7188817\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7188824\">",
"    <span class=\"h3\">",
"     Hypertensive disorders of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension is associated with development of hypertension later in life, and possibly associated with development of diseases related to hypertension. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29383?source=see_link&amp;anchor=H19#H19\">",
"     \"Gestational hypertension\", section on 'Maternal prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7188831\">",
"    <span class=\"h3\">",
"     Spontaneous pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of spontaneous pregnancy loss, but not induced abortion, have been shown to have a higher risk of myocardial infarction later in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/128-130\">",
"     128-130",
"    </a>",
"    ]. Among 11,518 women in the EPIC cohort (mean follow-up 10.8 years) who had ever been pregnant, there was a significantly greater risk of myocardial infarction, even after adjusting for traditional risk factors, among women with any history of miscarriage (adjusted HR 1.42 compared with no pregnancy loss, 95% CI 1.14-1.78) or stillbirth (adjusted HR 2.65, 95% CI 1.37-5.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/130\">",
"     130",
"    </a>",
"    ]. Women with recurrent miscarriages (more than three) were at the highest risk of myocardial infarction (adjusted HR 8.90, 95% CI 3.18-24.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/130\">",
"     130",
"    </a>",
"    ]. While the exact nature of this risk is not fully elucidated, it may relate to procoagulant and proinflammatory states that are associated with recurrent miscarriages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267687\">",
"    <span class=\"h2\">",
"     Socioeconomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various socioeconomic factors, including where a person lives, his or her education, occupation, and income, or combinations of these, have been associated with an increased risk for CVD, especially coronary heart disease, and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/131-135\">",
"     131-135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1268156\">",
"    <span class=\"h2\">",
"     Vitamins, antioxidants and homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are available assessing the effects of numerous vitamins, antioxidants, and homocysteine on CHD risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxidation of LDL particles appears to be associated with an increased risk of atherosclerosis, suggesting that antioxidant therapy may reduce the incidence of CVD. Despite this association, randomized prospective studies of vitamin E, vitamin C, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      have shown no clear evidence of benefit. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both cross-sectional and prospective studies have linked elevated levels of homocysteine to increased risk for CHD. Higher serum homocysteine concentrations are frequently accompanied by reduced levels and intake of folate and vitamin B12. However, numerous prospective randomized trials of folate supplementation to lower serum homocysteine have demonstrated no reduction in major cardiovascular outcomes (eg, death, myocardial infarction, stroke). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of homocysteine\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The addition of a serum homocysteine measurement to the Framingham risk score has been shown to improve risk prediction, with net reclassification of between 13 and 20 percent of patients from two cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/136\">",
"       136",
"      </a>",
"      ]. The majority of those affected were reclassified to a higher risk level. The estimation of cardiovascular risk is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Cysteine is structurally and metabolically related to homocysteine, and the plasma total cysteine concentration is strongly related to several risk factors for CVD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/137\">",
"       137",
"      </a>",
"      ]. Although both low and high plasma total cysteine concentrations have been associated with an increased risk of peripheral vascular disease, there is no significant relationship to coronary disease after adjustment for plasma homocysteine (",
"      <a class=\"graphic graphic_figure graphicRef55858 \" href=\"mobipreview.htm?33/1/33822\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/37/34394/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect of calcium supplementation on risk of cardiovascular disease is controversial. While calcium supplementation may result in improvements in weight, blood pressure, and serum cholesterol concentrations (of about 5 percent) in patients with mild to moderate hypercholesterolemia, several meta-analyses have come to differing conclusions regarding CVD outcomes, with some suggesting an increased risk of CVD and others suggesting no increase in CVD risk. None of the trials (included in the meta-analyses), however, were designed to assess the effects of calcium or vitamin D on cardiovascular outcomes. As such, we do not restrict the use of calcium supplementation in patients with or at high risk for CVD and recommend optimal daily intake as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H13#H13\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Side effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H6#H6\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Optimal intake'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10122293\">",
"    <span class=\"h1\">",
"     MULTIVARIATE RISK PROFILES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multivariate risk models, such as the Framingham risk score and the SCORE project in Europe, have been developed in an attempt to estimate short-term (eg, 10 year) cardiovascular risk in patients without known CVD. These models and the clinical use of risk assessment are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most risk-score algorithms assess risk over an intermediate follow-up interval of approximately 10 years and can help to guide interventions because categories of the risk factors are provided. Research from long-term cohort studies has also provided lifetime risk estimates.",
"   </p>",
"   <p>",
"    Less detail on the individual risk factors is available with multivariable approaches to lifetime risk, but they can be used to help motivate patients to adhere to interventions. For example, the lifetime risk of CVD in a 50-year-old man with one major risk factor is approximately 10 percent by age 60 and rises to nearly 70 percent for men who live to age 90 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475085\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the commonly recognized risk equivalents and risk factors for cardiovascular disease (CVD), there are a number of other factors which have a weaker or proposed association with a greater risk of developing CVD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular factors that have been associated with greater risk of CVD include arterial intima-media thickness, arterial stiffness, arterial calcification, endothelial dysfunction, higher resting heart rates, and left ventricular hypertrophy. (See",
"      <a class=\"local\" href=\"#H1265268\">",
"       'Cardiovascular factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic conditions associated with greater risk of CVD include collagen vascular disease, androgen deficiency, infection, iron overload, obstructive sleep apnea, and being born small for gestational age. (See",
"      <a class=\"local\" href=\"#H1265276\">",
"       'Other systemic conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Circulating serum or plasma markers associated with greater risk of CVD include aldosterone, antibodies against oxidized LDL, BNP, coagulation factors, homoarginine, leptin, phosphate, and uric acid. (See",
"      <a class=\"local\" href=\"#H1265284\">",
"       'Circulating serum or plasma markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors such as genetic markers, air pollution, socioeconomic factors, and spontaneous pregnancy loss have also been reported to be associated with greater risk of CVD. (See",
"      <a class=\"local\" href=\"#H1267013\">",
"       'Miscellaneous factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/1\">",
"      Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/2\">",
"      Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/3\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/4\">",
"      Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/5\">",
"      Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/6\">",
"      Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/7\">",
"      Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/8\">",
"      de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109:III33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/9\">",
"      Bots ML, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 2007; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/10\">",
"      Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/11\">",
"      J&auml;rvisalo MJ, Jartti L, N&auml;nt&ouml;-Salonen K, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 2001; 104:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/12\">",
"      Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/13\">",
"      O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/14\">",
"      Simons PC, Algra A, Bots ML, et al. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999; 100:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/15\">",
"      Touboul PJ, Elbaz A, Koller C, et al. Common carotid artery intima-media thickness and brain infarction : the Etude du Profil G&eacute;n&eacute;tique de l'Infarctus C&eacute;r&eacute;bral (GENIC) case-control study. The GENIC Investigators. Circulation 2000; 102:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/16\">",
"      Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/17\">",
"      Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/18\">",
"      Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/19\">",
"      Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/20\">",
"      Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/21\">",
"      Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/22\">",
"      Agmon Y, Khandheria BK, Meissner I, et al. Independent association of high blood pressure and aortic atherosclerosis: A population-based study. Circulation 2000; 102:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/23\">",
"      Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 2000; 283:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/24\">",
"      Bastos Gon&ccedil;alves F, Vo&ucirc;te MT, Hoeks SE, et al. Calcification of the abdominal aorta as an independent predictor of cardiovascular events: a meta-analysis. Heart 2012; 98:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/25\">",
"      Rifkin DE, Ix JH, Wassel CL, et al. Renal artery calcification and mortality among clinically asymptomatic adults. J Am Coll Cardiol 2012; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/26\">",
"      Hunziker PR, Imsand C, Keller D, et al. Bedside quantification of atherosclerosis severity for cardiovascular risk stratification: a prospective cohort study. J Am Coll Cardiol 2002; 39:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/27\">",
"      Daviglus ML, Liao Y, Greenland P, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA 1999; 281:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/28\">",
"      Chou R, Arora B, Dana T, et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/29\">",
"      Auer R, Bauer DC, Marques-Vidal P, et al. Association of major and minor ECG abnormalities with coronary heart disease events. JAMA 2012; 307:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/30\">",
"      Nakamura Y, Okamura T, Higashiyama A, et al. Prognostic values of clockwise and counterclockwise rotation for cardiovascular mortality in Japanese subjects: a 24-year follow-up of the National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in the Aged, 1980-2004 (NIPPON DATA80). Circulation 2012; 125:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/31\">",
"      Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/32\">",
"      Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 1987; 60:85I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/33\">",
"      Desai CS, Ning H, Lloyd-Jones DM. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart 2012; 98:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/34\">",
"      Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/35\">",
"      Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/36\">",
"      Sch&auml;chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/37\">",
"      Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/38\">",
"      Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/39\">",
"      Schmidt-Lucke C, R&ouml;ssig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/40\">",
"      Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/41\">",
"      Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007; 49:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/42\">",
"      Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/43\">",
"      Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/44\">",
"      Valkonen VP, P&auml;iv&auml; H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/45\">",
"      Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/46\">",
"      B&ouml;ger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/47\">",
"      Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/48\">",
"      Ekelund LG, Haskell WL, Johnson JL, et al. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 1988; 319:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/49\">",
"      Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 1999; 149:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/50\">",
"      Kristal-Boneh E, Silber H, Harari G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000; 21:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/51\">",
"      Nauman J, Janszky I, Vatten LJ, Wisl&oslash;ff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/52\">",
"      Lauer MS, Okin PM, Larson MG, et al. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996; 93:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/53\">",
"      Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/54\">",
"      McGeechan K, Liew G, Macaskill P, et al. Meta-analysis: retinal vessel caliber and risk for coronary heart disease. Ann Intern Med 2009; 151:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/55\">",
"      Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011; 58:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/56\">",
"      Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/57\">",
"      Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/58\">",
"      Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/59\">",
"      Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/60\">",
"      Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/61\">",
"      Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007; 28:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/62\">",
"      Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999; 34:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/63\">",
"      Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/64\">",
"      Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/65\">",
"      Barker DJ. Fetal origins of coronary heart disease. BMJ 1995; 311:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/66\">",
"      Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993; 306:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/67\">",
"      H&uuml;binette A, Cnattingius S, Ekbom A, et al. Birthweight, early environment, and genetics: a study of twins discordant for acute myocardial infarction. Lancet 2001; 357:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/68\">",
"      Tomaschitz A, Pilz S, Ritz E, et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/69\">",
"      Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/70\">",
"      Mustafa A, Nityanand S, Berglund L, et al. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/71\">",
"      Inoue T, Uchida T, Kamishirado H, et al. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/72\">",
"      Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/73\">",
"      Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000; 102:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/74\">",
"      Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/75\">",
"      Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/76\">",
"      Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/77\">",
"      Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112:3080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/78\">",
"      Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/79\">",
"      Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/80\">",
"      Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/81\">",
"      Whincup PH, Danesh J, Walker M, et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/82\">",
"      Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation 2008; 118:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/83\">",
"      Rosendaal FR, Varekamp I, Smit C, et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/84\">",
"      Rosendaal FR, Bri&euml;t E, Stibbe J, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/85\">",
"      Sr&aacute;mek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/86\">",
"      Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108:4045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/87\">",
"      M&auml;rz W, Meinitzer A, Drechsler C, et al. Homoarginine, cardiovascular risk, and mortality. Circulation 2010; 122:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/88\">",
"      Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/89\">",
"      Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/90\">",
"      Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/91\">",
"      Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/92\">",
"      Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/93\">",
"      Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/94\">",
"      Niskanen LK, Laaksonen DE, Nyyss&ouml;nen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/95\">",
"      Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/96\">",
"      Kuo CF, See LC, Yu KH, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/97\">",
"      Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 2005; 16:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/98\">",
"      Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005; 118:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/99\">",
"      Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/100\">",
"      Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/101\">",
"      Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/102\">",
"      Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/103\">",
"      Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol 2011; 23:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/104\">",
"      Miller KA, Siscovick DS, Sheppard L, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med 2007; 356:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/105\">",
"      Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 2004; 109:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/106\">",
"      Pope CA 3rd, Burnett RT, Thun MJ, et al. Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA 2002; 287:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/107\">",
"      Samet JM, Dominici F, Curriero FC, et al. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000; 343:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/108\">",
"      Forastiere F, Stafoggia M, Picciotto S, et al. A case-crossover analysis of out-of-hospital coronary deaths and air pollution in Rome, Italy. Am J Respir Crit Care Med 2005; 172:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/109\">",
"      Pope CA 3rd, Muhlestein JB, May HT, et al. Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation 2006; 114:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/110\">",
"      Jerrett M, Burnett RT, Pope CA 3rd, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/111\">",
"      Clancy L, Goodman P, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study. Lancet 2002; 360:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/112\">",
"      Ruidavets JB, Cournot M, Cassadou S, et al. Ozone air pollution is associated with acute myocardial infarction. Circulation 2005; 111:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/113\">",
"      Mustafic H, Jabre P, Caussin C, et al. Main air pollutants and myocardial infarction: a systematic review and meta-analysis. JAMA 2012; 307:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/114\">",
"      Brook RD, Brook JR, Urch B, et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 2002; 105:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/115\">",
"      Pekkanen J, Peters A, Hoek G, et al. Particulate air pollution and risk of ST-segment depression during repeated submaximal exercise tests among subjects with coronary heart disease: the Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air (ULTRA) study. Circulation 2002; 106:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/116\">",
"      Sun Q, Hong X, Wold LE. Cardiovascular effects of ambient particulate air pollution exposure. Circulation 2010; 121:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/117\">",
"      Bauer M, Moebus S, M&ouml;hlenkamp S, et al. Urban particulate matter air pollution is associated with subclinical atherosclerosis: results from the HNR (Heinz Nixdorf Recall) study. J Am Coll Cardiol 2010; 56:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/118\">",
"      CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/119\">",
"      Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/120\">",
"      Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009; 150:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/121\">",
"      Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA 2010; 303:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/122\">",
"      Dutta A, Henley W, Lang IA, et al. The coronary artery disease-associated 9p21 variant and later life 20-year survival to cohort extinction. Circ Cardiovasc Genet 2011; 4:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/123\">",
"      Dandona S, Stewart AF, Chen L, et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol 2010; 56:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/124\">",
"      Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/125\">",
"      Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005; 293:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/126\">",
"      Harrison SC, Cooper JA, Li K, et al. Association of a sequence variant in DAB2IP with coronary heart disease. Eur Heart J 2012; 33:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/127\">",
"      Paynter NP, Chasman DI, Par&eacute; G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 2010; 303:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/128\">",
"      Smith GC, Pell JP, Walsh D. Spontaneous loss of early pregnancy and risk of ischaemic heart disease in later life: retrospective cohort study. BMJ 2003; 326:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/129\">",
"      Kharazmi E, Fallah M, Luoto R. Miscarriage and risk of cardiovascular disease. Acta Obstet Gynecol Scand 2010; 89:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/130\">",
"      Kharazmi E, Dossus L, Rohrmann S, Kaaks R. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011; 97:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/131\">",
"      Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993; 88:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/132\">",
"      Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med 2001; 345:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/133\">",
"      Boehm JK, Peterson C, Kivimaki M, Kubzansky LD. Heart health when life is satisfying: evidence from the Whitehall II cohort study. Eur Heart J 2011; 32:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/134\">",
"      Kivim&auml;ki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet 2012; 380:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/135\">",
"      Virtanen M, Heikkil&auml; K, Jokela M, et al. Long working hours and coronary heart disease: a systematic review and meta-analysis. Am J Epidemiol 2012; 176:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/136\">",
"      Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011; 58:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/137\">",
"      El-Khairy L, Ueland PM, Nyg&aring;rd O, et al. Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine Study. Am J Clin Nutr 1999; 70:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/37/34394/abstract/138\">",
"      El-Khairy L, Ueland PM, Refsum H, et al. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001; 103:2544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16307 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34394=[""].join("\n");
var outline_f33_37_34394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H475085\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10122097\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1265268\">",
"      CARDIOVASCULAR FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10122160\">",
"      Arterial intima-media thickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10122167\">",
"      Arterial stiffness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268867\">",
"      Arterial calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268874\">",
"      Coronary artery calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281747\">",
"      Electrocardiographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H283124\">",
"      - ECG changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H283187\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269183\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1269190\">",
"      - Endothelial progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1269197\">",
"      - Asymmetrical dimethylarginine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269565\">",
"      Heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10122202\">",
"      Retinal vessel caliber",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1265276\">",
"      OTHER SYSTEMIC CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268070\">",
"      Androgen deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1270017\">",
"      Collagen vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10122216\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267528\">",
"      Iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24276712\">",
"      Nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267737\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267603\">",
"      Small for gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1265284\">",
"      CIRCULATING SERUM OR PLASMA MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4242103\">",
"      Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268642\">",
"      Antibodies against oxidized LDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268557\">",
"      BNP and N-terminal pro-BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10122223\">",
"      Coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4242132\">",
"      Homoarginine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268588\">",
"      Leptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1266837\">",
"      Serum phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1265380\">",
"      Uric acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1267013\">",
"      MISCELLANEOUS FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267133\">",
"      Air pollution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267867\">",
"      Genetic markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7188817\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7188824\">",
"      - Hypertensive disorders of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7188831\">",
"      - Spontaneous pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1267687\">",
"      Socioeconomic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1268156\">",
"      Vitamins, antioxidants and homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10122293\">",
"      MULTIVARIATE RISK PROFILES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H475085\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/16307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16307|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/26/37294\" title=\"figure 1\">",
"      Age adjusted death rates for CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/58/14254\" title=\"figure 2\">",
"      Deaths from cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/10/15535\" title=\"figure 3\">",
"      Impaired coronary artery vasoreactivity predicts CV events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/51/39741\" title=\"figure 4\">",
"      Endotoxemia and atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/1/33822\" title=\"figure 5\">",
"      Relation cysteine atheroscler",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25160?source=related_link\">",
"      Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6089?source=related_link\">",
"      Chronic obstructive pulmonary disease: Risk factors and risk reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38105?source=related_link\">",
"      Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_37_34395="Common brand and generic names PI";
var content_f33_37_34395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of common brand and generic names",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        US brand name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Can you get less costly generic copies yet?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microzide&reg;",
"       </td>",
"       <td>",
"        hydrochlorothiazide",
"        <strong>",
"         or",
"        </strong>",
"        HCTZ",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenormin&reg;",
"       </td>",
"       <td>",
"        atenolol",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norvasc&reg;",
"       </td>",
"       <td>",
"        amlodipine",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasotec&reg;",
"       </td>",
"       <td>",
"        enalapril",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipitor&reg;",
"       </td>",
"       <td>",
"        atorvastatin",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crestor&reg;",
"       </td>",
"       <td>",
"        rosuvastatin",
"       </td>",
"       <td>",
"        Not yet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plavix&reg;",
"       </td>",
"       <td>",
"        clopidogrel",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    To find out if your medicine comes as a generic copy, ask your pharmacist or use this government website:",
"    <a href=\"file://www.accessdata.fda.gov/scripts/cder/ob/default.cfm\" target=\"_blank\">",
"     file://www.accessdata.fda.gov/scripts/cder/ob/default.cfm",
"    </a>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34395=[""].join("\n");
var outline_f33_37_34395=null;
var title_f33_37_34396="Requirements for off-site surgical backup";
var content_f33_37_34396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCF/AHA/SCAI expert consensus document requirements for off-site surgical backup",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         1.",
"        </strong>",
"        Interventional cardiologists establish a working relationship with cardiac surgeons at the receiving facility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2.",
"        </strong>",
"        Cardiac surgeon must have privileges at the referring facility to allow review of treatment options as time allows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3.",
"        </strong>",
"        Cardiac surgeon and receiving hospital agree to provide cardiac surgical backup for urgent cases at all hours and for elective cases at mutually agreed hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         4.",
"        </strong>",
"        Surgeon and receiving facility ensure that patients will be accepted based on medical condition, capacity of surgeon to provide services at the time of request, and availability of resources. If this cannot be ensured before the start of an elective procedure, the case should not be done at this time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         5.",
"        </strong>",
"        Interventional cardiologists must review with surgeons the immediate needs and status of any patient transferred for urgent surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         6.",
"        </strong>",
"        Hospital administrations from both facilities endorse transfer agreement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         7.",
"        </strong>",
"        Transferring and receiving facilities establish a rigorous protocol for rapid transfer of patients, including the proper personnel with appropriate experience",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         8.",
"        </strong>",
"        A transport provider is available to begin transport within 20 min of the request and provide vehicle/helicopter with necessary life-sustaining equipment, including IABP and monitoring capability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         9.",
"        </strong>",
"        Transferring physician obtains consent for surgery from patient or appropriate surrogate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         10.",
"        </strong>",
"        Initial informed consent for PCI discloses that the procedure is being done without on-site surgical backup and acknowledges the possibility of risks related to transfer. The consent process should include the risk of urgent surgery (approximately 0.3 percent) and state that a written plan for transfer exists.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         11.",
"        </strong>",
"        As part of the local continuous quality improvement program, a regular review of all patients transferred for emergency surgery with the outcome of surgery and identification of any improvement opportunities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IABP: intra-aortic balloon pump; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions.",
"    </div>",
"    <div class=\"reference\">",
"     From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34396=[""].join("\n");
var outline_f33_37_34396=null;
var title_f33_37_34397="Trauma scoring children";
var content_f33_37_34397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trauma triage scoring systems for children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tbody>",
"         <tr>",
"          <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"           Revised trauma score*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2\">",
"           Clinical Parameter",
"          </td>",
"          <td class=\"subtitle2\">",
"           Parameter Category",
"          </td>",
"          <td class=\"subtitle2\">",
"           Score",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"5\">",
"           RR",
"          </td>",
"          <td>",
"           10-24",
"          </td>",
"          <td>",
"           4",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           25-35",
"          </td>",
"          <td>",
"           3",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &gt;35",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &lt;10",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           0",
"          </td>",
"          <td>",
"           0",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"5\">",
"           SBP",
"          </td>",
"          <td>",
"           &gt;90",
"          </td>",
"          <td>",
"           4",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           70-90",
"          </td>",
"          <td>",
"           3",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           50-69",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &lt;50",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           0",
"          </td>",
"          <td>",
"           0",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"5\">",
"           GCS",
"          </td>",
"          <td>",
"           14-15",
"          </td>",
"          <td>",
"           5",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           11-13",
"          </td>",
"          <td>",
"           4",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           8-10",
"          </td>",
"          <td>",
"           3",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           5-7",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           3-4",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"        </tbody>",
"       </table>",
"       &nbsp;",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tbody>",
"         <tr>",
"          <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"           Pediatric trauma score&Delta;&nbsp;",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle2\">",
"           Clinical Parameter",
"          </td>",
"          <td class=\"subtitle2\">",
"           Parameter Category",
"          </td>",
"          <td class=\"subtitle2\">",
"           Score",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           Weight (kg)",
"          </td>",
"          <td>",
"           &ge;20",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           10-20",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &lt;10",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           Airway",
"          </td>",
"          <td>",
"           Normal",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Maintainable",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Unmaintainable",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           SBP",
"          </td>",
"          <td>",
"           &ge;90",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           50-90",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           &lt;50",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           Central nervous system",
"          </td>",
"          <td>",
"           Awake",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Obtunded/Loss of consciousness",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Coma or decerebrate",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           Open wound",
"          </td>",
"          <td>",
"           None",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Minor",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Major/penetrating",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td rowspan=\"3\">",
"           Skeletal",
"          </td>",
"          <td>",
"           None",
"          </td>",
"          <td>",
"           2",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Closed fracture",
"          </td>",
"          <td>",
"           1",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Open/multiple fractures",
"          </td>",
"          <td>",
"           -1",
"          </td>",
"         </tr>",
"        </tbody>",
"       </table>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The revised trauma score utilizes respiratory rate, systolic blood pressure, and Glasgow coma score. Unlike the trauma score, it does not include subjective variables such as respiratory effort and capillary refill. The revised trauma score is the sum of the values given for each parameter. Triage to a trauma center is recommended for patients with a score of &le;11.",
"     <br>",
"      &Delta; The pediatric trauma score is the sum of the values given for each parameter. Triage to a trauma center is recommended for patients with a score of &le;8.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Furnival, RA, Schunk, JE. Pediatr Emerg Care 1999; 15:215.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34397=[""].join("\n");
var outline_f33_37_34397=null;
var title_f33_37_34398="VWF mRNA and functional domains";
var content_f33_37_34398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    The structure of von Willebrand factor including common mutations and binding sites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 340px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34398=[""].join("\n");
var outline_f33_37_34398=null;
var title_f33_37_34399="Ocular cicatricial pemphigoid squamous metaplasia";
var content_f33_37_34399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvzcZJOTjPSnxOkoyCQayYrpgTuUY9akF0N/ynBrRwPTdF7Gmy5OCTmopkAU7mqAXasOeGplzJlAwNJJijTlfUhPOQSaoTxyZ+VjVmSZW5UYPrSCN2GQeSK0Wh2R93Vmfh1+9mkKk9zV5UDZEnBpws933SKvmRr7RLczwGHc4+tG05zk/nV5rI92AqSCwxycmlzITrRRnKJPfFWYlY8ZOavNakcBatW1pjkipc0Zyrq1yrb27NjOavrFtFWFQAdKesResnK5xzq3KEhI6ZqS3ilLAnIFWjaEvu7VbhTA5qXIiVVJaBCCBzmpQT60Yx0oqDlbuLk+ppwJ9TTaWgQ4E+poBPrSCloAXJ9TRk+poopDDJ9TSZPqaKMUAJk+ppCT60tNNADWJ9aYSfU080xqAGZPqaUE+ppDRnFAC5PqaMn1NFFABk+tLk+ppKWmAuT6mlBPqaSnCkIUE+tKc+tIKWmAZPqaOfU0UUgDJ9aMn1NFFAC5PqaOfWkpaAFyfU0ZPqaSlpgBJ9TSZPrS0hoEISfU0hJ9TRSUAISfWkyfU0ppDTATJ9TSZJ7mlpDQAZPrSZPqaWmk0AJuPqaQk+tKaaaQwJPqaTJz1NFFACg8jk0Ui/eFFMRxvmEk7WzzUsJbGGH41kMZI2YopZQe1WbbUNzBJFKt713NH0Mo9jTUEnHepSXCbMg1Rluo0Gc5PpTrW6Exz09qixlyvcsKuWUPwB2rQgYR8heKpswC5FSR3LKmGAIqHqZzTlsX1NvOcEYarC2MfBVqz4ZI2Oehqz54UY3VDT6HPKMlpEuJYxE881ZWBEGAKzY52U5zkVoQTrIOtQ0znmprqNMAJyBTxBUwNLU3M+dkIhANSKuKXFKKRLbYUUGigQtFFKKACgUUtABSikpaBi0UClpAJQaWkNADTSGnU2gBhprVIaYRQBGwptPIphoAXNLmm0ZoAfRSUZzTAcDS5pmaXNAiQGimA0uaAHClFNpaQC0UUUAFFAooAWikooAWkzR60maYgNITQaSgApKKQ0wA0hopKAA0hopKQCGkNLSUDENJS0hoAUfeFFC9RRQI5E2bwkrkNzWVrVtJHB55bBQ9AK6OKzUTs7yO5z36VHqsCywmPGc11Kep7EK3vq5zMCSXCK2CARmtXTogH+8Dir8NrGkSqV6DFW7e2iQZVME1TqLYueITuVJhxhenvTUcEFe4rS8kdSKiNqgbeo5qFJGcaq6kdqEdSG4NNcZfAORViWIqoKY+lMMZ27hSuCld3IFleNuvFWYrrB4ODUflebntUJtX8zg9KNHuU1CW5uW96SAHq9FKHHBrDgjZANxzV6LKDKGs3FdDhq049DTpaq28+84NWRWZzyTT1FopKM0Ei0opBS0ALRSZpksqxqSxxQNK5IKUVSN1lRt71ZiOYwT3osU4tbktKKbS0iR3akopKAA000ppDQAhpppxpOtADCOKYakNMNADDSGnHrTTQAA07NM70uaAFzQDSdqKAHZpwNMpw6UwH0tNFOpCFooFFAC0UUlAC0hoooASig0lMQUnelopgJSGlpDQAlJS0GgBtFLSGkA09aQ06koGJ2pKU0lAAPvCilX71FAGYVwxxioHVi+SKsE5Jx60hJzyOK2O1aEQVUG49KIJElzsOanBGMYBpUjQH5VCk0BfuMkQsnyNtanRqcANgmibEY3GkhG0Z3ZzSFfQcV2nPakC+nSnk+tQSFlYYPFA1qSCMenNORVHWnJyopwUAcc0g5hAgByOlK2AOKevFBxjkUibkSko29a0reTzEB71mv/sn8KnsJDu2nrQ9UTUjeNzQoopKg5haWm0uaAEY4BrnL+8LXDRhsgdq3buTbExHWuXdc3fmN3NXBHdhIJttm5YOzRKHFaiDCiq9ooEK7RxirNS2c1SV2OozSUZqTIdSUZooGFIaKDQAlIaWmmgBDTDTzTe9ADTSdqcRSUAMNJTjSUAJS5ooxQAopy03pTqAHCnU0U4daBC0tIKWgAxRS0lACUUpopiG0GlNFACUUtJQAlJTjSGmIbRilNIaQxDSGlPSmmgBKSlopDG0UtJQADqKKVeoooAyJmK52daahLr83BqJnHmEbu9SRdc9q6DvtZDxvXpUyP60keGHWgDBNSS9SRwrrg8ios4GE7U8528U2OIKSaCVoMaLeMF2FOijCcMS1Pdh0HWnKwxzSuO7FA7CnA8YNMJx0NVrlZ2IMTDHcUAlcvJg9Kcx46VXhYgAHrU4ORSJaIfKG/evftR5gSQetDSAHFRSjcA3cUyku5sxPvQGnVXsmzCKsVmzkkrMBSP8AcNFDfcP0oA5++uH+cK1V7RTPKoI5B61JdRtNO+0dKvaNaNGxZxxWraSPTco06fmalqhSIKampBxS1kzzG7u4tJRRSELRSGkoGOzR1ptLQAGkNLSGgBtJTjSUANpDTqaaAGsaYeacaMUAIKdSUoPNAC0tFFACilFJSg0CHClpBS0ALSUtJQAUUUlMQUUUlAC0maQ0UxBSGikJoAKSiikMDTTSmkpAHekpaSgYlJSmigBB94UUD7w+tFMDBa1VZGOTkn1qWMbTgVI5LMeO9Ki1u2d3M7ajwNoHFJjvUgx0psnC8CpITEJCqSTSFtwGDUKHe7A5qUEDgUWKsOVeKHBUE5/Coo5QXK45p8xPlNjrigXUj3SHkEZ9KnQkDJ61kWImMjGVjjPArXh4XmhqxdSPLoPY7l44NLGxxzwabxQaRmRS/e3VKwxbjd1oXk1HdNhQM9aClq0i7pz/ALsDPNXaqWCgRg1bqHuctR+8xGOBk1C86sGUHmo9Rm8mImqNjCZxuLEc5ppdTSFNcvOyxYQlpWZvWtNV2jimRKEGAKfSbM5z5ncWiiipIFopM0UAIaKTNFAxaXNNooAUmimk0ZoAU0UmaTNAATSE0ZpKYCUUUUgCiiigABpaQUo60CFpw6U3NFADgaXNMzS5pgPzS0zNLkUCFoNJmjNABSUd6SmIWkoooADzTTS0UAJRRRSGJSdqWkpDCkpaQ0AFNNLRQAg6iilHUUUAZZAyaUtjjFKcBjjrmo5T610HUtWSodxODSueMGoom20jkk0gtqIWGSBTRkc5oRTkluKTPJoNEL/HkdakkbP1qIcmlLYRifSgGV4CRO25QFHv1q6WyRisi1uBdTuoTG09aSbU4ophEzHdntQ0aunKb0RuJ70knB5plnIJYgwORUd24GRznGanqc9nzWLa44xVDUZtrhR61PaymRSegqhqJzOopxWppSj79mbFhchkC55rRzXOadn7QtdEOlTJWZz4iCjLQzNbbKAdyat6agS3HvWdrLgyRjPetW0/490+lD2KnpSiicGlzTaAag5h+aM03NGaAHZpKSigBaM4pKQmgYuaTNIaSgBA2TTgajxgk04UDY4mkJppYUxnAoFYkLUgIqlcXKoPU+lUWvZN+FIxTUWzaNGUtTbzS1ji8fAIqxBfq3DnDUcrFKjJamhRVY3UYPJFKt1GxADDJpWI5JdielpoYGlzQSLRnikzRQIXNGaSloAXNGaTNFMQ4GjNIKKAFzRRRQIKWkpaACk+tLSUhiUlLQaQCYoNFFAxKQ0tBoAbSUtJQADqKKF6iigDMmbbIQB0qvLIc5xk1O0DGRmZs5NOFuK6DrTiimrMWzVlMtR5ADVIBtFA3JPYjYAcVHgbual3UwgZzSGgUHrT9o2H5TmlRT609W2HrmkJsrw2iJvYKFZhWH/ZJe8aTeM561u3U4jIZs8nFLAiMC6jGaabRpTqzp3a6kdsnkRgAkgVDJM00gEakkcGtBk+THqKz9Ptpbe6kdzlCc0txKSacnuXUURpjpWfqI/eqfWtGXLfdrP1BvLkTcM0R3HR+IdZnF2gFdFu+WuZtZFkvtyjAHFbrORFRNEYmN2jI1JTJdDbzityzJ+zruHaq0NuHbeavAAACpk+hlWqJxUV0HZozTSPSlqTnFzRmkopAOzRmm5paBi5pM03rRQA6jNJSE0AKaYWxTJZAo61RuL1FyAQWppGkKblsWLidY1JY1j3Wq4JCnFJPL5mSzVhXfLkJ09a2hBdT0cPho/aNIXm98noepq2jK4+T8axYAEXk5NaFnJwVqnE2qU0loWWJ7Hio3Xcy8+9R3EojQeppkdyGJb8KSRKg7XHSDnOT+dRgsr7kYgipSwYH0qtPKsY561SRpHXQ04NRlXG/BFXTfhlG2sCGZWXcTUizYmCk9RnFQ4Ixnh4t3sbovtoGefpVu3uUlGVIrmvM+bJPXtUkEhRwUJFL2ZhLCpo6oGlqhb3BMY3dauI24ZFZNWOGUHHcfQKBS0EBS0lLQIBS0gpaQBRRSUAKaSikpAFFFFAwpDS0lACGkpTSUAJSd6WigAH3hRQvUUUAZSXKPdPGGyQelTn71QyiCJ2kCgMT1qeAqwBzW5vbS4xsk8DinYBqXYDnNQOpDfKKVxp3EZQM45qtBlmOQR9atj72Ke6jGRTuVzW0KRlCS7dwz6VITk0SIhOSgJ9aZ2xQXuNmj81CoFWYIxHGqjsKZD1Oan2gcikyZPoI3UCq80vly7QeT0FTvnimPEjurEfMvekKPmETMwy4wfSqWrjMakCrkoYEYqjrTBbcE01ua0vjTRW0pgl8ATXRS4d1C1y9tnzwy9BWza3BN4vB561U11NMTTvLmXY10XYuBTxSCisTzRaDRiigQUUUUAFAooNIYUlKKTpQAGoZZAo5ps8wQHJrA1LUtxMcJ+rVUYtm9Gi6j0JNV1HafLiOX7n0rFaRuSScmg9z1Pc00kdK6IwSPYpUo01ZDHumPBaiFg74/Wq86YJIpkblWzWljpUFbQ0pwEIxwKjDsoypxUgZZo1yeake1OzgjFT6mN0tGVZZHkGepFOjG4E9+4qIq8cmO1DuRnb6c07FJdi1FLg4PSq94RNkA4NQQzb2K9xT/l8z3otYEkmNOYo8Ak4qaC8/dqXXn1PWo7gZX5RzVJXLSFG6ina5aipLU1ROHK45q/A2GGax7NsYPUE9KutPsNS0Y1Ia2R0do4dRjpWlA4YAZrE0wEJk9G6VeV2ifdtyMVzyR5FeGrSNOlqOCQSxhl6VLUHI1YSlooFIApaQUooAQ0GiigBKKKKQBRSUGgApKWigBKSlpDQAhoNFJQADqKKB94UUAUJI1myGA60yIOkhAUbfWpgRzx3pFIbpW1zpvYcXIGaVDn8abKuCoJ61UvroWskalsbjQhKPNoi00ZDHBpQx70qMXUN2NNcbeaA8mI68ZpgTj1qcfMnApmME+tA0yNVw3pUqtk4NN2/NmqOrXRtI1cKTz2o3KS5nZFy4ydoU800FhMFA47mltJRNAsnHIp6HqcYOaBbaDyuRkmszXIw1gw9K1H4UVk664W1C5+8cUR3LoX50UdMOHjDjgityG1k8zcowKy7GL/SIeOgrqR0FOb1LxdVxlp1BAQoB6gUtFFZHnhRS0UAJSiiigBKDS0hoAKhnkCA84p8r7RXOavf5zFGee5HaqjG5vRpOpKyK+sXzzMYoThf4mrHkJXCryTUkjYBOahZiRkDmuqMbI9ynTUFZE6nC81XZ28zAHFSoTt+ah1JQ460ythpBAy3SkKL1FKpIUB+tI3H3aZSEbIHynir1pc/u/Lk/A1TUZHvTCSr4I4pNXJmlLRlq4fc9RY70gpR+lFg2IzEFbcopxjDuGOc1L1FIvWmF7kcytgbaryxgrvIwwq+zbRVO8OF46GhBB3YtsQAR70+ZS27nIxVFpCiFxxgU1L75dwycnBxTt1NXFt3R1em3DSWkJXBIGDW15q7RnqRXEadPJasSrZRjkCtn7YbmFGRsMrYYVhOGp5uIw75rrY6ixACHb0PNWqr2cey3QdeKsVzs8mWrYUUUtIkKKSlpAJRRRQAGkNLSGgBpozk0vajFACUtFFACUhpaQ0AJRQaTtQAL94UUDqKKYFCUNuIB4qNT5anb196lBPzUkcQYktzWp1+ojo0uxi23FNmtIppFkf5mXpmrTKowAKQ0rkJ9gX5Y/aqskw5yadNNsJjIAJGRWCsu67IklLjP3QOBVJXNqVLmu2dBBKDGNvNI77TnFVzKkVvlMAAdqr2lwl9AwDMpB60WBU3rLoag+Zc5oljSaPY4BFUdKnWUtFuyUOOetaW3DdKT0Mpe67EEaLFiNegqYjAp5AxkdaYrZpE3vqMkHyNWFr5wbYHOCa6FgCCKxvEcf8AoSSgZ8o5NOO5vhnaoi5pyD7RGSO3FbVYmhyrcqkkZyoHWtulPcwxF+ezEpaKKgwCilooEJRS0UDEpCcDNLVW/nEELMTgAZpocU5OyM7Wbzy1KIfnNc1I3J9fWrFzM0zmRup/QVTkOeldMI2R7uHpKnGw2TB61HuyaRjk0uMYrQ6rWHhsH6U9SWz6VEBuHXNXrSJJoCcjI7UmTJqKuyk64qCWYxjkVYuUKOVJ4NRiNXGxvWqQ1tcdE+VBp+7NBQKMDpTYiDKgPQnFIXmG7nFOU5zSaii28hCsG4zxVaznMi59DT3VwVpK6LYBpGbb1qQYI96jlj3qPWkIefmUdxUN1gJzUsXyjaajmGeDQOOjM+YhYSxHy45qvaQqkTPFyh5xV64CgFH+63FNs4Vg+QdKu+hrzaD7JxIrHnIPQir9wogtxOhwrEZFV3VU+6ME+lCxzPGVzkDsazlqYSV3uehWEiyWkLKc/KKsjNYOjGSFYlzmMj8q3RzXE1Znz9WHJJoUUtAopGYUUUdqQCUUCigApKKKADFJilooASiig0AIaSlpKAENJS0UAIPvCigdaKYFQEZIxTg3ZRTLfcSS4p4wGIHUVozoe43J3GlHNRrMhmMeeakk4TI5oG0QajHmHzFbawGMmuftoirO9yFYNnBHBrppYluINrniue1YDzhbxg/LyMVcH0OvDSuuQl0eRHZ0MeEBwCTmpls5TdMsbKsWc8CqkYa2tpQoVH6g1r6fN5tupYgt3xTk+qKqtxvKPULS0htp2kUfMe9XycjIqEAE1MAAuDWbZwzd3djSfkqN+xWpSPlxUQGevagSHA81FdxiW2lQgYKmpQQW4pzqCh4oBOzuc78PZMwXUJ+9HIRiuvxXHeEk+y67qEPZzvFdlTqfEXjv4zfezCiiioOQKKWikAlFLRQAh71zPia5LOkCH7xyfpXQ3UgiiLHjFcdeSme4eU9+B9K1pq7ud2Cp3lzPoVJjhDVaNi0ZY9+lTXJ+Q1Xz+4ytdKPYitAJ+YHsKcIi54zTNuVT8639MtPMIcj5RSk7ImpU5FdmQkBBIz1FMjLoSVyD3FdFc2cZc7RtcdDVO7sWERlC89xUqaZnHERluY9w5dTn7wqJX6NTpSFG7NQ4JlVlOVNaI6kkW1cOvvVcZJ69DTlfYxPakdgH3DoaASsKVLnDHP1pyRrGcAYFCHccHr14pzEjO6gm9yQHjFPByB6ioInByKc2R06GkTYkJGc0xxkZFNJ6807cPLPtQO1ircpvx7VIihmUdwKiRzJKwPTFWEA3BvSm9CntoOeDz2VFODniugsrPyoR5w5xWDDMVnVgOAa6izuEukA43d6xqNnFiXJLTYmhAGzaPlFayngVmsAq/StKP7gPtXMzyquuo+iigVJiFJ0paKAEooooAQ0UGigApKWkNABRRSUAFJS0lACUGikoAB1FFKvUUUwKm7BOPWs28E8N6s0O51c4YelX8gsSOKVSCjb+K1Wh17DIVRn34wTVkDIweazJ2lguYTEm6Lq5q7HcCZCyUNEyTHhdpYDnjpWfDbmSQyvGQ2cYNWE81ZiScg1YR/nKnNGxSk43sU5bdGJLICabpVuYEkBHU9avzIShCnBPeljG2IKxyR3pX0B1G42G42sKfjcMg0hOVzQmOaRm+4vJTNQjGSMc1ODwaYQM++KaBEKqQ+c8GpjwKiU5B5pXY7D9KBvVmNZrt8RiQfxDBrrK41JjHq8JIxubFdiOmac+hWLTvF+QtGKKWszjEoxS4ooGJQaKWgDM19iuntg4rk5DxxXT+Jm22P1Ncq5ygNdFLY9fAr92Qz5ZCKj27IVB7CpScimSHII/CtrnoIbA24j0rrdKx9mXB7VyNrEVQg9exrqdCZmtsN1FZ1djlxivC5ZxuuDikmByVI6iraoAxPeqhBZyffFYI4Iu7OOu4SlxMrcAnioo4yuR27Vs6nbN9ocsPlPIpltYOy/d4NdKloevGrHluzIdSUYDrTVXMIB65rXk0+RUkOORVSGydxwOM1XMi1OLV7kDfJhu4GKWVsovriluVaB2WQfd9ajDCRcjtT8wS1uPhUAmpyRt57VEOBn1phbJIFLcLXYu7Dc0kkojxnoeDSKNy57imzxb0wfXNMp2HgCNWY/hS5Pl5FKfur6EU2WYoyqq8Y5pE2H28gfoOa1tLSSC5RyDtPBrLiAxvXr1rqbSRJoEK4xisqjsc+JnyxtbcsyNlc1pWxLQqT1xWHcSbZI17FhW+nCgDpXMzyKqskOooFFSc4tJRS0AJRRRQAlFFFACUUUUgCkpTSUAJRRRTASkpaQ0AA60UDqKKAKEgKyfU1WvIriSN9jbF7Eda0biMOPMHrUIfBA6itkzrjK+qIbLc1sFkJLDg5qSIojFSAqipXCnGzC+uKqXkH2qErE+1geSKL3Hfm8i6ksZZ1Byyinq48sPjrVSwiKRMZDlzxn1q4QAgFJmTSTsNDjHzUHqe9Jt4zSE4U0h2HAEkelLtAbINMRulODDkmgGg/iwOlI64UnNIfmOVpjZwetAWI0BVcZzzSyNsCk9DxT0HGaimw4Kmge7MHVV8rUYmxwrBq7KJg0an1Ga5fVId+x+uBitnTZf9Eiyc8YqpapF4j3oRfY06WmqcilrM4goozRQAUUUUgMbxOf9ET/erl5R8vHpXTeJGzAo9DXNMM100tj2cErU0VgCFzSBc/lUp44pgOGz7Vsd1x8XVcDnOK6uwgEcKnpmuRSVWO6I4ZTyK62BjLZgZ6gEVjVOLF35UWbaXzkYYIZGKmlkQYBApytja2OSOfrUuASf5Vhc829mZGoKQArLnPQ1H5E8UKeWodiemcVpuYZ5DbscSjkA9aZcQnCh8gg5BFUpG6q6KJSdGAw4warbfLUBR0rUnx5ZaTjA61nWUy3CSFRkIdpNUmbU5NxuZHiJFKxOOvQ1kEFYsLwTW1rpDlQOqnke1ZQQsdo7VvB6Ho0V+7VwVjsAb71OiTBLdaSJQXIJ6U5GwQPWqLk7KyEf5U3evWi3cTJx1BpJWDMUqGwjMTOCeCeKOgW01JWfLPGv3lGacgDY3jnFJ5YErS98U5HyenFIEadlprSQ+ap49K1rSFbWEjv1qDRLkNEYieRV2VS0bD2rnm3ex5tac3JxkUoA9zcGQ/cHSuhsXLRbWOStYWjsvkyQ5+eNiDWpp7bZSD3qJHPiFe67GlS0lFZnCFFAooAKKKSgANFHtRQAlJS0lABSUtJSAKSlpKAEoopDQAo6j60Ug6iimARYZHRuuaoSRSRsxLZXPFWFkxz3qyiLIuWHBrS9jZPkdygh2x5xyaSMqpOByetPmzFOVXO3FMCndkdBTNVqrkySxBgrHDntUrFcH6VRRFkkWSSPDjvVqSRQQcYHShkONmNtpDI7A/d7U9wADREEU5HSpHKsPpSBvUgLqKeACuai2h1zg4pyKCOtIpobFODevCAcKuc09uQaUAAE8bvWm5/lTEMYbQKidMndnrUknTFNT+76UDKUsoaQIeQKsac2Y2A+6GqrcR7JCvUHnPpUuj5YNj7u6qexpUS5Lm9F0FSU1BgAU6sjhEpAefalNIKAFoNJmkJpgYGvtkke9YJPWtnWGDlsdQ3NYcnQ1009j28KvcSK1w5XYw/vYNP3DftNRTcyBP8AgVSgKQWJxitTs0IiFXLRsMjqK67SpPNsY3/CuSEG5t8Zrr9Li2WqAcZGayq7HJi7KCLjuiRruOBnAqV5VR4yTjdVZ4EvrKSKQkZ4BHUH1pLy0MtlFHJIfMiwdy98VhoeZZXsyzPbxyzxykYeM8MOv0p8+Hjb1XmiLJjG48kU3OFweSKRHX0KryxTrJEeSi/MvtUOl20X2Yi3xs9PekuilkZLs52kBXA9Kk0yBLecvGzMkvOOwqumh0PSD5XoUNTsfNDOg+f+dUINLcqS/wAprp9WXyLKWZF3FBnFU4JVlgjfaV3Lk57VUZuxtTxE+S62OaNg0MhVuc8g1WuYWjQnFdZcoqrvC7q57UZPMYgDbWkZNs7KNZ1GYQ3vLxVtMh8GoHjZZsDgd6mbO4fStjrepaLBSq4+9VO6nFu5yOKssMBSaifZMTuXp3qUZRJbWdxJG8J+Y9K6mF3W1zN941jaNp/zLM/3eqit7bn73IrCo1c48TOLdkZ1qhi1CZjxuAIrWtwRMhHTNUSon1HC9EXmry5Tbz0NZyOas7mvRSDoPpRWZ5wtJRQaACijvRQAlFFFIBKKWm0wCiikpABooooASkpTSUAA+8KKQfeFFMZhJqiG9Fv8w3DIJHeuhtm/dLk5rPubG2mlVwo3jowqaOMgqik57mtZNPY6KnLJaaDrsbpjx0FRRv8ALjHNLNIUkOetMBGc0DitCSQjaMj7ozVZJVvY3QDb2FVdcu2tbJmQgORXO+HLx31Vd0pbf1HarjC6udNPDSlSdTsddpKuIWSU5dDj8KtoMsSe1LEVj3Z+8aC/ynjkms3qcjbbIifm2gUpGPpQRgg02TIgf1ApDElbbAz9gM1FbSb0Rj3FEq+bZMF/iWoLRTFZrnllFV0LS0LjDJzUMynYzLwcU26m8m1ExH4Us7brYEHAbFFhJMzJXk2NuO5gOa1NHQLAo79TWLDciOa4VuVPANbmlIy2+49zkU57GuIVoWNYU6okB71KKyPPEIpp4FPpjDKmgRCrZJFOZgoyTUcZBJ9ar6kSFUDPNNas0jG7sYmoDM1w+OCRisa5cKSO9auozEyCIdB1rImjJuGb+ErXXA9rDq0dSGVczow6gYNOGHDLnlulKw/eH0xUFxG5w8ZwVNaHX0LNkriaNOhLYrsVbyhGuOMYrlLFsyRyNwykGuxgIZQeoNYVTz8Y7WCyeOSHdEeCSPoamkUucKcEDBplukcO9IxgE7se9Tw8u2etYM82Ts7kcWd5UnkD86Mbj71I6kPkdKpRXsX2iWNmwY3A596NxpOWqJmjR9ySoGRhgqadbRRpwOFUcCp2wfrUezOAPxFK4ua6K0F2uoWl2nK7cqD61z6XtxavZq6iWKTKHHXFbSPbRGSGAqHU5Kg+tSi0iMkbOg8yMkofTNWnY6YSjTumtH/kHlCOLaenasnULITDjCsOhrfnGV56is+6AC0osVGo07o42WPZKUk6jio2j2jP41rahZyS3YdEyp61Fd2jwxl3X5TxXSpbHrxqJ27meGDjb096gilP2mWNxhVGRWgbXFuGRTnuapyIN+f4iu3NUncqOqOstpYzZwFCMEDFWGYgdeoqhp1iIbWJdxbAyParO/fc7PSuZ26HmTSvoJYYWSY4+Zuc1bLbjt75rItb6NdUey5MnLD6VrEYOaUlZkVFZ3ZsIMIoznApe1RwNuhQ+1SVkee9wooFFAgopKKAA0lLSUABoopDSAKSiigApKKDQAhoNBpKYAOoooXqKKAMrRb2G9gGx8kVpA+VKpH3ehrzPwjfSQausOfkdulelMQ3BraS1uup6mPw31ery9GSXcQdN61SCkH6Vo2xBQqTkjtUFwgDn0qU+hxQnb3Wc14n0+S9tlMTHI7Z61F4VsI9OjWa7TZPKdqA10YAY4Kgr71BemF7mDev7xfu47ValpY7PrM/Z+xWxdGGBPGRTiMkYqMR8A5+tKrYYZqDk9CMy7rh0H8I5qT7ykEdRUCoY7uRgMq/OasxkE96GN7EaoAmBwBUOfLcKRw3ereQFqJlDMCcGi4J9yOWJZcK4yvWodRKRwfypdRuTBsRPvscCqFxDcTyrGDuJPPtVRXVm1OF7SbsiPRLI3FxJuz5Wc811CwquMDp0ptlbJbQhFHPerA6VEpXZz16zqyv0EApRRRUmAtNPSjmigCoVKT57GpWRXHzDNPkAK81GgPH1oKucjqpEeoyrjjOKpSHnBrR11AdUfvwDWbKQCxNdkNke7Q1gmVCz+Yd2OuB9KlhBkLJ3AzTZCAuf9qp4QqksPvYq2dDemglsCSNnXOCK66xDLAobtXL6VGX1BCPXNdk3MfA61hVfQ8/Gz1URrgBgwqRoy0oeNsZXaRTLUM1uDIMHGDUyLhBz7Vjc86TEXc0G2Q/N0zVJrBZLdUdt0ikHfjnrV3G7g07GwFh0A5ovYFNx2GbSMN2qJ4nWYS7zgdR6irYwy4qpfzLBayu+cYxx70kEG27Ix9IhhGp3iSKXYESB2689q3pQflb1qGJUVF+UbsDJ7mpgc/KT0pt3dzSrNzlcVACp71Vmi35HpVgEbsdKWQguNv40kZpuLMpoyM5xmoJofNGG+76VrXC5PA4qpg5xiqTOmFTqZ7rgyYX5NvSuejt5Z3YxoSAa6iUD7SFPRhinrEkKhY1AFaKdjqhX9mvUZYBvITcpBAwc1IqgTFsUtw/kRbgCc8ADuaSDzNweTC/7NZvXU5nK7bMvRNNMep3l7IxYuxCA9hWwwycVMBjnGAaa+MjHWhybdyZVHN3ZoWwxAo9qkFQ2hbyQG6dqnrM45bidqPpRRQSFFFFACGiiigBKKKKQCUUUUAJQaKQ0ABpKKKABev40UL94UUwPLPCNs8+tb1HCZJNeloAqbm6j1qhoOmwWUJaKMx7znDdatajdNDaSPHEZWHRF6mtpO7sj1cdifrNW8di1Zt8596ddOu8LjJ71StC7LG2ChIyVPalVsOxY5JPWlbU4uT3rkoIDYNSGJCQ5Ubh0Jpqf6zIxiqmrvKkURgfDbxn6Ulqx2u7IuxkgnPIpJFxk44pgYjaexGaleTBUEdaROtxmc9fyqQfMOOKjbrSngjFA2MnZkRtvXHFVNOMnlkSnLhqsTgupA4zSxKVPv0p9C1ZRMbU5SNYh7hRnFauhsXllZvvGsLVYWbUkk3YCdRXTaLCY7be3V+auXwm9e0aKL/eloNJWB5otJRRmmAhpM80402gBGqC6cxwMwqxVPUjiDAOMmmty4K8kjm9SA8/d1JHNY1+WEZI67hW3qCEOrdiKy5xkEHnmuuDPcofCind828mDyMGiJ3WSNsEqRzTpBy3oRUySbFAAGMdKs6Hsa2lQF7nzIzgYrpMfugMcjrXP6FPH86ZweuDW/bsGUnOa5ql7nk4pvm1JZGJQY70D/Ug55pEYMpzwc1VltnLzBJmw/zIOykVmciS2ZeLZXJ60vHl8/Qiq1p5rQKLhQJRwQOlTW7CUSJ/EhwaQpRsCt5akE5x0pGRJQQ6hgexpHG3kgnnFLH8w4oDzQybbHGXJwFFZc+qW9tPiWQAMPl9zV26ine7UIVNsylZAeue2Kp3uj2spiIj/eR/dbNUrdTekofbZehkWaIODwacG2oShye1Z2iWtzbLd/aJAUaT5FHYVoLtwpTG2k1Z6EzSTaWw8Nvjy3GKjYLjOKcOM+hpkpAiOBzSJRgpcC58RGCLO23T94fc9K0ruN2eMLwM5Y06ztEhd5QoEkuCxHerDffxVuWuhtKaurdCGfakQLcgdKhJJmQgfKQatywq5Tf0U5xTAVycDjpU3JUh6sSuO9MVCrbj0p4UjkYqTbkANQTexbhGIlqSmqMKBS9Kg5mFFFJQIKKWkoAKSlNJSAKDRSUABpKWkoAKSiigBD1pKWkNACr94UUg6iimBzVpqd1eaiY2CpGvQd62lyjM3Rz1JqhaGBRuwAT/ABVe3E55B4reXkds3G/uqyJFcrGxzlmqOMZ+8OaRWfAEgAPtUd5OLWDzCjSMpyAKkSi72W7LoPlx+/pSbFkjBcZ74qOKTzAkhBAIzg9qsMy7fekZu6GnnHHSmYy2DxjkULJ+7Ibr2qNWVTgsCx96BpEjOAeepoBOSSPalVQPrSN97FIAI+YZp5A7VDJIIyueSTgVKnIFAmZktkLmWYltrKPzrZ0yFobREc5aoLJA1zODyOBWkOBiiTewVqrfudBKKU0lQcwmKKWkNMBKKKKBh2qjqaZRW9DV41S1N1SFQ/G44px3Lp/ErHPazMsMSF+grJdtzE9sZrV16BZrdee9ZI5YgdhiuqFrHuYe3KREgg5FPACoHODtqHeqmYHqvNSI3mQrjoeas6GSJMJP3kfyyL6d66vSHY2imT7zVzGmWTXFztHyoo5NdbFF5UCKvIHGaxqtbHBjJKyj1J4hkn2NPGAcN61URtl66AnGwNVocnPasWefJExKn7tRwjZOzf3sCpV2svHUVGOuM1Jmuwl7GWjTB6OCfpT1Uovymq8Bu2muPO2GHI8vHUD3q0/yjg032G7r3SBty9MU3yBNIzFmAA6CnnGGI+9VWe9ktZreNIWlMrfNjsPWha7FRTfw7jyONo6VWs7f7KZRvJR23AHsavSx7JScDaaim5I7Yp3KjLSyFDflUMxEkR8vqOaHYohIBbvgdTVbTr23u/MWLcsin543GGFCXUpK2pahmVlUEgE0rDJqpePbK4WSRIjnrVoD5AByPWnYGrajWOR/OkjXcuaCD+dTQp8nFJg3ZCbeMDgURZLAU5v9WQOtOhHzL2pGdy32pTRRUmAUUUlABRRRQAlFFFIBKKKSgA70UUlAAaDRRQAhpKWkoAB1FFA6iimBz8MQhuGDngPjnpWyu3aWBB4rm9PkubiDdeY3+Zit3GFVRgE1vNHXUi76jo284ZIwKa6/vQRzTd+HKDtVkARgAck9akNgwcA9vSkO45Yj5RViJAVy3FV5STFIiA9OtK5Cd3YhimWVtqnkdc01oit0hC59/SucsXnbXgu5vlP3QvBHvXYtwDVSXKb1o+zaSe41jUZfHIHNPJG33oABOccVBgtCPbkgtzUqYU+1NHXPamzOEjY0D30JNMOZpz6nrWjWfpHzW7P/AHjV8GlLcxq/ExaDSUCpMwooooATvRS0UwENYfieQLBCued2a3DXPeKk3mAHgHNVT+I6MMr1UYrsXjGWJHXFVAdpJ9TVg4RAAe1UrjdmML3PNdSPcgiGSHddSHPDLipov3NsuR93inuoEgb2oOHTkgZ7VVy3sbfhubzElUgBuDW4DtGexNcppkjWt3HgEq3ymuvKjyxxnv8ASuaorM8rFR5Z37kDgG4WQL82Np+lPnkaJNyqXIGcDvUvyke9NUhlzjpWZzXJFbhWUYJ6inPtDe9Q55qUdV5waRDQ1S2XUjHcH1pZHZcjGf6UFsg4pEbkgjg0B5jHdVHQmmeci3MLFghI2c96esgRm3jn0qG7RZoTn5T1qkWktmXLggROz8YrOin3Ll0I+tX5CqWybmDKMbi3eoVigvInaKQFDxleaSFBpLUiEiM3ysv0zUDWsZuvtBUB8Y3DgmqUeg29vdiUXUsmGyUzxWmCW7cVTstjXRfCzJ1jTGuY1kgJ3owbB9q0bSbzrdWbh+6+lV7uKS3uPPjLtuADLngD2FWYCjoHjUfN1Peh7FSleKj2H55BIyKlTIbOeDUZPHPy05WGAAcgVJkx/GfenwHMuPSozzyOtS2a4yxPNJmctizRRmkpGQUUd6KAA0lFFABSUtIaACkoooASkoNNNAC5ozTc8UoFAC0GikoAUfeFFIPvCigDGWDfEuPl2ndV2ILNErbg2OhFQlctMp4QjGaWyjS3tkhRiVHIJrZ6nW7sdHDIZpWcYQYwfWrKAnn0pFdwpx92mh2UptQ/N61O5LbZZU5GO1ICMfKKNhYjkZpdu1evNIz0I9kaOWVAHPcDmgn5gDyTS8qeTzVW3jmVnedgST8uOwoLSuTtyTSEkcd6UHJoIOfegY9QQBnvVTUGyBEDy3FWiQiktxiotOiM9y1w4+UcLmmu44vlvJ9DRtYhDAkY/hFS0UVByN3d2FFFFIAopKM0wCilpM0gCuZ8UzgXESZGAM101cn4wtAB5pfLSHCj0rSn8R1YO3tVcy5HUkLnnGaYR0PpTQoyHb723FI7dFzya6ke0kQzv84T+9zSiPfJgfhRLGC8bZ5FWYIhJgZ47027FOVkaWgKnmssnLD7ua6MfMu0HDdKxtIssSGboOgWtjoemSK5ajuzyMTJSndDSu3I/Wnxj5SKhXcyjemG7ipOQmO9QYsrapO1pAsiJvG8KfoTV0tuQUgwYgHUMD1BpdwBoJburEcUIRnZSfnOSKl2qi7zzimFxxkck01yxOFOQeuaA1b1Ejkt7yMzQOHAJBI9aGwoAIyTUaPa2JS3ICGUkj3NSyfKR6etBXXTYydUtRewqNzZUnKA4Bp/h65tLa2FtGTuH3mAOCauyKkcbv36msbw7qEFxe3EI3gN9wEce5q94s6VepRktbI1Io0jdyoO1iTSXUu2NhGQG7U6QYcKM/Wn7ARg1PmZX1uzlZbvUlhkkdlcxv8AdxyRWnZ3wmi823XgjLoeCDU1/AIpRJtyD1PpUcKbZGwBgjJxWjaa2NnKM1oi/HKskQdlOD2NSKoU/L09KgV8kYHSpkOT6VmzGSsOkUyAYYrznir1sMJVVQCKtwDCe9SzCo9LEmaSiikZB3opO9FABRQaKACkooNIBDSGlpDQA2mnmnEUmKADHFApaKACkpTSUAC/eFFA6iimBlalcJbIHfOC2MD1qXcGVW4GRTbtR88cgU85waiilV4wFHB/Stuh3JKysWVckEKeBVmLE6KwbleKq2kZXO7vyKtW0PkxEg/ebNSzKbXQlwQcHrRIW2jHXPNAJJ57U0vyeeKRmhpzimscim+YRKUI4PINO69KZYgHQU9QKbjNRXUwghyfvHoKNx2cnZDcNd3JiDYRfvVrxosaBUGFHSqOkWzQxNJLzJIcn2rQqZPoZ1pXfKtkLSUUUjEWikFFABRRRSABRRRTASua8ZR5+yvk8HFdLXOeKyXe3TPyrliKun8SOrBu1ZM55pFMnl55Aziq7RsbtG7Y5qUQlLmSTPBGKVuASOorqR7aDhnK9hTjJsyF6d6htH325JPOanjXcPc9qGrClc6nR5CbSP5t2BV6Q7UJPXrWLob7S0Y6YzWneNttZHPYVyyXvHkVY2qWLOA+Gpm35mpIX3RKc9gaA2XNQY2sNjfLFecCphx/OoGwjDbjn19asMfkBxzimwkN2hu/NBJ3bRgUIQBnFQPKyyIEXf5jY/D1pAk2VNeso7hElkfYYPmD5/Sr0chlt42K4BUHBpZYg6lHww9DTYU8uNUJHHFO+hXNeKXYSQAxMD1rLtDHeKxt4fsvltjeoALGtWUggjvUESLEm1QBzk/WmtC4SsjOs5ZIbmaC5kZzyy5OSfwq3b3KToWhYlelZniApbeXeKD5ysAD7VdsGiaItCOWO4j0Jq3qrm843ip9yyzAjB/WqjnypcL0b9KskM3GMVVuI2d1UHaAetSiYWJVz9asJz2qIIVAGcirCDjmkyJsmjAGKtqAF4qtGvNWhwKg5ZhSZ5paY3tQQLmlqNCT1qSkDCkpaSmAGkpaSkAd6SikNABRSUUAL2pO1FFACGig0hpgKOoopF6iigDOu4YZLgyZy5OetRRQ+XKUzkYyDXPXN9NBqYuCcQuwUoPT1rqIsS+WR1H8q3a5UenVpSpRV3oyzEu4AZ/GnlykbDrjnFV1cq4A6ZpTOPPA9aixytNk8ZLwo5GN3UU0jGQaklcrExHbmoUPmJv6E0ExA4MhOOgxTj6Cg4Cj3oHJoKG7wpOar2ifbb0uwzHGeB70t5+7hlf24qxoKgWCN3bk09lct+7ByXoaY4FFFFZnEFFFFABRRRQAUUCkoAKKWkoAK5rxIhF2rZ4K10tcz4ofF1Co/umrp/EdWD/iowycvimNwfxpN26V1PVaHwQDiuo9tDXARTgYpschadQBjmiZ9y4HrU9uY4z5hG7B+760dAeiOn0dIxb7lHzHrVu4QSwuhGcgis7QZzMkvyBVDZArR37ZSuecZrlkvePGqpqbuRKjRrEoPC4B9xU7YUE+gpMZcZqOdiCqquQxwT6UtyNwjxND8w69qtHPl7e+KrooABHSrOARnPakyZMiAJYAcUqADB7g8Uy3372MgwM/KPapUDE/MMc8UhMq6hOYnjywXJGM1FeXsdveQQSBsy5w3YVPfRxTRiNvmwc47inssG1WlQNsxtJGcVSsUmrIhvrmOzh82Y4XoPemRSiRN38R5I9KbdJDfxtExzsb8jUgURjC0bIuKVvMpavB9pjRSu7B6VPBCsChVAApZSWX5OvrUazNlUdOf73anraxpduKj0LCsOQCPf2qoS32nH/LMjr71YCAOWHUjFOWNS4HOO9ISaiAABAXkVJ0pCgB46e9KwOPakZvUs25yasVWswACQetWTSOeW4lIaWg0hCYFFFFABRRSUAFFFFACUhpaSgBDS4oooASkNLSUAFNpTRQAL1FFA6iigDm9b0d2tg5ILoS2Rx+FTeHLhprdUkI3jit7UY1NjJkdc1y2kqIiDGNp3Gt4vmi0z1Kc3WpOMuh0B2hCe+ab5OSGBxUpUbjx1FTRIpK5FTscz0RTUPukjdjgjg1NCQIlX8M1NIi7ulN2KCABS3RO4xxx9KaOWFWXRfSm7F9KBorzoJYyrdKTQ5MI8HeM4H0qyUXA4qrZqF1Ntoxkc0dLFfFBo2KKkVRjpS7R6VBxEVFS7RjpRsX0oAhPSipti56UbF9KAIKWpQo9KNo9KAIqKl2L6UbR6UAQ1yPiaQnVEXsq12e0elcl4ijT+0s45wKul8R2YL+IYzBN5IAzjrUZHy1M6L9oxjjHrQUXIGK6T2FoUIhlmLdAalRSkmQcoaWONQkvH8XrVy3jVoBkZxTZcnpc6TTURbSPysYIzUzBfMPHz44p2nRItvGFXAxUerfu40ZOG3AZH1rl3lY8R+9OxJGCQM1FeOyQuUGWA4FWowNlNlRcjil1JS1IoQTCM8HFSIN0BRvTFSFRsHFSxovXHNIiTKkEpeJWkQxvyMGqGn3882oXFvcR7Av3D6ite6RcZx2puxT5TEDPrTQ01Z6FO1sfs93c3AkL+bztPaqEWpNEl3JO2VjPAPat9kUZIHNcl4qjSOxCoMCST5sd6qHvOzN8PFVJcsuti5p+oLd2jXKx7QGw20cketaZ2lMjnIqvoVvFFo0IjQKCuTVlEUqMilK19CZ25mkcvfa4bS6kh8thg9SMDFTQ6lFexrt3jcduQa3prWCXcJIkYEdxWBLaQW1yggjCAt2rROL0sdUHCatbU3UQrGoz0FPD4XHf3qWJQVGR2pVRfl471kcjGAZAzilC5qwY19KERd/SkZi26YFTEVKqLt6UuxfSpMXqQUhFT7Fx0pCi+lAiECipgoz0o2LxxQBDiipti56UbFx0oAgIoxU20elG0elAEFFTbRjpQVHpQBBRipti46UBFx0oAgIpMVY2L6UhRfSgCuaMVPtHpSbR6UAQqORRUyqMjjvRTA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin, 100x. Note the squamous metaplasia, with loss of nuclei in the superficial layers of the conjunctival epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_37_34399=[""].join("\n");
var outline_f33_37_34399=null;
